data_1ksr_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ksr _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 83' ' ' LEU . 34.1 t0 . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.54 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.542 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.503 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 26' ' ' ILE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.657 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.657 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.464 ' C ' HG13 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.644 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.471 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.463 ' N ' HG21 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.715 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.704 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.527 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.626 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.542 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.559 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.559 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.443 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.527 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.469 ' O ' HD23 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.589 ' CG2' HD21 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.468 HG21 ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.641 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.539 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.539 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.476 HG11 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.633 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.621 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.461 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.565 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.421 ' C ' HG11 ' A' ' 67' ' ' VAL . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.654 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.621 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.641 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.704 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.527 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.468 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.633 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.408 HG11 ' O ' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.585 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.462 ' O ' ' N ' ' A' ' 46' ' ' THR . 3.8 m120 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.62 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.53 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.59 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.53 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.558 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.591 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.62 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.545 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.538 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.644 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.715 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.56 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 39.7 t0 . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.56 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.516 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.598 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.696 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.696 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.634 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.558 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.502 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.719 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.616 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.532 HG12 ' CB ' ' A' ' 8' ' ' ALA . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 35' ' ' HIS . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.524 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.436 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.619 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.574 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.578 ' HB3' ' CE2' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.557 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.53 HG23 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.492 ' CG2' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.65 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 73' ' ' GLU . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.537 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.537 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.639 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.639 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.593 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.503 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.499 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.619 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.578 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.658 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.593 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.462 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.547 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 76' ' ' ASP . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.609 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.462 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.574 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.723 ' HB3' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.557 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.598 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.621 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.555 HG22 ' CG ' ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.46 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.723 ' CD2' ' HB3' ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.562 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.634 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.719 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.456 ' O ' ' HB3' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.566 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 15.5 t0 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.566 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.454 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.496 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.552 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.553 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.672 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.672 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.462 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.678 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.497 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.463 ' N ' ' O ' ' A' ' 15' ' ' GLY . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.614 ' CD1' HG23 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.63 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' C ' HG22 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.436 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.462 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 20.3 m80 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.553 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' A' ' 37' ' ' THR . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.614 HG23 ' CD1' ' A' ' 26' ' ' ILE . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.486 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.626 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.488 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.582 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.616 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.523 ' CE ' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.405 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.622 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.616 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.512 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.581 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.645 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 5.9 m120 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.697 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.54 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.592 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.697 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.553 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.678 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.454 HG21 ' N ' ' A' ' 97' ' ' VAL . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.5 mttt . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.562 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.677 0.275 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.562 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 88' ' ' VAL . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.55 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.51 ' HB3' HG12 ' A' ' 26' ' ' ILE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 9' ' ' GLU . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.551 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.686 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.686 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.436 ' C ' HG13 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.659 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.467 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 15' ' ' GLY . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.695 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.563 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' NE2' ' O ' ' A' ' 15' ' ' GLY . 16.2 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.472 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.604 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.576 HG23 ' CZ ' ' A' ' 43' ' ' PHE . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.616 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.509 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.57 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' C ' HG22 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.459 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.616 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 59.2 m80 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.559 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.654 ' CD2' ' CE1' ' A' ' 65' ' ' TYR . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.552 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.575 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.632 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.488 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.428 HG13 HG23 ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.609 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.609 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.615 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.421 ' C ' HG21 ' A' ' 58' ' ' VAL . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.421 HG21 ' C ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.495 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.558 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.421 ' C ' HG11 ' A' ' 67' ' ' VAL . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.615 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.632 ' CD1' HG22 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.472 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.471 ' O ' ' O ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.488 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.577 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.642 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.622 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.552 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.593 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.588 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.599 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CE2' ' CG2' ' A' ' 79' ' ' ILE . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.546 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.564 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.659 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.695 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.569 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 120.71 0.29 . . . . 0.0 110.511 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.598 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.561 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.673 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.673 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.436 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.654 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.473 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.472 ' O ' HG23 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.701 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.607 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.606 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 64' ' ' THR . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.52 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.584 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.584 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HB3' HG22 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.461 HG22 ' HB3' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.581 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.542 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 37' ' ' THR . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.568 ' CD2' HD21 ' A' ' 83' ' ' LEU . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.571 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.479 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.634 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.531 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.403 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.562 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.601 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.601 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.616 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.472 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.462 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.581 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.524 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.656 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.616 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.634 ' CD1' HG22 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.507 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.46 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.624 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.643 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.494 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.676 ' HB3' ' CD2' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.571 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.624 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.553 HG22 ' CD1' ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.446 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.676 ' CD2' ' HB3' ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.513 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.567 ' H ' ' C ' ' A' ' 91' ' ' PHE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.654 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.701 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.567 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 24.4 t0 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.506 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 26' ' ' ILE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.562 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.66 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.449 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.676 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.52 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.439 ' C ' HG23 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.536 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.425 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.602 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.587 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB3' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.518 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' O ' HG22 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.595 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.546 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.468 ' OD2' ' O ' ' A' ' 35' ' ' HIS . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.578 ' CE2' ' HB3' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.587 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.54 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.54 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.576 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.624 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.485 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.595 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.453 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.624 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.621 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.466 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.61 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.628 ' CG2' ' CE1' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.487 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.4 m120 -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.657 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.561 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.503 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.578 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 10.8 m120 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.596 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.657 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.524 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.547 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.533 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.676 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.516 ' N ' HG11 ' A' ' 95' ' ' VAL . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.472 ' HD2' ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.593 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 22.6 t0 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 111.65 0.241 . . . . 0.0 111.65 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.509 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.539 ' HB2' ' CZ ' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.535 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.651 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.651 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.423 ' C ' HG12 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.518 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.489 ' N ' ' O ' ' A' ' 15' ' ' GLY . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.711 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.475 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 3.7 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.62 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.644 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.625 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.458 ' O ' HG22 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.622 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.644 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.535 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.561 ' CG2' HD21 ' A' ' 81' ' ' LEU . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.536 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.536 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.463 HG13 HG22 ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.649 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.649 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.615 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.468 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.519 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.622 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.615 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.468 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.57 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.47 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.529 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.602 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.586 ' HB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' PHE . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.535 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.592 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.605 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.62 ' CE2' ' HB2' ' A' ' 81' ' ' LEU . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.515 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.667 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.711 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.591 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.494 ' O ' HG23 ' A' ' 88' ' ' VAL . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' CB ' HD11 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.56 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.491 ' C ' HG12 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.554 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.486 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.716 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.433 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.534 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.601 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.6 HG23 ' CZ ' ' A' ' 43' ' ' PHE . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.574 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.562 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.562 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' O ' HG22 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.466 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 33' ' ' GLY . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.574 ' ND1' ' O ' ' A' ' 28' ' ' ALA . 2.1 m-70 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.539 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' A' ' 65' ' ' TYR . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.554 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.592 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.62 HG23 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.462 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.544 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.544 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.583 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.622 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.468 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.559 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.664 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.622 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD1' HG23 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.471 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.529 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.603 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.544 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.635 ' O ' ' HA ' ' A' ' 87' ' ' ASN . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.554 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.601 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.635 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.586 ' CG2' ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.538 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.573 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.667 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.52 ' N ' HG11 ' A' ' 95' ' ' VAL . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.716 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.619 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 . . . . . 0 N--CA 1.486 1.331 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.434 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.499 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.552 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.551 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.682 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.682 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.669 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.522 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.457 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.735 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.612 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.551 ' CD1' HG23 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.629 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' C ' HG21 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.463 HG21 ' C ' ' A' ' 32' ' ' ASP . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.629 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 7.2 m80 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.623 ' CZ ' ' CB ' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.717 ' CE2' HD22 ' A' ' 81' ' ' LEU . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.551 HG23 ' CD1' ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.642 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.56 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.56 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.584 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.584 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.618 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.41 ' C ' HG11 ' A' ' 67' ' ' VAL . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.618 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.642 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.524 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.445 ' HB3' ' HA ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.509 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.589 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.76 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.497 ' N ' HG13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.717 HD22 ' CE2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.561 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.574 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.453 ' HA ' HG21 ' A' ' 82' ' ' THR . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.615 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.76 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.511 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.481 HG21 ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.669 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.458 ' N ' HG11 ' A' ' 95' ' ' VAL . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.735 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.445 ' HA ' ' HB3' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.605 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.588 0.232 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.605 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.536 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.561 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.455 ' O ' ' HG3' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.574 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.685 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.685 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.448 ' C ' HG12 ' A' ' 95' ' ' VAL . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.628 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.537 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.483 ' C ' HG23 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.718 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.435 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.609 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.515 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.52 ' CG1' ' HG2' ' A' ' 5' ' ' LYS . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.624 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' O ' HG22 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.426 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.591 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.624 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.496 ' O ' ' OG1' ' A' ' 37' ' ' THR . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.594 ' CZ ' HG23 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.527 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.406 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.54 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.549 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.549 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.649 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.649 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.612 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.591 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.666 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.612 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.462 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 98' ' ' LYS . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.515 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.587 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.449 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.56 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m120 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.702 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.527 ' OG1' HG11 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.583 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' HA ' ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.556 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.464 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.702 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.515 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.557 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.628 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.424 HG21 ' N ' ' A' ' 97' ' ' VAL . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.718 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.439 ' HA ' ' HB3' ' A' ' 74' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.605 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.564 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.605 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.541 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.51 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.544 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.671 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.671 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.476 ' C ' HG12 ' A' ' 95' ' ' VAL . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.663 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.488 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.45 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.696 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.681 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.605 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.578 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.628 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.541 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.469 ' O ' HG22 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.423 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.621 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.547 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.467 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.473 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.469 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.506 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.578 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.471 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.63 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.539 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.496 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.546 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.578 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.619 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.621 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.619 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.63 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.681 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.496 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.478 ' N ' ' OD1' ' A' ' 76' ' ' ASP . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.607 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.422 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.592 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.2 m120 -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.637 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.526 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.598 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.585 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.576 ' CG2' HD11 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.436 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.637 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.559 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.663 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.696 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.541 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 120.501 0.191 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.541 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.575 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.539 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.494 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.672 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.672 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.709 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.534 HG21 ' CB ' ' A' ' 8' ' ' ALA . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.525 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' N ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.555 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.47 ' HB2' ' OD2' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.606 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.572 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.53 ' O ' ' N ' ' A' ' 43' ' ' PHE . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.57 ' CE1' ' HB2' ' A' ' 83' ' ' LEU . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.537 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 26' ' ' ILE . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.507 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.67 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.553 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.522 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.492 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.492 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.574 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.614 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.464 ' O ' ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.444 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.455 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.606 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.465 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.653 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.614 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.67 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.411 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.522 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.461 ' CG1' ' OE1' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.735 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.51 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.669 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.574 ' CG2' ' ND2' ' A' ' 87' ' ' ASN . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.494 ' O ' ' CG2' ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.735 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.525 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.675 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.465 ' N ' HG11 ' A' ' 95' ' ' VAL . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.709 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.627 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 120.557 0.218 . . . . 0.0 110.777 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.627 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.525 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.534 ' O ' HG23 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.528 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.518 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.546 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.656 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.525 ' N ' HD22 ' A' ' 13' ' ' LEU . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.648 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.51 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.443 ' C ' HG23 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.72 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.548 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.549 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.627 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.441 ' C ' HG22 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.441 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.573 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.566 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.507 ' HA ' ' CD ' ' A' ' 36' ' ' ARG . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.627 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.503 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.549 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.485 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.531 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.572 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.572 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.625 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.573 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.625 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.621 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.469 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.527 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.605 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.583 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.8 m120 -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.642 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.536 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.594 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.536 ' O ' ' CG2' ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.576 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 4.0 t-20 -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.575 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.648 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.562 ' N ' HG11 ' A' ' 95' ' ' VAL . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.72 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 74' ' ' ALA . 3.0 mtmt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.579 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 33.3 t0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.822 0.304 . . . . 0.0 111.822 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.579 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.462 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 88' ' ' VAL . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.592 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.558 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.681 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.681 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.468 ' C ' HG12 ' A' ' 95' ' ' VAL . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.662 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.503 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.455 ' C ' HG23 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.709 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.624 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.505 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.663 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.643 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' O ' HG22 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.62 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.529 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.487 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.643 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.543 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.598 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.651 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.548 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.573 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.696 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.696 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.627 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.434 ' O ' ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.627 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.668 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.467 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.6 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.595 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.3 m120 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.651 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.543 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.596 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.517 ' O ' ' HA ' ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.64 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.554 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.651 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.513 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.552 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.662 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.709 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.614 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.51 -0.181 . . . . 0.0 110.51 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.614 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.418 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.56 ' HB2' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.68 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.656 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.471 ' C ' HG21 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.508 ' N ' ' O ' ' A' ' 15' ' ' GLY . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.712 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.443 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.617 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.601 ' O ' ' CG ' ' A' ' 35' ' ' HIS . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.552 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.571 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.475 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.614 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.617 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.535 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.616 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.649 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.53 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.553 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.49 HG22 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.678 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.678 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.608 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.46 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.614 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.539 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.657 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.608 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.665 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.49 ' HG3' HG22 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.455 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.626 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.615 ' HB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.645 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.535 ' OG1' HG11 ' A' ' 44' ' ' VAL . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.566 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' O ' ' CG2' ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.611 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 2.0 m-80 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.527 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.656 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.516 ' N ' HG11 ' A' ' 95' ' ' VAL . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.712 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.452 ' O ' ' HB3' ' A' ' 74' ' ' ALA . 15.9 mttt . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.593 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.725 0.298 . . . . 0.0 110.48 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.593 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.5 ' O ' HG23 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.577 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.667 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.667 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.473 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.657 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.521 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.469 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.714 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.455 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.609 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.611 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.651 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 35' ' ' HIS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.477 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.438 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.511 ' O ' ' C ' ' A' ' 35' ' ' HIS . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.612 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.531 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.459 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.651 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.562 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.611 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.459 HG21 ' HE2' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.651 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.546 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.454 HG13 HG23 ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.644 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.644 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.61 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.605 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.658 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.61 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.651 ' CD1' HG22 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.47 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.461 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.49 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.584 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.424 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.722 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.712 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.562 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.571 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' CG2' ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.469 ' HA ' HG21 ' A' ' 82' ' ' THR . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.566 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.722 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.509 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.572 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.657 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.714 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.558 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 36.0 t0 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 111.513 0.19 . . . . 0.0 111.513 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.562 ' HB3' ' CG1' ' A' ' 26' ' ' ILE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.567 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.659 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.659 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.442 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.518 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.455 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.451 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.451 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.607 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.651 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.616 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.474 ' HB ' ' OD1' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.608 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.567 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.651 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.531 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.576 ' CG2' HD21 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.446 HG21 ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.618 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.528 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.568 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.568 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.734 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.734 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.612 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.466 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.608 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.523 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.612 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.62 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.482 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.404 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.62 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.481 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.623 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.1 m120 -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.605 ' O ' ' HA ' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.592 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.513 ' O ' ' CG2' ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.605 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.572 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.623 ' CE2' ' CG2' ' A' ' 79' ' ' ILE . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.533 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.675 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' A' ' 74' ' ' ALA . 11.1 mttt . . . . . 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.617 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.617 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.422 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.549 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.505 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.425 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.547 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.66 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.652 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.536 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.469 ' C ' HG23 ' A' ' 97' ' ' VAL . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.714 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.619 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.597 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.632 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.568 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.554 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.444 ' HB3' HG22 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 33' ' ' GLY . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.618 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 15.8 m80 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.568 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.632 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.544 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.597 HG23 ' CD1' ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.655 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.484 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.546 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.478 HG11 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.625 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.484 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.451 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.451 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.618 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.625 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.655 ' CD1' HG22 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.484 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.45 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.6 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.662 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.498 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.668 ' HB2' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.544 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.576 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.668 ' CE2' ' HB2' ' A' ' 81' ' ' LEU . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.561 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.652 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.714 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.619 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.454 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.571 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.652 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.652 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.66 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.498 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' A' ' 15' ' ' GLY . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.719 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.494 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.603 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.54 HG21 ' CB ' ' A' ' 8' ' ' ALA . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.444 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.615 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.529 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.465 ' C ' HG21 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.465 HG21 ' C ' ' A' ' 32' ' ' ASP . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.628 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.2 m80 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.562 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.509 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.598 ' CD2' ' CD1' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.577 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.548 ' CG2' HD21 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.637 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HB2' ' OE2' ' A' ' 73' ' ' GLU . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.53 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.614 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.614 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.611 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.41 ' ND2' ' OD2' ' A' ' 66' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.628 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.67 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.611 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.637 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.532 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.48 ' N ' ' OD1' ' A' ' 76' ' ' ASP . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.594 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.587 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 46' ' ' THR . 5.1 m120 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.657 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.577 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.584 HD13 ' HB3' ' A' ' 2' ' ' ASP . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.541 ' O ' ' CG2' ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.521 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.657 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.566 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.518 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.66 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.719 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 mttm . . . . . 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.472 0.177 . . . . 0.0 110.95 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.495 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' SER . . . . . 0.528 ' O ' HG21 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.53 ' CE2' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.562 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.666 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . 0.46 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.666 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.486 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.463 ' O ' HG23 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.696 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.616 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.401 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.3 OUTLIER -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.523 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.623 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . 0.582 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.53 ' HB2' ' CE2' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.583 ' O ' ' CG ' ' A' ' 35' ' ' HIS . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.515 ' OD2' ' CG2' ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.426 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.515 ' CG2' ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.524 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' CD2' ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.578 ' CZ ' HG23 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.548 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.582 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.453 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLU . . . . . 0.533 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.585 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.59 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.59 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.453 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.501 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PHE . . . . . 0.657 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.616 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.537 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.454 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.657 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.464 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.549 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 7.2 m120 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.705 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.548 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . 0.589 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' HA ' ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.567 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.459 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.705 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.558 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . 0.571 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.666 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.529 ' N ' HG11 ' A' ' 95' ' ' VAL . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.696 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.7 mttm . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.51 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.526 0.679 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 83' ' ' LEU . 34.1 t0 -115.92 47.25 0.53 Allowed Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.437 -0.79 . . . . 0.0 111.667 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.54 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.542 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.503 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.536 ' HB3' ' CG1' ' A' ' 26' ' ' ILE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.657 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.657 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.464 ' C ' HG13 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.644 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.471 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.463 ' N ' HG21 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.715 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.704 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.527 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.527 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.626 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.542 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.559 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.559 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.443 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.527 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.469 ' O ' HD23 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.527 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.589 ' CG2' HD21 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.468 HG21 ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.641 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.539 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.539 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.476 HG11 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.633 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.621 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.461 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.565 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.421 ' C ' HG11 ' A' ' 67' ' ' VAL . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.654 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.621 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.641 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.704 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.527 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.468 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.633 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.408 HG11 ' O ' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.585 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.462 ' O ' ' N ' ' A' ' 46' ' ' THR . 3.8 m120 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.62 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.53 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.59 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.53 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.558 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.591 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.62 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.545 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.538 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.644 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.715 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.63 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.55 -173.34 0.34 Allowed Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.63 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 27.9 Cg_endo -69.09 91.06 0.45 Allowed 'Trans proline' 0 C--N 1.32 -0.931 0 C-N-CA 121.246 1.297 . . . . 0.0 110.507 -177.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.655 ' HB2' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.302 -1.487 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.485 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.524 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.655 0.741 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.56 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 39.7 t0 -114.01 45.95 0.35 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.552 -0.717 . . . . 0.0 112.099 -178.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.56 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.516 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.419 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.598 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.549 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.486 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.696 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.696 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.634 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.558 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.502 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.719 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.572 ' CD2' ' HB3' ' A' ' 100' ' ' ALA . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.616 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.532 HG12 ' CB ' ' A' ' 8' ' ' ALA . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.526 ' O ' ' HA ' ' A' ' 35' ' ' HIS . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.524 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.436 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.619 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.574 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.578 ' HB3' ' CE2' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.557 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.53 HG23 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.492 ' CG2' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.65 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 73' ' ' GLU . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.537 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.537 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.639 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.639 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.593 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.503 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.499 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.619 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.578 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.658 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.593 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.65 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.462 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.547 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.424 ' OD1' ' C ' ' A' ' 76' ' ' ASP . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.609 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.462 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.574 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.472 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.723 ' HB3' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.557 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.598 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.621 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.555 HG22 ' CG ' ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.46 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.723 ' CD2' ' HB3' ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.562 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.634 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.719 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.594 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -122.89 -63.84 0.03 OUTLIER Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.594 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.8 Cg_endo -75.63 85.71 1.57 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 C-N-CA 121.573 1.515 . . . . 0.0 112.745 -177.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.572 ' HB3' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.516 ' C ' ' CD ' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.542 0.687 . . . . 0.0 109.562 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.566 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 15.5 t0 -113.76 42.79 0.26 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.472 -0.767 . . . . 0.0 111.58 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.566 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.454 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.496 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.552 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.553 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.672 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.672 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.462 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.678 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.497 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.463 ' N ' ' O ' ' A' ' 15' ' ' GLY . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.728 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.464 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.614 ' CD1' HG23 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.63 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' C ' HG22 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.436 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.462 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 20.3 m80 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.553 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' A' ' 37' ' ' THR . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.471 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.54 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.614 HG23 ' CD1' ' A' ' 26' ' ' ILE . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.486 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.626 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.488 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.582 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.616 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.523 ' CE ' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.405 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.622 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.616 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.512 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.581 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.645 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 5.9 m120 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.697 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.54 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.592 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.697 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.522 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.553 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.678 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.454 HG21 ' N ' ' A' ' 97' ' ' VAL . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.66 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.5 mttt -95.69 -170.7 0.23 Allowed Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.66 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 28.4 Cg_endo -69.04 86.92 0.47 Allowed 'Trans proline' 0 C--N 1.322 -0.818 0 C-N-CA 121.322 1.348 . . . . 0.0 110.253 -178.421 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.728 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.571 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.509 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.51 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.574 0.702 . . . . 0.0 109.812 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.562 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 -122.54 52.26 3.92 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.693 -0.629 . . . . 0.0 110.931 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.562 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 88' ' ' VAL . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.55 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.51 ' HB3' HG12 ' A' ' 26' ' ' ILE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 9' ' ' GLU . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.551 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.686 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.686 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.436 ' C ' HG13 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.659 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.467 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 15' ' ' GLY . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.695 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.743 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' NE2' ' O ' ' A' ' 15' ' ' GLY . 16.2 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.472 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.604 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.576 HG23 ' CZ ' ' A' ' 43' ' ' PHE . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.616 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.509 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.57 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' C ' HG22 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.459 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.616 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 59.2 m80 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.559 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.654 ' CD2' ' CE1' ' A' ' 65' ' ' TYR . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.552 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.575 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.632 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.488 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.428 HG13 HG23 ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.609 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.609 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.615 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.421 ' C ' HG21 ' A' ' 58' ' ' VAL . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.421 HG21 ' C ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.495 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.558 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.421 ' C ' HG11 ' A' ' 67' ' ' VAL . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.615 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.632 ' CD1' HG22 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.472 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.471 ' O ' ' O ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.506 ' CB ' ' HA ' ' A' ' 99' ' ' PRO . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.488 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.577 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.642 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.622 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.552 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.593 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.588 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.599 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CE2' ' CG2' ' A' ' 79' ' ' ILE . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.546 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.564 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.659 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.695 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.592 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -95.18 -175.35 0.46 Allowed Pre-proline 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.592 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 28.0 Cg_endo -68.67 86.37 0.45 Allowed 'Trans proline' 0 C--N 1.318 -1.042 0 C-N-CA 121.122 1.215 . . . . 0.0 109.749 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.743 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.392 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.343 -179.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.513 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.653 0.74 . . . . 0.0 109.609 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.569 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 -122.01 51.0 2.72 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.638 -0.664 . . . . 0.0 110.511 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.598 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.561 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.673 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.673 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.436 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.654 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.473 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.472 ' O ' HG23 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.701 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.624 ' CD2' ' HB3' ' A' ' 100' ' ' ALA . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.606 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 64' ' ' THR . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.52 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.584 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.584 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HB3' HG22 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.461 HG22 ' HB3' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.581 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.542 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 37' ' ' THR . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.568 ' CD2' HD21 ' A' ' 83' ' ' LEU . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.571 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.514 HG23 ' CD1' ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.479 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.634 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.531 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.403 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.562 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.562 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.601 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.601 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.616 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.472 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.462 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.581 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.524 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.656 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.616 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.634 ' CD1' HG22 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.507 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.46 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.624 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.643 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.494 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.676 ' HB3' ' CD2' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.571 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.624 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.553 HG22 ' CD1' ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.446 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.676 ' CD2' ' HB3' ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.513 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.567 ' H ' ' C ' ' A' ' 91' ' ' PHE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.654 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.701 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.591 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -94.47 179.31 1.24 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.591 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 27.1 Cg_endo -65.96 81.05 0.27 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.682 1.588 . . . . 0.0 110.843 -178.098 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.624 ' HB3' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.615 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.508 ' C ' ' CD ' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.503 0.668 . . . . 0.0 109.695 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.567 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 24.4 t0 -115.26 44.93 0.38 Allowed Pre-proline 0 C--N 1.3 -1.554 0 O-C-N 121.562 -0.711 . . . . 0.0 111.651 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.506 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.521 ' CB ' HG22 ' A' ' 26' ' ' ILE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.562 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.66 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.449 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.676 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.52 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.439 ' C ' HG23 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.571 ' CE1' ' CB ' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.425 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.602 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.587 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB3' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.518 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' O ' HG22 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.595 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.546 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.468 ' OD2' ' O ' ' A' ' 35' ' ' HIS . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.578 ' CE2' ' HB3' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.587 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.463 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.54 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.54 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.576 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.624 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.485 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.595 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.453 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.624 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.621 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.466 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.61 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.628 ' CG2' ' CE1' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.487 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.4 m120 -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.657 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.561 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.503 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.578 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 10.8 m120 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.596 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.657 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.524 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.547 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.533 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.676 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.516 ' N ' HG11 ' A' ' 95' ' ' VAL . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.586 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -120.2 -67.53 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.586 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.4 Cg_endo -73.13 78.63 2.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.656 1.571 . . . . 0.0 111.708 -178.437 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.571 ' CB ' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.925 . . . . 0.0 109.749 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.523 ' C ' ' CD ' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.556 0.693 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.593 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 22.6 t0 -113.73 41.08 0.24 Allowed Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.479 -0.763 . . . . 0.0 111.65 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.509 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.539 ' HB2' ' CZ ' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.535 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.651 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.651 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.423 ' C ' HG12 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.518 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.489 ' N ' ' O ' ' A' ' 15' ' ' GLY . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.711 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.475 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 3.7 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.62 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.644 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.625 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.458 ' O ' HG22 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.622 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.644 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.535 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.561 ' CG2' HD21 ' A' ' 81' ' ' LEU . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.46 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.536 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.536 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.463 HG13 HG22 ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.649 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.649 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.615 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.468 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.519 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.622 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.615 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.468 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.57 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.471 ' O ' ' HB1' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.529 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.602 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.586 ' HB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.489 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 91' ' ' PHE . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.535 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.592 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.567 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.605 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.62 ' CE2' ' HB2' ' A' ' 81' ' ' LEU . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.515 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.667 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.711 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.599 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.5 OUTLIER -125.89 -65.61 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.599 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.21 73.35 3.86 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 121.566 1.511 . . . . 0.0 111.791 -178.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.471 ' HB1' ' O ' ' A' ' 73' ' ' GLU . . . . . . . . 0 N--CA 1.492 1.628 0 O-C-N 121.13 -0.981 . . . . 0.0 109.341 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.502 ' HB2' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.591 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 -116.1 43.36 0.37 Allowed Pre-proline 0 C--N 1.3 -1.568 0 O-C-N 121.439 -0.788 . . . . 0.0 111.699 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.494 ' O ' HG23 ' A' ' 88' ' ' VAL . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' CB ' HD11 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.56 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.491 ' C ' HG12 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.554 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.486 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.716 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.57 ' CE1' ' CB ' ' A' ' 100' ' ' ALA . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.433 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.534 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.601 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.6 HG23 ' CZ ' ' A' ' 43' ' ' PHE . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.574 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.562 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.562 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' O ' HG22 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.466 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 33' ' ' GLY . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.574 ' ND1' ' O ' ' A' ' 28' ' ' ALA . 2.1 m-70 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.539 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.635 ' CD2' ' CE1' ' A' ' 65' ' ' TYR . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.554 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.592 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.62 HG23 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.462 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.544 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.544 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.583 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.622 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.468 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.559 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.664 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.622 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.62 ' CD1' HG23 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.471 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.529 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.408 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.603 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.544 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.635 ' O ' ' HA ' ' A' ' 87' ' ' ASN . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.554 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.601 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.523 ' O ' ' CG2' ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.635 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.586 ' CG2' ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.538 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.573 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.527 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.667 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.52 ' N ' HG11 ' A' ' 95' ' ' VAL . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.716 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.593 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -118.78 -65.69 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.593 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.9 Cg_endo -74.07 80.66 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 C-N-CA 121.604 1.536 . . . . 0.0 111.732 -178.081 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.57 ' CB ' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.171 -0.955 . . . . 0.0 109.831 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.433 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.391 0.615 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.619 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 45.16 51.8 9.54 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.434 -0.791 . . . . 0.0 110.288 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.434 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.499 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.552 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.551 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.499 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.682 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.682 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.669 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.522 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.457 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.735 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.612 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.551 ' CD1' HG23 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.629 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' C ' HG21 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.463 HG21 ' C ' ' A' ' 32' ' ' ASP . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.629 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 7.2 m80 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.623 ' CZ ' ' CB ' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.717 ' CE2' HD22 ' A' ' 81' ' ' LEU . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.561 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.551 HG23 ' CD1' ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.478 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.642 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.56 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.56 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.584 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.584 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.618 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.41 ' C ' HG11 ' A' ' 67' ' ' VAL . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.618 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.642 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.524 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.445 ' HB3' ' HA ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.509 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.589 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.76 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.497 ' N ' HG13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.717 HD22 ' CE2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.561 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.574 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.453 ' HA ' HG21 ' A' ' 82' ' ' THR . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.615 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.76 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.511 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.481 HG21 ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.669 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.458 ' N ' HG11 ' A' ' 95' ' ' VAL . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.735 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.599 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -124.41 -65.71 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.599 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.1 Cg_endo -74.71 71.96 4.61 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 121.564 1.51 . . . . 0.0 112.038 -178.065 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.471 ' HB3' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 120.97 -1.081 . . . . 0.0 108.648 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.51 ' HA ' ' OD2' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.804 0.812 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.605 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 41.89 53.89 8.09 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.605 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.536 ' O ' HG23 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.561 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.455 ' O ' ' HG3' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.574 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.685 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.685 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.448 ' C ' HG12 ' A' ' 95' ' ' VAL . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.628 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.537 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.483 ' C ' HG23 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.718 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.545 ' CE2' ' HB3' ' A' ' 100' ' ' ALA . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.435 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.609 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.515 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.52 ' CG1' ' HG2' ' A' ' 5' ' ' LYS . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.624 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' O ' HG22 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.426 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.591 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.624 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.496 ' O ' ' OG1' ' A' ' 37' ' ' THR . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.594 ' CZ ' HG23 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.527 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.406 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.644 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.54 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.549 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.549 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.649 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.649 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.612 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.591 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.486 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.666 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.612 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.644 ' CD1' HG22 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.462 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 98' ' ' LYS . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.515 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.587 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.449 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.56 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.535 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m120 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.702 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.527 ' OG1' HG11 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.583 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' HA ' ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.671 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.556 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.464 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.702 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.515 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.557 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.628 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.424 HG21 ' N ' ' A' ' 97' ' ' VAL . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.718 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.575 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.1 OUTLIER -125.37 -63.9 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.575 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.38 72.95 4.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 121.548 1.498 . . . . 0.0 112.041 -178.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.545 ' HB3' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.974 . . . . 0.0 109.452 178.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.474 ' O ' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.673 0.749 . . . . 0.0 109.485 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.605 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 43.53 53.09 9.45 Favored Pre-proline 0 C--N 1.3 -1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 110.564 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.605 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.541 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.51 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.544 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.671 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.671 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.476 ' C ' HG12 ' A' ' 95' ' ' VAL . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.663 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.488 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.45 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.696 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.681 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.605 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.578 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.628 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.541 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.469 ' O ' HG22 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.423 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.621 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.547 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.467 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.473 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.469 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.506 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.578 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.471 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.63 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.539 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.496 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.546 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.546 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.578 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.578 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.619 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.621 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.488 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.619 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.63 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.681 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.496 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.478 ' N ' ' OD1' ' A' ' 76' ' ' ASP . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.607 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.422 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.592 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.486 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.2 m120 -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.637 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.526 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.598 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.585 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.576 ' CG2' HD11 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.436 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.637 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.549 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.559 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.663 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.696 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.596 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.2 OUTLIER -94.88 -176.57 0.57 Allowed Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.596 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 26.7 Cg_endo -66.64 85.92 0.29 Allowed 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.315 1.343 . . . . 0.0 110.299 -178.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.65 ' HB2' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.556 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.29 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.528 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.601 0.715 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.541 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 -117.06 48.9 0.76 Allowed Pre-proline 0 C--N 1.3 -1.553 0 O-C-N 121.572 -0.705 . . . . 0.0 111.102 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.541 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.575 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.539 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.494 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.672 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.672 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.469 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.457 ' O ' HG23 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.709 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.725 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.534 HG21 ' CB ' ' A' ' 8' ' ' ALA . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.525 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' N ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.555 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.47 ' HB2' ' OD2' ' A' ' 30' ' ' ASP . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.606 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.572 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.53 ' O ' ' N ' ' A' ' 43' ' ' PHE . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.57 ' CE1' ' HB2' ' A' ' 83' ' ' LEU . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.537 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.532 HG23 ' CD1' ' A' ' 26' ' ' ILE . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.507 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.67 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.553 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.522 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.492 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.492 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.574 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.614 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.464 ' O ' ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.444 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.455 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.606 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.465 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.653 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.614 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.67 ' CD1' HG22 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.411 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.522 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.461 ' CG1' ' OE1' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.735 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.51 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.669 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.574 ' CG2' ' ND2' ' A' ' 87' ' ' ASN . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.494 ' O ' ' CG2' ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.735 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.525 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.675 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.465 ' N ' HG11 ' A' ' 95' ' ' VAL . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.709 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.652 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -95.02 -170.81 0.23 Allowed Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.652 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 29.2 Cg_endo -69.42 88.79 0.49 Allowed 'Trans proline' 0 C--N 1.321 -0.906 0 C-N-CA 121.135 1.223 . . . . 0.0 110.376 -178.294 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.725 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.408 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.519 ' HB1' ' NH2' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.652 0.739 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.627 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 47.85 51.38 10.5 Favored Pre-proline 0 C--N 1.299 -1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 110.777 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.627 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.525 ' HG2' ' CG1' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.534 ' O ' HG23 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.528 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.518 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.546 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.656 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.525 ' N ' HD22 ' A' ' 13' ' ' LEU . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.648 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.51 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.443 ' C ' HG23 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.72 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.565 ' CD1' ' HB3' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.549 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.627 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.441 ' C ' HG22 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.441 HG22 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.573 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.566 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.507 ' HA ' ' CD ' ' A' ' 36' ' ' ARG . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.627 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.549 HG23 ' CD1' ' A' ' 26' ' ' ILE . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.485 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.531 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.531 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.572 ' N ' ' CD ' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.572 ' CD ' ' N ' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.625 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.573 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.625 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.621 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.469 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.527 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.605 ' CE2' ' HA2' ' A' ' 15' ' ' GLY . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.583 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.8 m120 -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.642 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.536 ' CG2' ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.594 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.536 ' O ' ' CG2' ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.576 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 4.0 t-20 -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.642 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.575 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.648 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.562 ' N ' HG11 ' A' ' 95' ' ' VAL . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.72 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.586 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 3.0 mtmt -121.41 -64.35 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.586 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.7 Cg_endo -74.83 76.69 3.25 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 121.495 1.464 . . . . 0.0 111.596 -178.075 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.565 ' HB3' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 110.026 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.502 ' HB2' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.527 0.68 . . . . 0.0 109.624 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.579 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 33.3 t0 -116.09 44.43 0.41 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.807 . . . . 0.0 111.822 -179.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.579 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.462 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 88' ' ' VAL . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.592 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.558 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.681 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.681 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.468 ' C ' HG12 ' A' ' 95' ' ' VAL . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.662 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.503 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.455 ' C ' HG23 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.709 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.624 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.505 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.663 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.643 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' O ' ' ND1' ' A' ' 35' ' ' HIS . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' O ' HG22 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.442 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.62 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.529 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.487 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.463 ' O ' HD23 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.643 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.543 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.598 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.419 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.651 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.548 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.573 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.573 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.696 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.696 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.627 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.434 ' O ' ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.437 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.627 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.668 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.467 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.434 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.6 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.595 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.3 m120 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.651 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.543 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.596 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.517 ' O ' ' HA ' ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.64 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.554 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.651 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.513 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.552 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.662 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.709 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.663 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.76 -175.42 0.47 Allowed Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.663 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 27.1 Cg_endo -66.42 84.62 0.28 Allowed 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.565 1.51 . . . . 0.0 110.904 -177.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.619 ' HB2' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.301 -1.526 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.505 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.511 ' HA ' ' OD2' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.766 0.793 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.614 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 44.01 52.77 9.65 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.191 -0.943 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.614 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.418 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.56 ' HB2' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.454 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.548 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.68 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 12' ' ' GLY . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.656 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.471 ' C ' HG21 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.508 ' N ' ' O ' ' A' ' 15' ' ' GLY . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.712 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.443 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.617 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.601 ' O ' ' CG ' ' A' ' 35' ' ' HIS . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.552 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.571 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.475 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.475 HG22 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.614 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.465 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.617 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.535 HG11 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.616 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.649 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.53 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.553 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.553 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.49 HG22 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.678 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.678 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.608 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.46 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.614 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.539 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.657 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.608 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.665 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.49 ' HG3' HG22 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.455 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.626 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.615 ' HB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.645 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.535 ' OG1' HG11 ' A' ' 44' ' ' VAL . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.566 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' O ' ' CG2' ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.611 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 2.0 m-80 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.527 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.656 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.516 ' N ' HG11 ' A' ' 95' ' ' VAL . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.712 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.638 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 15.9 mttt -123.12 -66.74 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.638 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 36.8 Cg_endo -77.15 73.42 5.48 Favored 'Trans proline' 0 C--N 1.317 -1.126 0 C-N-CA 121.683 1.589 . . . . 0.0 112.468 -177.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.58 ' HB3' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.493 1.717 0 O-C-N 120.742 -1.224 . . . . 0.0 108.273 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.516 ' O ' ' CD1' ' A' ' 83' ' ' LEU . . . . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.485 0.66 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.593 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 47.84 56.98 18.01 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 110.48 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.593 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.5 ' O ' HG23 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.577 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.667 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.667 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.473 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.657 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.521 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.469 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.714 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.51 ' CE2' ' CB ' ' A' ' 100' ' ' ALA . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.609 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.611 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.651 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 35' ' ' HIS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.477 ' O ' HG22 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.438 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.511 ' O ' ' C ' ' A' ' 35' ' ' HIS . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.612 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.531 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.459 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.651 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.562 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.611 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.459 HG21 ' HE2' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.651 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.546 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.541 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.541 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.454 HG13 HG23 ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.644 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.644 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.61 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.605 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.658 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.61 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.651 ' CD1' HG22 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.47 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.471 ' O ' ' HB1' ' A' ' 100' ' ' ALA . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.49 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.409 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.584 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.424 HG11 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.722 ' CG1' ' CE2' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.712 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.562 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.571 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' CG2' ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.469 ' HA ' HG21 ' A' ' 82' ' ' THR . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.566 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.722 ' CE2' ' CG1' ' A' ' 79' ' ' ILE . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.509 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.572 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.657 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.714 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.559 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -123.1 -63.24 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.559 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.8 Cg_endo -75.5 72.96 4.77 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 C-N-CA 121.535 1.49 . . . . 0.0 112.345 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.51 ' CB ' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.053 -1.029 . . . . 0.0 109.221 178.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.515 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.442 0.639 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.558 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 36.0 t0 -116.68 47.12 0.59 Allowed Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.529 -0.732 . . . . 0.0 111.513 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.558 ' CD ' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.562 ' HB3' ' CG1' ' A' ' 26' ' ' ILE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.567 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.659 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.659 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.442 ' C ' HG12 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.518 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.455 ' C ' HG23 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.713 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.451 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.451 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.607 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.651 ' CG2' ' CZ ' ' A' ' 43' ' ' PHE . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.616 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.474 ' HB ' ' OD1' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.608 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.567 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.651 ' CZ ' ' CG2' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.531 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.576 ' CG2' HD21 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.446 HG21 ' HG2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.618 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.528 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.568 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.568 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.734 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.734 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.612 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.466 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.608 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.523 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.612 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.62 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.482 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.404 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.62 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.481 ' CG1' ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.623 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.1 m120 -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.605 ' O ' ' HA ' ' A' ' 87' ' ' ASN . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.531 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.592 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.513 ' O ' ' CG2' ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.605 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.572 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.623 ' CE2' ' CG2' ' A' ' 79' ' ' ILE . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.533 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.548 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.675 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.713 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.597 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 11.1 mttt -127.74 -65.76 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.597 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.4 Cg_endo -75.12 68.73 5.8 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.521 1.481 . . . . 0.0 111.78 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.494 ' HB3' ' HB2' ' A' ' 18' ' ' CYS . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 120.908 -1.12 . . . . 0.0 108.768 178.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.525 ' CB ' ' HD2' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.499 0.666 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.617 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 43.24 51.77 7.51 Favored Pre-proline 0 C--N 1.303 -1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 110.168 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.617 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.422 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.549 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.505 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.425 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.547 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.66 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.652 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.469 ' C ' HG23 ' A' ' 97' ' ' VAL . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.714 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.734 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.619 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.597 ' CD1' HG23 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.632 ' CB ' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.549 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.568 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.554 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.444 ' HB3' HG22 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 33' ' ' GLY . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.618 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 15.8 m80 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.568 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.632 ' CE2' ' CB ' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.544 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.597 HG23 ' CD1' ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.655 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.484 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.546 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.546 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.478 HG11 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.625 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.484 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.451 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.451 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.618 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.625 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.655 ' CD1' HG22 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.484 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.45 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.487 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.454 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.6 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.662 ' CG2' ' CE2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.498 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.668 ' HB2' ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.544 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.588 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.508 ' O ' HG23 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.576 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.59 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.668 ' CE2' ' HB2' ' A' ' 81' ' ' LEU . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.523 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.561 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.652 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.714 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.647 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -94.81 -171.19 0.24 Allowed Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.647 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 29.1 Cg_endo -70.11 89.33 0.56 Allowed 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 121.205 1.27 . . . . 0.0 110.629 -178.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.734 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.452 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.88 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.47 ' O ' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.693 0.758 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.619 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 49.95 48.18 5.7 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.462 -0.774 . . . . 0.0 110.378 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.619 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.5 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' CB ' HG21 ' A' ' 26' ' ' ILE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.454 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.571 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.652 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.652 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.66 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.498 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' ' O ' ' A' ' 15' ' ' GLY . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.719 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.578 ' CD2' ' HB3' ' A' ' 100' ' ' ALA . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.494 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.603 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.54 HG21 ' CB ' ' A' ' 8' ' ' ALA . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.444 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.615 ' O ' ' CD2' ' A' ' 35' ' ' HIS . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.529 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.465 ' C ' HG21 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.465 HG21 ' C ' ' A' ' 32' ' ' ASP . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.628 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.2 m80 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.562 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.509 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.598 ' CD2' ' CD1' ' A' ' 65' ' ' TYR . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.577 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.548 ' CG2' HD21 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.637 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HB2' ' OE2' ' A' ' 73' ' ' GLU . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.53 ' CB ' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.614 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.614 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.611 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.41 ' ND2' ' OD2' ' A' ' 66' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.628 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.67 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.611 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.637 ' CD1' HG22 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.471 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.532 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.48 ' N ' ' OD1' ' A' ' 76' ' ' ASP . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.594 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.587 ' N ' ' CD1' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.494 ' O ' ' N ' ' A' ' 46' ' ' THR . 5.1 m120 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.657 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.577 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.584 HD13 ' HB3' ' A' ' 2' ' ' ASP . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.541 ' O ' ' CG2' ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.521 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.657 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.566 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.518 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.66 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.719 HG12 ' N ' ' A' ' 18' ' ' CYS . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.581 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 1.6 mttm -124.87 -63.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.581 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.9 Cg_endo -75.02 82.29 2.04 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 121.616 1.544 . . . . 0.0 112.012 -177.61 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.578 ' HB3' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.324 -0.86 . . . . 0.0 108.83 178.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.533 ' O ' ' CD1' ' A' ' 83' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.398 0.618 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 53.28 48.25 4.91 Favored Pre-proline 0 C--N 1.299 -1.59 0 O-C-N 121.651 -0.656 . . . . 0.0 110.95 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.495 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.528 ' O ' HG21 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.53 ' CE2' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.562 ' HB1' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.53 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.666 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . 0.46 ' C ' HG13 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.666 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.486 ' N ' HG21 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.463 ' O ' HG23 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.696 ' N ' HG12 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.627 ' CE2' ' HB2' ' A' ' 100' ' ' ALA . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.401 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.3 OUTLIER -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.523 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.623 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.582 ' CD1' ' CG2' ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.53 ' HB2' ' CE2' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.583 ' O ' ' CG ' ' A' ' 35' ' ' HIS . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.516 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.515 ' OD2' ' CG2' ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.426 ' C ' HG21 ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.515 ' CG2' ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.524 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' O ' ' CD2' ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.578 ' CZ ' HG23 ' A' ' 26' ' ' ILE . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.548 ' CG1' ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.582 ' CG2' ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.453 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.621 HG22 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.533 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.445 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.585 ' CB ' ' CD ' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.59 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.59 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.471 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.453 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.501 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . 0.657 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.616 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.537 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.454 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.657 ' CD2' ' HZ ' ' A' ' 69' ' ' PHE . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.464 HG11 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.549 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 7.2 m120 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.705 ' HB3' ' CG ' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.548 ' OG1' ' CG1' ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . 0.589 ' O ' ' CB ' ' A' ' 84' ' ' ASP . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.524 ' O ' ' HA ' ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.567 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.459 ' O ' HD13 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.705 ' CG ' ' HB3' ' A' ' 81' ' ' LEU . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.558 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . 0.571 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.666 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.529 ' N ' HG11 ' A' ' 95' ' ' VAL . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.696 HG12 ' N ' ' A' ' 18' ' ' CYS . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.634 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.7 mttm -93.89 -172.67 0.31 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.634 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 28.5 Cg_endo -68.4 95.82 0.46 Allowed 'Trans proline' 0 C--N 1.322 -0.835 0 C-N-CA 121.367 1.378 . . . . 0.0 111.114 -177.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.627 ' HB2' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.18 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.713 ' HB3' HD12 ' A' ' 83' ' ' LEU . 34.1 t0 . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.551 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.486 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 1.006 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.601 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.983 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.576 ' C ' HG11 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.664 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.681 ' N ' HG22 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.783 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.684 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.539 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.932 HD13 HG21 ' A' ' 45' ' ' VAL . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.087 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.551 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.546 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.404 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.709 ' CD ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.581 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.087 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.998 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.061 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.566 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.468 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.967 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.967 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.534 HG12 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.672 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.672 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.454 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.625 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.676 HG13 HD11 ' A' ' 26' ' ' ILE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.635 ' O ' HG11 ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.684 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.511 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.513 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.78 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.662 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 46' ' ' THR . 4.2 m-80 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.061 HD23 HG22 ' A' ' 45' ' ' VAL . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.998 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.713 HD12 ' HB3' ' A' ' 2' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.568 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.811 ' CG2' HD12 ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.006 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.598 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.517 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.664 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.783 HG11 ' SG ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.663 ' HB3' HD12 ' A' ' 83' ' ' LEU . 39.7 t0 . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.631 ' O ' HG22 ' A' ' 88' ' ' VAL . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.992 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.992 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.772 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.42 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.722 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.602 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.956 ' CD1' HG21 ' A' ' 45' ' ' VAL . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.898 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.63 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.64 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.606 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.539 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.898 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.049 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.956 HG21 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.802 HG23 ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.686 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.57 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.024 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.024 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 53' ' ' VAL . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.715 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.715 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.649 HG11 ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.802 ' SD ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.488 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.64 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.873 HG11 HG11 ' A' ' 45' ' ' VAL . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.649 ' O ' HG11 ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.686 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.478 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.582 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.949 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.679 ' C ' HD13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.778 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.522 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.122 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.049 ' OG1' HG13 ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.835 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.461 ' C ' HG22 ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.632 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 1.033 HG21 HD21 ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.122 ' CE1' HD23 ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.628 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.541 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.866 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.949 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.429 ' O ' ' HB2' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.598 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 15.5 t0 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.598 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.942 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.599 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.501 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.998 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.998 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.711 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.705 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.507 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.971 HD12 HG21 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.032 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.593 ' O ' HG23 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.645 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 24.3 m-70 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.676 ' NE ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.446 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.577 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.032 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.002 HG22 HD23 ' A' ' 81' ' ' LEU . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.66 HG12 HG23 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.539 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.936 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.936 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.6 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.6 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.655 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.558 ' O ' ' HE2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.426 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.645 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.655 ' O ' HG11 ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.426 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.536 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.55 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.816 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.504 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.793 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.513 ' O ' ' N ' ' A' ' 46' ' ' THR . 6.3 m-80 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.002 HD23 HG22 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.756 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.612 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.718 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.942 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.603 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.793 ' O ' HD12 ' A' ' 79' ' ' ILE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.521 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.842 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.816 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.5 mttt . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.594 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.677 0.275 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.565 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.963 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.598 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 1.002 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.002 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.503 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.684 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.5 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.628 ' N ' HG22 ' A' ' 97' ' ' VAL . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.756 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.563 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.628 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.893 HG23 ' HB2' ' A' ' 8' ' ' ALA . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.62 ' HB3' ' HE1' ' A' ' 35' ' ' HIS . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG23 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.62 ' HE1' ' HB3' ' A' ' 27' ' ' HIS . 48.2 m-70 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.581 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.1 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.659 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.533 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.975 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.975 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.704 HG12 ' CG2' ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.629 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.629 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.704 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.505 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.57 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.425 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.731 ' OH ' HG21 ' A' ' 97' ' ' VAL . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.673 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.693 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.1 HD23 HG22 ' A' ' 45' ' ' VAL . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.047 ' OG1' HG13 ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.85 ' O ' HG22 ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.601 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.5 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.771 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.963 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.584 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.537 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.684 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.756 HG11 ' SG ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.627 ' HB3' HD12 ' A' ' 83' ' ' LEU . 24.4 t0 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 120.71 0.29 . . . . 0.0 110.511 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.601 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.775 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.615 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.971 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.971 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.523 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.681 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.525 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.601 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.73 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.605 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.619 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.989 HD12 HG21 ' A' ' 45' ' ' VAL . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.6 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.6 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.501 ' C ' HG23 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.604 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.558 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.503 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.862 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.06 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.989 HG21 HD12 ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.543 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.658 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.532 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.425 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.64 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.64 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.4 t-20 -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.604 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.867 HG11 HG11 ' A' ' 45' ' ' VAL . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.646 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.658 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.605 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.507 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.81 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.748 HG22 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.543 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.112 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.06 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.805 ' O ' HG22 ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.957 HG21 HD21 ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.613 ' N ' HG12 ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.112 ' CE1' HD23 ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.679 ' O ' HD12 ' A' ' 79' ' ' ILE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.574 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.681 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.518 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.81 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.59 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.59 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.958 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.613 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.926 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.581 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.579 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.645 ' N ' HG22 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.716 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.536 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.42 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.979 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.535 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.613 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' PHE . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.525 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.979 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.037 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.056 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.516 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.646 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.51 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.61 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.632 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.48 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD2' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.613 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.817 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.926 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 0.9 OUTLIER -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.056 HD23 HG22 ' A' ' 45' ' ' VAL . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.037 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.79 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.591 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 12.9 m-80 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.758 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.958 ' CE2' ' HB3' ' A' ' 8' ' ' ALA . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.65 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 98' ' ' LYS . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.817 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.493 ' HD2' ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.622 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 22.6 t0 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 111.65 0.241 . . . . 0.0 111.65 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.622 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.483 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.977 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.949 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.949 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.425 ' C ' HG11 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.694 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.596 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.632 ' N ' HG22 ' A' ' 97' ' ' VAL . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.537 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.481 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 12.8 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.613 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.109 HD13 HG21 ' A' ' 45' ' ' VAL . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.11 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.554 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.11 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.953 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.109 HG21 HD13 ' A' ' 26' ' ' ILE . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.674 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.504 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.62 HG12 ' CG2' ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.681 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.681 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.63 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.674 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.537 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.47 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.565 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.835 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.611 HD13 HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 46' ' ' THR . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.992 HD23 HG22 ' A' ' 45' ' ' VAL . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.953 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.581 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.75 ' CG2' HD12 ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.977 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.51 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.835 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.621 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.485 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.827 ' HB2' HD13 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.63 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.465 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.709 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.713 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.45 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.546 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.608 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.106 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.924 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.579 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.579 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.508 ' C ' HG23 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.763 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 41.0 m170 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.724 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.924 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.084 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.106 HG21 ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.534 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.666 HD11 HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.511 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.988 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.988 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.497 HG12 HG22 ' A' ' 56' ' ' VAL . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.593 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.593 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.653 HG11 ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.456 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.587 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.681 HG11 HG11 ' A' ' 45' ' ' VAL . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.653 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.635 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.487 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.566 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.841 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.424 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.563 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.097 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.084 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.73 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.866 ' O ' HG22 ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.642 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.876 HG23 ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.684 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.841 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.647 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 . . . . . 0 N--CA 1.486 1.331 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.647 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.449 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.874 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.589 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.995 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.995 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.699 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.628 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.701 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.617 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.968 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.007 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.468 ' C ' HG23 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.628 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.637 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.9 m-70 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 1.007 ' CZ ' ' HB3' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.807 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.056 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.968 HG21 HD12 ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.536 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.9 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.573 ' O ' HG12 ' A' ' 53' ' ' VAL . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.692 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.637 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.734 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.692 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.671 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.91 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.9 HD12 HD11 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.92 HD23 HG22 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.056 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.973 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.818 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.874 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.663 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.958 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.91 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.632 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.588 0.232 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.632 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.506 ' O ' HG22 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.516 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.971 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.638 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.981 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.981 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.661 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.683 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.501 ' N ' HG22 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.682 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.443 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.128 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.529 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.654 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.571 ' O ' HG23 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.699 ' C ' HG23 ' A' ' 37' ' ' THR . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.699 HG23 ' C ' ' A' ' 36' ' ' ARG . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.8 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.128 HG21 ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.448 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.644 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.983 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.983 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.478 HG12 ' CG2' ' A' ' 56' ' ' VAL . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.716 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.716 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.626 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 45' ' ' VAL . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.626 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.478 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.542 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.925 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.644 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.707 HD13 HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m-80 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.047 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.8 ' OG1' HG13 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.755 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.61 HG23 ' CD2' ' A' ' 81' ' ' LEU . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.584 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.971 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.642 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.532 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.84 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.925 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.625 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.564 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.937 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.969 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.969 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.526 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.682 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.773 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.623 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.898 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.081 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.559 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.643 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.55 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.081 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.907 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.015 HG22 HD23 ' A' ' 81' ' ' LEU . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.66 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.583 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.545 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.448 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.643 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.51 HG22 ' HA ' ' A' ' 27' ' ' HIS . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.669 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.66 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.656 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.527 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.545 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.858 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.583 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.607 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.8 OUTLIER -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.015 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.93 HG22 ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.76 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.93 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.649 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.526 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.592 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.771 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.858 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.578 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 120.501 0.191 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.578 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 1.02 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.584 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.986 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.986 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.409 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.707 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.612 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.72 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 17' ' ' GLU . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.958 HD12 HG21 ' A' ' 45' ' ' VAL . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.74 ' HB2' ' CE1' ' A' ' 43' ' ' PHE . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.544 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.662 ' HB3' ' HB3' ' A' ' 28' ' ' ALA . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.57 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.55 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.74 ' CE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.053 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 67' ' ' VAL . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.557 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.891 ' CG1' HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.743 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.546 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.904 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.904 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.604 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.557 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.458 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.458 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.625 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.699 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.654 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.546 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.8 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.743 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.891 HD12 ' CG1' ' A' ' 47' ' ' ILE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.523 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.01 HD23 HG22 ' A' ' 45' ' ' VAL . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.053 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.915 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.911 ' O ' HG22 ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.02 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.599 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.514 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.903 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.8 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.656 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 120.557 0.218 . . . . 0.0 110.777 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.516 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.534 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.985 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.597 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.744 ' O ' HG11 ' A' ' 95' ' ' VAL . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.534 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.586 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.611 ' N ' HG22 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.727 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.548 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.86 HG23 ' HB2' ' A' ' 8' ' ' ALA . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.097 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.565 ' C ' HG23 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.565 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.589 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.597 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 43' ' ' PHE . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.586 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.097 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.877 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.127 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.649 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.534 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.953 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.953 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.544 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.594 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.594 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.629 HG11 ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.629 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.649 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.469 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.569 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.789 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.732 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.757 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 1.0 OUTLIER -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.127 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.963 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.702 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.963 ' O ' HG22 ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.723 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.1 OUTLIER -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.985 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.664 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.533 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 13' ' ' LEU . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.789 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.718 ' HB3' HD12 ' A' ' 83' ' ' LEU . 33.3 t0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.822 0.304 . . . . 0.0 111.822 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.51 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.807 ' HB2' ' CD1' ' A' ' 81' ' ' LEU . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.607 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.692 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.605 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.539 ' N ' HG22 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.718 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.624 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.543 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.671 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.133 ' CD1' HG21 ' A' ' 45' ' ' VAL . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.992 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.642 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.533 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.528 ' O ' ' N ' ' A' ' 43' ' ' PHE . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.992 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.133 HG21 ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.45 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.708 HG12 HG23 ' A' ' 79' ' ' ILE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.654 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.737 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.737 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.43 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.642 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.648 ' O ' HG11 ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.69 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.567 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.504 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.887 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.701 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.712 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.2 m-80 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.852 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.766 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.576 ' O ' HG22 ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.656 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' CD2' ' A' ' 81' ' ' LEU . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.737 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.616 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.726 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.887 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.51 -0.181 . . . . 0.0 110.51 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.881 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.707 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.911 HD12 HD13 ' A' ' 79' ' ' ILE . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.664 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.73 ' HA3' HG12 ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.513 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.706 ' N ' HG22 ' A' ' 97' ' ' VAL . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.675 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.45 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.165 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.948 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.602 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.584 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.641 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.996 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.165 HG21 ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.689 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.563 ' O ' HG12 ' A' ' 78' ' ' VAL . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.745 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.745 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.645 HG11 ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.641 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.608 ' HB2' HD12 ' A' ' 26' ' ' ILE . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.66 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.645 ' O ' HG11 ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.689 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.469 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.555 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.672 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.911 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.996 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.97 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.802 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.97 ' O ' HG22 ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.627 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 6.7 m120 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.64 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.59 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.881 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.666 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.73 HG12 ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.706 HG22 ' N ' ' A' ' 17' ' ' GLU . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.9 mttt . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.606 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.725 0.298 . . . . 0.0 110.48 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.606 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.413 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.501 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 1.019 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.616 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.626 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.588 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.697 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.455 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.597 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.093 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.098 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.547 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.637 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.474 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.511 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.162 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.095 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.093 HG21 ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.525 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.861 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.7 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.989 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.989 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.688 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.673 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.673 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.688 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.525 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.522 HG22 ' HA ' ' A' ' 27' ' ' HIS . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.722 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.652 ' O ' HG11 ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.491 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.461 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.522 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.874 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.7 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.861 HD12 HD11 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.162 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.095 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.934 ' O ' HG22 ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.568 HG23 ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.019 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.637 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.551 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.927 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.874 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.595 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 36.0 t0 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 111.513 0.19 . . . . 0.0 111.513 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.912 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.635 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.529 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.973 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.973 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.422 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.703 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.594 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.717 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.462 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.592 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.72 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.977 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.084 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.492 ' CG ' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.492 HG23 ' CG ' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.569 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.084 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.011 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.72 HD12 ' HZ ' ' A' ' 24' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.977 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.977 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.799 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.799 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.654 HG11 ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.453 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.63 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.654 ' O ' HG11 ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.647 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.505 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.513 ' HB1' ' HA ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.898 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.631 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 0.7 OUTLIER -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.011 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.996 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.736 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.91 ' O ' HG22 ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.62 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.632 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.486 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.912 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.62 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.53 ' HG2' ' N ' ' A' ' 94' ' ' THR . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.703 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.898 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.513 ' HA ' ' HB1' ' A' ' 74' ' ' ALA . 11.1 mttt . . . . . 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.643 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.643 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.573 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.978 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.44 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.961 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.961 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.687 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.718 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.709 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.571 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.044 HD12 HG21 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 1.071 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.573 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.587 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.574 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.43 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.639 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 30.0 m-70 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.587 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.544 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 1.071 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.965 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.044 HG21 HD12 ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG12 HG23 ' A' ' 79' ' ' ILE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.528 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.02 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.02 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.488 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.62 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.47 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.473 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.473 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.639 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.68 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.463 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.491 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.539 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.912 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.442 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.817 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.508 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.981 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.965 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.718 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.59 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.624 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.978 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.626 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.817 ' O ' HD12 ' A' ' 79' ' ' ILE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.907 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.912 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.652 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.476 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.967 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.452 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.624 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.972 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.496 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.689 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.585 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.502 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.616 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.695 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.459 ' HB3' ' HE1' ' A' ' 35' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.84 ' HB2' ' HE1' ' A' ' 43' ' ' PHE . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.469 ' C ' HG23 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.649 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.7 m-70 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.58 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.84 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.061 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.083 HG22 HD23 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.673 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.497 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.98 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.98 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.436 HG22 ' H ' ' A' ' 53' ' ' VAL . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.685 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.685 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.469 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.42 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.649 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 45' ' ' VAL . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.633 ' O ' HG11 ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.497 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.477 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.798 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.68 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.783 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 5.1 m-80 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 1.083 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.061 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.958 ' O ' HG22 ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.527 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.741 ' CG2' HD12 ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.967 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.569 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.539 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.575 HG23 ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.739 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.798 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 mttm . . . . . 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ASP . . . . . 0.66 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.472 0.177 . . . . 0.0 110.95 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.66 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.425 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 6' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.954 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.645 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.686 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.624 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.729 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.607 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.42 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 2.7 tt0 -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.529 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 1.142 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.916 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.57 ' OD2' HG21 ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.411 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG21 ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.632 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.523 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.74 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.916 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 1.142 HG21 ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.647 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLU . . . . . 0.549 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.492 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 56' ' ' VAL . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.627 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.627 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.447 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.632 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PHE . . . . . 0.68 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.452 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.762 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.549 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 1.096 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.546 ' O ' ' N ' ' A' ' 46' ' ' THR . 8.2 m-80 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.89 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 42' ' ' GLY . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.703 ' O ' HG22 ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.619 ' HB ' HD22 ' A' ' 81' ' ' LEU . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.628 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.954 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.686 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LYS . . . . . 0.544 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.686 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.762 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.7 mttm . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.566 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.526 0.679 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.713 ' HB3' HD12 ' A' ' 83' ' ' LEU . 34.1 t0 -115.92 47.25 0.53 Allowed Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.437 -0.79 . . . . 0.0 111.667 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.551 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.486 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 1.006 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.601 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.983 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.576 ' C ' HG11 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.664 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.681 ' N ' HG22 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.783 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.94 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.539 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.932 HD13 HG21 ' A' ' 45' ' ' VAL . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.087 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.551 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.546 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.404 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.709 ' CD ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.581 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.087 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.998 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.061 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.566 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.468 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.967 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.967 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.534 HG12 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.672 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.672 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.454 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.625 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.676 HG13 HD11 ' A' ' 26' ' ' ILE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.635 ' O ' HG11 ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.684 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.74 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.511 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.513 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.78 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.662 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.566 ' ND2' ' O ' ' A' ' 46' ' ' THR . 4.2 m-80 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.061 HD23 HG22 ' A' ' 45' ' ' VAL . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.998 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.713 HD12 ' HB3' ' A' ' 2' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.568 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.811 ' CG2' HD12 ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.006 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.598 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.517 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.664 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.783 HG11 ' SG ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.666 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.55 -173.34 0.34 Allowed Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.74 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 27.9 Cg_endo -69.09 91.06 0.45 Allowed 'Trans proline' 0 C--N 1.32 -0.931 0 C-N-CA 121.246 1.297 . . . . 0.0 110.507 -177.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.94 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.302 -1.487 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.485 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.579 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.655 0.741 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.663 ' HB3' HD12 ' A' ' 83' ' ' LEU . 39.7 t0 -114.01 45.95 0.35 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.552 -0.717 . . . . 0.0 112.099 -178.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.631 ' O ' HG22 ' A' ' 88' ' ' VAL . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.992 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.992 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.772 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.42 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.722 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.93 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.602 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.956 ' CD1' HG21 ' A' ' 45' ' ' VAL . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.898 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.63 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.64 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.606 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.539 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.898 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.049 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.956 HG21 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.802 HG23 ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.686 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.57 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.024 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.024 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 53' ' ' VAL . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.715 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.715 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.649 HG11 ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.802 ' SD ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.488 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.64 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.873 HG11 HG11 ' A' ' 45' ' ' VAL . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.649 ' O ' HG11 ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.686 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.478 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.582 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.949 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.679 ' C ' HD13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.778 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.522 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.122 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.049 ' OG1' HG13 ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.835 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.461 ' C ' HG22 ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.632 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 1.033 HG21 HD21 ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.122 ' CE1' HD23 ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.628 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.541 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.866 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.949 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.611 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -122.89 -63.84 0.03 OUTLIER Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.611 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.8 Cg_endo -75.63 85.71 1.57 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 C-N-CA 121.573 1.515 . . . . 0.0 112.745 -177.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.93 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.606 ' HB1' HH21 ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.542 0.687 . . . . 0.0 109.562 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.598 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 15.5 t0 -113.76 42.79 0.26 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.472 -0.767 . . . . 0.0 111.58 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.598 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.942 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.599 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.501 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.998 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.998 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.711 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.705 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.728 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.507 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.971 HD12 HG21 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.032 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.593 ' O ' HG23 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.645 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 24.3 m-70 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.676 ' NE ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.446 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.577 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.032 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.002 HG22 HD23 ' A' ' 81' ' ' LEU . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.66 HG12 HG23 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.539 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.936 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.936 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.6 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.6 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.655 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.558 ' O ' ' HE2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.426 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.645 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.655 ' O ' HG11 ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.426 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.701 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.55 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.816 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.504 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.793 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.513 ' O ' ' N ' ' A' ' 46' ' ' THR . 6.3 m-80 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.002 HD23 HG22 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.756 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.612 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.718 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.942 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.603 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.793 ' O ' HD12 ' A' ' 79' ' ' ILE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.521 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.842 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.816 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.696 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.5 mttt -95.69 -170.7 0.23 Allowed Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.701 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.4 Cg_endo -69.04 86.92 0.47 Allowed 'Trans proline' 0 C--N 1.322 -0.818 0 C-N-CA 121.322 1.348 . . . . 0.0 110.253 -178.421 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.728 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.571 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.509 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.561 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.574 0.702 . . . . 0.0 109.812 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.594 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 -122.54 52.26 3.92 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.693 -0.629 . . . . 0.0 110.931 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.565 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.963 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.598 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 1.002 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.002 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.503 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.684 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.5 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.628 ' N ' HG22 ' A' ' 97' ' ' VAL . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.756 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.743 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.628 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.893 HG23 ' HB2' ' A' ' 8' ' ' ALA . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.62 ' HB3' ' HE1' ' A' ' 35' ' ' HIS . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG23 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.62 ' HE1' ' HB3' ' A' ' 27' ' ' HIS . 48.2 m-70 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.581 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.1 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.659 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.533 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.975 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.975 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.704 HG12 ' CG2' ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.629 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.629 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.704 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.505 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.57 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.425 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.845 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.731 ' OH ' HG21 ' A' ' 97' ' ' VAL . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.673 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.693 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.1 HD23 HG22 ' A' ' 45' ' ' VAL . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.047 ' OG1' HG13 ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.85 ' O ' HG22 ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.601 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.5 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.771 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.963 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.584 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.537 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.684 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.756 HG11 ' SG ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.628 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -95.18 -175.35 0.46 Allowed Pre-proline 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.845 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.0 Cg_endo -68.67 86.37 0.45 Allowed 'Trans proline' 0 C--N 1.318 -1.042 0 C-N-CA 121.122 1.215 . . . . 0.0 109.749 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.743 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.392 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.343 -179.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.564 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.653 0.74 . . . . 0.0 109.609 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.627 ' HB3' HD12 ' A' ' 83' ' ' LEU . 24.4 t0 -122.01 51.0 2.72 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.638 -0.664 . . . . 0.0 110.511 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.601 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.775 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.615 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.971 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.971 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.523 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.681 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.525 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.601 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.73 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.887 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.619 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.989 HD12 HG21 ' A' ' 45' ' ' VAL . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.6 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.6 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.501 ' C ' HG23 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.604 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.558 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.503 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.862 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.06 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.989 HG21 HD12 ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.543 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.658 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.532 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.425 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.64 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.64 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.4 t-20 -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.604 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.867 HG11 HG11 ' A' ' 45' ' ' VAL . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.646 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.658 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.605 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.878 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.507 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.81 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.748 HG22 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.543 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.112 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.06 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.805 ' O ' HG22 ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.957 HG21 HD21 ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.613 ' N ' HG12 ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.112 ' CE1' HD23 ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.679 ' O ' HD12 ' A' ' 79' ' ' ILE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.574 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.681 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.518 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.81 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.62 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -94.47 179.31 1.24 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.878 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 27.1 Cg_endo -65.96 81.05 0.27 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.682 1.588 . . . . 0.0 110.843 -178.098 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.887 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.615 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.553 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.503 0.668 . . . . 0.0 109.695 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.59 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 -115.26 44.93 0.38 Allowed Pre-proline 0 C--N 1.3 -1.554 0 O-C-N 121.562 -0.711 . . . . 0.0 111.651 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.59 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.958 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.613 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.926 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.581 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.579 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.645 ' N ' HG22 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.716 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.04 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.42 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.979 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.535 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.613 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' PHE . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.525 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.979 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.037 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.056 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.516 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.646 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.51 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.61 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.632 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.48 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD2' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.613 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 100' ' ' ALA . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.817 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.926 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 0.9 OUTLIER -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.056 HD23 HG22 ' A' ' 45' ' ' VAL . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.037 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.79 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.591 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 12.9 m-80 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.758 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.958 ' CE2' ' HB3' ' A' ' 8' ' ' ALA . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.65 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 98' ' ' LYS . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.817 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.61 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -120.2 -67.53 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.61 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.4 Cg_endo -73.13 78.63 2.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.656 1.571 . . . . 0.0 111.708 -178.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 1.04 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.925 . . . . 0.0 109.749 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.555 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.556 0.693 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.622 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 22.6 t0 -113.73 41.08 0.24 Allowed Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.479 -0.763 . . . . 0.0 111.65 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.622 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.483 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.977 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.949 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.949 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.425 ' C ' HG11 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.694 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.596 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.632 ' N ' HG22 ' A' ' 97' ' ' VAL . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.787 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.481 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 12.8 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.613 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.109 HD13 HG21 ' A' ' 45' ' ' VAL . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.11 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.554 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.11 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.953 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.109 HG21 HD13 ' A' ' 26' ' ' ILE . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.674 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.504 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.62 HG12 ' CG2' ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.681 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.681 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.63 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.674 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.537 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.47 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.565 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.835 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.611 HD13 HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 46' ' ' THR . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.992 HD23 HG22 ' A' ' 45' ' ' VAL . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.953 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.581 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.75 ' CG2' HD12 ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.977 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.51 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.835 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.619 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.5 OUTLIER -125.89 -65.61 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.21 73.35 3.86 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 121.566 1.511 . . . . 0.0 111.791 -178.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.787 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.492 1.628 0 O-C-N 121.13 -0.981 . . . . 0.0 109.341 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.548 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.621 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 -116.1 43.36 0.37 Allowed Pre-proline 0 C--N 1.3 -1.568 0 O-C-N 121.439 -0.788 . . . . 0.0 111.699 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.485 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.827 ' HB2' HD13 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.63 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.465 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.709 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.713 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.048 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.45 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.546 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.608 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.106 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.924 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.579 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.579 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.508 ' C ' HG23 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.763 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 41.0 m170 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.724 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.924 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.084 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.106 HG21 ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.534 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.666 HD11 HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.511 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.988 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.988 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.497 HG12 HG22 ' A' ' 56' ' ' VAL . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.593 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.593 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.653 HG11 ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.456 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.587 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.681 HG11 HG11 ' A' ' 45' ' ' VAL . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.653 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.635 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.487 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.566 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.841 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.424 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.563 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.097 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.084 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.73 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.866 ' O ' HG22 ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.642 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.876 HG23 ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.684 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.841 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.612 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -118.78 -65.69 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.612 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.9 Cg_endo -74.07 80.66 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 C-N-CA 121.604 1.536 . . . . 0.0 111.732 -178.081 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 1.048 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.171 -0.955 . . . . 0.0 109.831 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.391 0.615 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.647 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 45.16 51.8 9.54 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.434 -0.791 . . . . 0.0 110.288 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.647 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.449 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.874 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.589 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.995 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.995 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.699 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.628 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.701 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.617 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.968 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.007 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.468 ' C ' HG23 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.628 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.637 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.9 m-70 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 1.007 ' CZ ' ' HB3' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.807 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.056 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.968 HG21 HD12 ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.536 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.9 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.573 ' O ' HG12 ' A' ' 53' ' ' VAL . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.692 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.637 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.734 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.692 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.671 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.91 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.9 HD12 HD11 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.92 HD23 HG22 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.056 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.973 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.818 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.874 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.663 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.958 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.91 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.621 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -124.41 -65.71 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.1 Cg_endo -74.71 71.96 4.61 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 121.564 1.51 . . . . 0.0 112.038 -178.065 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 120.97 -1.081 . . . . 0.0 108.648 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.681 ' HB1' ' OD1' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.804 0.812 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.632 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 41.89 53.89 8.09 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.632 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.506 ' O ' HG22 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.516 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.971 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.638 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.981 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.981 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.661 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.683 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.501 ' N ' HG22 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.682 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.899 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.443 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.128 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.529 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.681 ' OD1' ' HB1' ' A' ' 1' ' ' ALA . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.571 ' O ' HG23 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.699 ' C ' HG23 ' A' ' 37' ' ' THR . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.699 HG23 ' C ' ' A' ' 36' ' ' ARG . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.8 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.128 HG21 ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.448 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.644 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.983 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.983 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.478 HG12 ' CG2' ' A' ' 56' ' ' VAL . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.716 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.716 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.626 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 45' ' ' VAL . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.626 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.478 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.542 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.925 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.644 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.707 HD13 HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m-80 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.047 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.8 ' OG1' HG13 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.755 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.61 HG23 ' CD2' ' A' ' 81' ' ' LEU . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.584 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.971 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.642 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.532 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.84 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.925 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.59 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.1 OUTLIER -125.37 -63.9 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.59 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.38 72.95 4.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 121.548 1.498 . . . . 0.0 112.041 -178.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.899 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.974 . . . . 0.0 109.452 178.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.673 0.749 . . . . 0.0 109.485 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.625 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 43.53 53.09 9.45 Favored Pre-proline 0 C--N 1.3 -1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 110.564 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.937 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.969 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.969 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.526 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.682 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.773 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.927 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.623 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.898 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.081 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.559 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.643 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.55 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.081 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.907 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.015 HG22 HD23 ' A' ' 81' ' ' LEU . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.66 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.583 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.545 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.448 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.643 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.51 HG22 ' HA ' ' A' ' 27' ' ' HIS . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.669 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.66 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.656 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.708 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.545 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.858 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.583 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.607 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.8 OUTLIER -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.015 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.93 HG22 ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.76 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.93 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.649 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.526 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.592 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.771 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.858 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.63 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.2 OUTLIER -94.88 -176.57 0.57 Allowed Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.708 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 26.7 Cg_endo -66.64 85.92 0.29 Allowed 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.315 1.343 . . . . 0.0 110.299 -178.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.927 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.556 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.29 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.584 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.601 0.715 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.578 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 -117.06 48.9 0.76 Allowed Pre-proline 0 C--N 1.3 -1.553 0 O-C-N 121.572 -0.705 . . . . 0.0 111.102 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HD3' ' C ' ' A' ' 1' ' ' ALA . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 1.02 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.584 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.986 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.986 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.409 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.707 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.612 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.72 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.725 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 17' ' ' GLU . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.958 HD12 HG21 ' A' ' 45' ' ' VAL . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.74 ' HB2' ' CE1' ' A' ' 43' ' ' PHE . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.544 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.662 ' HB3' ' HB3' ' A' ' 28' ' ' ALA . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.57 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.55 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.74 ' CE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.053 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 67' ' ' VAL . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.557 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.891 ' CG1' HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.743 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.546 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.904 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.904 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.604 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.557 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.458 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.458 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.625 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.699 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.654 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.747 ' HB2' ' HA ' ' A' ' 99' ' ' PRO . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.546 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.8 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.743 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.891 HD12 ' CG1' ' A' ' 47' ' ' ILE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.523 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.01 HD23 HG22 ' A' ' 45' ' ' VAL . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.053 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.915 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.911 ' O ' HG22 ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.02 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.599 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.514 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.903 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.8 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.686 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -95.02 -170.81 0.23 Allowed Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HA ' ' HB2' ' A' ' 74' ' ' ALA . 29.2 Cg_endo -69.42 88.79 0.49 Allowed 'Trans proline' 0 C--N 1.321 -0.906 0 C-N-CA 121.135 1.223 . . . . 0.0 110.376 -178.294 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.725 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.408 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.652 0.739 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.656 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 47.85 51.38 10.5 Favored Pre-proline 0 C--N 1.299 -1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 110.777 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.516 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.534 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.985 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.597 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.744 ' O ' HG11 ' A' ' 95' ' ' VAL . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.534 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.586 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.611 ' N ' HG22 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.727 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.86 HG23 ' HB2' ' A' ' 8' ' ' ALA . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.097 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.565 ' C ' HG23 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.565 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.589 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.743 ' CZ ' ' HB3' ' A' ' 1' ' ' ALA . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 43' ' ' PHE . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.586 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.097 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.877 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.127 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.649 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.534 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.953 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.953 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.544 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.594 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.594 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.629 HG11 ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.629 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.649 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.596 ' O ' ' HB2' ' A' ' 100' ' ' ALA . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.569 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.789 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.732 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.757 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 1.0 OUTLIER -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.127 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.963 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.702 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.963 ' O ' HG22 ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.723 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.1 OUTLIER -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.985 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.664 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.533 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 13' ' ' LEU . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.789 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.601 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 3.0 mtmt -121.41 -64.35 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.601 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.7 Cg_endo -74.83 76.69 3.25 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 121.495 1.464 . . . . 0.0 111.596 -178.075 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 1.045 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 110.026 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.546 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.527 0.68 . . . . 0.0 109.624 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.718 ' HB3' HD12 ' A' ' 83' ' ' LEU . 33.3 t0 -116.09 44.43 0.41 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.807 . . . . 0.0 111.822 -179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.51 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.807 ' HB2' ' CD1' ' A' ' 81' ' ' LEU . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.607 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.692 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.605 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.539 ' N ' HG22 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.718 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.915 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.543 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.671 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.133 ' CD1' HG21 ' A' ' 45' ' ' VAL . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.992 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.642 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.533 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.528 ' O ' ' N ' ' A' ' 43' ' ' PHE . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.992 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.133 HG21 ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.45 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.708 HG12 HG23 ' A' ' 79' ' ' ILE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.654 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.737 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.737 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.43 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.642 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.648 ' O ' HG11 ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.69 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.504 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.887 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.701 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.712 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.2 m-80 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.852 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.766 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.576 ' O ' HG22 ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.656 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' CD2' ' A' ' 81' ' ' LEU . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.737 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.616 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.726 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.887 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.696 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.76 -175.42 0.47 Allowed Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.696 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 27.1 Cg_endo -66.42 84.62 0.28 Allowed 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.565 1.51 . . . . 0.0 110.904 -177.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.915 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.301 -1.526 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.505 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.581 ' HB1' ' OD1' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.766 0.793 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 44.01 52.77 9.65 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.191 -0.943 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.881 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.707 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.911 HD12 HD13 ' A' ' 79' ' ' ILE . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.664 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.73 ' HA3' HG12 ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.513 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.706 ' N ' HG22 ' A' ' 97' ' ' VAL . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.675 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.851 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.45 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.165 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.948 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.602 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.584 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.641 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.996 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.165 HG21 ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.689 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.563 ' O ' HG12 ' A' ' 78' ' ' VAL . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.745 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.745 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.645 HG11 ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.641 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.608 ' HB2' HD12 ' A' ' 26' ' ' ILE . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.66 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.645 ' O ' HG11 ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.689 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.469 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.555 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.672 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.911 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.996 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.97 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.802 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.97 ' O ' HG22 ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.627 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 6.7 m120 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.64 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.59 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.881 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.666 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.73 HG12 ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.706 HG22 ' N ' ' A' ' 17' ' ' GLU . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.663 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 15.9 mttt -123.12 -66.74 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.663 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 36.8 Cg_endo -77.15 73.42 5.48 Favored 'Trans proline' 0 C--N 1.317 -1.126 0 C-N-CA 121.683 1.589 . . . . 0.0 112.468 -177.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.851 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.493 1.717 0 O-C-N 120.742 -1.224 . . . . 0.0 108.273 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.707 ' HB3' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.485 0.66 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.606 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 47.84 56.98 18.01 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 110.48 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.606 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.413 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.501 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 1.019 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.616 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.626 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.588 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.697 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.878 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.597 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.093 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.098 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.547 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.637 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.474 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.511 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.162 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.095 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.093 HG21 ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.525 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.861 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.7 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.989 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.989 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.688 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.673 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.673 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.688 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.525 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.522 HG22 ' HA ' ' A' ' 27' ' ' HIS . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.722 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.652 ' O ' HG11 ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.491 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.461 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.522 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.874 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.7 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.861 HD12 HD11 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.162 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.095 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.707 ' OD1' ' HB3' ' A' ' 1' ' ' ALA . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.934 ' O ' HG22 ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.568 HG23 ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.019 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.637 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.551 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.927 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.874 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.574 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -123.1 -63.24 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.574 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.8 Cg_endo -75.5 72.96 4.77 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 C-N-CA 121.535 1.49 . . . . 0.0 112.345 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.878 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.053 -1.029 . . . . 0.0 109.221 178.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.568 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.442 0.639 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.595 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 36.0 t0 -116.68 47.12 0.59 Allowed Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.529 -0.732 . . . . 0.0 111.513 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.912 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.635 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.529 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.973 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.973 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.422 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.703 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.594 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.717 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.462 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.592 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.72 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.977 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.084 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.492 ' CG ' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.492 HG23 ' CG ' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.569 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.084 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.011 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.72 HD12 ' HZ ' ' A' ' 24' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.977 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.977 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.799 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.799 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.654 HG11 ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.453 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.63 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.654 ' O ' HG11 ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.647 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.505 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.513 ' HB1' ' HA ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.898 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.631 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 0.7 OUTLIER -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.011 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.996 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.736 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.91 ' O ' HG22 ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.62 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.632 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.486 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.912 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.62 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.53 ' HG2' ' N ' ' A' ' 94' ' ' THR . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.703 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.898 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.612 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 11.1 mttt -127.74 -65.76 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.612 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.4 Cg_endo -75.12 68.73 5.8 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.521 1.481 . . . . 0.0 111.78 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.49 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 120.908 -1.12 . . . . 0.0 108.768 178.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB1' ' HG3' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.499 0.666 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.643 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 43.24 51.77 7.51 Favored Pre-proline 0 C--N 1.303 -1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 110.168 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.643 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.573 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.978 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.44 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.961 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.961 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.687 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.718 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.709 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.734 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.571 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.044 HD12 HG21 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 1.071 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.573 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.587 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.574 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.43 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.639 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 30.0 m-70 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.798 ' HG3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.544 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 1.071 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.965 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.044 HG21 HD12 ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG12 HG23 ' A' ' 79' ' ' ILE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.528 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.02 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.02 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.488 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.62 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.47 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.473 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.473 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.639 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.68 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.463 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.491 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.731 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.539 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.912 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.442 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.817 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.508 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.981 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.965 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.718 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.59 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.624 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.978 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.626 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.817 ' O ' HD12 ' A' ' 79' ' ' ILE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.907 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.912 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.682 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -94.81 -171.19 0.24 Allowed Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.731 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 29.1 Cg_endo -70.11 89.33 0.56 Allowed 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 121.205 1.27 . . . . 0.0 110.629 -178.036 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.734 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.452 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.88 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.47 ' O ' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.693 0.758 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.652 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 49.95 48.18 5.7 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.462 -0.774 . . . . 0.0 110.378 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.476 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.967 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.452 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.624 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.972 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.496 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.689 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.585 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.886 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.502 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.616 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.695 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.459 ' HB3' ' HE1' ' A' ' 35' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.84 ' HB2' ' HE1' ' A' ' 43' ' ' PHE . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.469 ' C ' HG23 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.649 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.7 m-70 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.58 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.84 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.061 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.083 HG22 HD23 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.673 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.497 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.98 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.98 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.436 HG22 ' H ' ' A' ' 53' ' ' VAL . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.685 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.685 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.469 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.42 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.649 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 45' ' ' VAL . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.633 ' O ' HG11 ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.497 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.477 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.798 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.68 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.783 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 5.1 m-80 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 1.083 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.061 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.958 ' O ' HG22 ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.527 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.741 ' CG2' HD12 ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.967 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.569 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.539 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.575 HG23 ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.739 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.798 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.596 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 1.6 mttm -124.87 -63.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.596 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.9 Cg_endo -75.02 82.29 2.04 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 121.616 1.544 . . . . 0.0 112.012 -177.61 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.886 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.324 -0.86 . . . . 0.0 108.83 178.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.533 ' O ' ' CD1' ' A' ' 83' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.398 0.618 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASP . . . . . 0.66 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 53.28 48.25 4.91 Favored Pre-proline 0 C--N 1.299 -1.59 0 O-C-N 121.651 -0.656 . . . . 0.0 110.95 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.66 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.425 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.954 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.645 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.686 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.624 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.729 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.917 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.42 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 2.7 tt0 -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.529 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 1.142 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.916 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.57 ' OD2' HG21 ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.411 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG21 ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.632 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.523 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.74 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.916 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 1.142 HG21 ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.647 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.549 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.492 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 56' ' ' VAL . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.627 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.627 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.447 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.632 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PHE . . . . . 0.68 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.452 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.689 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.762 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.549 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 1.096 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.546 ' O ' ' N ' ' A' ' 46' ' ' THR . 8.2 m-80 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.89 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 42' ' ' GLY . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.703 ' O ' HG22 ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.619 ' HB ' HD22 ' A' ' 81' ' ' LEU . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.628 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.954 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.686 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LYS . . . . . 0.544 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.686 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.762 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.672 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.7 mttm -93.89 -172.67 0.31 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.689 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.5 Cg_endo -68.4 95.82 0.46 Allowed 'Trans proline' 0 C--N 1.322 -0.835 0 C-N-CA 121.367 1.378 . . . . 0.0 111.114 -177.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.917 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.18 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.713 ' HB3' HD12 ' A' ' 83' ' ' LEU . 34.1 t0 . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 111.667 0.247 . . . . 0.0 111.667 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.551 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.486 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 1.006 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.601 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.983 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.576 ' C ' HG11 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.664 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.681 ' N ' HG22 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.783 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.684 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.539 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.932 HD13 HG21 ' A' ' 45' ' ' VAL . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.087 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.551 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.546 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.404 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.709 ' CD ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.581 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.087 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.998 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.061 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.468 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.967 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.967 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.534 HG12 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.672 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.672 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.454 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.625 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.676 HG13 HD11 ' A' ' 26' ' ' ILE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.635 ' O ' HG11 ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.684 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.511 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.513 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.78 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.662 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.487 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 3.8 m120 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.061 HD23 HG22 ' A' ' 45' ' ' VAL . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.998 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.713 HD12 ' HB3' ' A' ' 2' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.568 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.811 ' CG2' HD12 ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.006 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.598 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.517 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.664 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.783 HG11 ' SG ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.663 ' HB3' HD12 ' A' ' 83' ' ' LEU . 39.7 t0 . . . . . 0 N--CA 1.486 1.334 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.631 ' O ' HG22 ' A' ' 88' ' ' VAL . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.992 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.992 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.772 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.42 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.722 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.602 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.956 ' CD1' HG21 ' A' ' 45' ' ' VAL . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.898 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.63 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.64 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.606 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.539 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.898 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.049 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.956 HG21 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.802 HG23 ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.686 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.57 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.024 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.024 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 53' ' ' VAL . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.715 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.715 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.649 HG11 ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.802 ' SD ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.488 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.64 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.873 HG11 HG11 ' A' ' 45' ' ' VAL . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.649 ' O ' HG11 ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.686 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.478 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.582 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.949 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.679 ' C ' HD13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.778 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.522 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.122 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.049 ' OG1' HG13 ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.835 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.461 ' C ' HG22 ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.632 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 1.033 HG21 HD21 ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.122 ' CE1' HD23 ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.628 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.541 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.866 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.949 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.429 ' O ' ' HB2' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.598 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 15.5 t0 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.598 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.942 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.599 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.501 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.998 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.998 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.711 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.705 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.507 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.971 HD12 HG21 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.032 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.593 ' O ' HG23 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.645 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 20.3 m80 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.676 ' NE ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.446 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.577 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.032 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.002 HG22 HD23 ' A' ' 81' ' ' LEU . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.66 HG12 HG23 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.539 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.936 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.936 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.6 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.6 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.655 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.558 ' O ' ' HE2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.426 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.645 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.655 ' O ' HG11 ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.426 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.536 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.55 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.816 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.504 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.793 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.513 ' O ' ' N ' ' A' ' 46' ' ' THR . 5.9 m120 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.002 HD23 HG22 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.756 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.612 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.718 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.942 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.603 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.793 ' O ' HD12 ' A' ' 79' ' ' ILE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.521 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.842 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.816 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.5 mttt . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.594 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.677 0.275 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.565 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.963 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.598 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 1.002 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.002 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.503 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.684 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.5 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.628 ' N ' HG22 ' A' ' 97' ' ' VAL . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.756 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.563 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' NE2' ' O ' ' A' ' 15' ' ' GLY . 16.2 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.628 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.893 HG23 ' HB2' ' A' ' 8' ' ' ALA . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.565 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG23 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.616 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 59.2 m80 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.581 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.1 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.659 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.533 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.975 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.975 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.704 HG12 ' CG2' ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.629 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.629 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.704 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.505 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.57 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.425 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.731 ' OH ' HG21 ' A' ' 97' ' ' VAL . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.673 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.693 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.1 HD23 HG22 ' A' ' 45' ' ' VAL . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.047 ' OG1' HG13 ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.85 ' O ' HG22 ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.601 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.771 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.963 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.584 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.537 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.684 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.756 HG11 ' SG ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.627 ' HB3' HD12 ' A' ' 83' ' ' LEU . 24.4 t0 . . . . . 0 N--CA 1.489 1.479 0 CA-C-O 120.71 0.29 . . . . 0.0 110.511 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.601 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.775 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.615 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.971 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.971 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.523 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.681 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.525 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.601 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.73 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.605 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.619 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.989 HD12 HG21 ' A' ' 45' ' ' VAL . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.6 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.6 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.501 ' C ' HG23 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.604 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.558 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.503 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.862 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.06 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.989 HG21 HD12 ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.543 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.658 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.532 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.425 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.64 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.64 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.604 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.867 HG11 HG11 ' A' ' 45' ' ' VAL . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.646 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.658 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.605 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.507 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.81 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.748 HG22 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.543 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.112 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.06 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.805 ' O ' HG22 ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.957 HG21 HD21 ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.613 ' N ' HG12 ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.112 ' CE1' HD23 ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.679 ' O ' HD12 ' A' ' 79' ' ' ILE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.574 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.681 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.518 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.81 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.59 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.59 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.958 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.613 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.926 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.581 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.579 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.645 ' N ' HG22 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.716 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.536 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.42 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.979 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.535 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.613 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' PHE . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.525 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.979 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.037 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.056 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.516 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.646 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.51 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.61 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.632 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.48 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD2' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.613 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.817 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.926 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.4 m120 -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.056 HD23 HG22 ' A' ' 45' ' ' VAL . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.037 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.79 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.591 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 10.8 m120 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.758 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.958 ' CE2' ' HB3' ' A' ' 8' ' ' ALA . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.65 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 98' ' ' LYS . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.817 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.493 ' HD2' ' CG2' ' A' ' 96' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.622 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 22.6 t0 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 111.65 0.241 . . . . 0.0 111.65 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.622 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.483 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.977 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.949 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.949 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.425 ' C ' HG11 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.694 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.596 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.632 ' N ' HG22 ' A' ' 97' ' ' VAL . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.537 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.481 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 3.7 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.613 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.109 HD13 HG21 ' A' ' 45' ' ' VAL . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.11 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.554 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.11 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.953 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.109 HG21 HD13 ' A' ' 26' ' ' ILE . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.674 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.504 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.62 HG12 ' CG2' ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.681 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.681 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.63 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.674 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.537 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.47 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.565 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.835 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.611 HD13 HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 46' ' ' THR . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.992 HD23 HG22 ' A' ' 45' ' ' VAL . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.953 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.581 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.75 ' CG2' HD12 ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.977 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.51 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.835 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.621 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 111.699 0.259 . . . . 0.0 111.699 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.485 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.827 ' HB2' HD13 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.63 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.465 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.709 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.713 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.45 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.546 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.608 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.106 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.924 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.579 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.579 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.508 ' C ' HG23 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.587 ' CB ' ' HA3' ' A' ' 63' ' ' GLY . 2.1 m-70 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.724 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.924 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.084 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.106 HG21 ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.534 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.666 HD11 HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.511 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.988 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.988 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.497 HG12 HG22 ' A' ' 56' ' ' VAL . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.593 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.593 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.653 HG11 ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.456 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.587 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.681 HG11 HG11 ' A' ' 45' ' ' VAL . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.653 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.635 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.487 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.566 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.841 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.424 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.563 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.097 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.084 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.73 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.866 ' O ' HG22 ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.642 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.876 HG23 ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.684 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.841 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.647 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 . . . . . 0 N--CA 1.486 1.331 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.647 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.449 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.874 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.589 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.995 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.995 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.699 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.628 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.701 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.617 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.968 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.007 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.468 ' C ' HG23 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.628 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.637 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.2 m80 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 1.007 ' CZ ' ' HB3' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.807 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.056 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.968 HG21 HD12 ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.536 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.9 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.573 ' O ' HG12 ' A' ' 53' ' ' VAL . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.692 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.637 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.734 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.692 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.671 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.91 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.9 HD12 HD11 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.92 HD23 HG22 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.056 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.973 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.818 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.874 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.663 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.958 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.91 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.632 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.588 0.232 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.632 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.506 ' O ' HG22 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.516 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.971 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.638 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.981 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.981 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.661 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.683 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.501 ' N ' HG22 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.682 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.443 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.128 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.529 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.654 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.571 ' O ' HG23 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.699 ' C ' HG23 ' A' ' 37' ' ' THR . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.699 HG23 ' C ' ' A' ' 36' ' ' ARG . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.8 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.128 HG21 ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.448 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.644 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.983 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.983 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.478 HG12 ' CG2' ' A' ' 56' ' ' VAL . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.716 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.716 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.626 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 45' ' ' VAL . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.626 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.478 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.542 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.925 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.644 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.707 HD13 HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m120 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.047 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.8 ' OG1' HG13 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.755 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.61 HG23 ' CD2' ' A' ' 81' ' ' LEU . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.584 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.971 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.642 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.532 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.84 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.925 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.625 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.564 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.937 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.969 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.969 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.526 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.682 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.773 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.623 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.898 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.081 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.559 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.643 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.55 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.081 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.907 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.015 HG22 HD23 ' A' ' 81' ' ' LEU . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.66 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.583 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.545 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.448 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.643 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.51 HG22 ' HA ' ' A' ' 27' ' ' HIS . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.669 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.66 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.656 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.527 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.545 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.858 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.583 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.607 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.2 m120 -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.015 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.93 HG22 ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.76 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.93 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.649 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.526 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.592 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.771 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.858 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.578 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 . . . . . 0 N--CA 1.488 1.455 0 CA-C-O 120.501 0.191 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.578 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 1.02 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.584 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.986 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.986 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.409 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.707 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.612 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.72 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 17' ' ' GLU . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.958 HD12 HG21 ' A' ' 45' ' ' VAL . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.74 ' HB2' ' CE1' ' A' ' 43' ' ' PHE . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.544 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.662 ' HB3' ' HB3' ' A' ' 28' ' ' ALA . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.57 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.55 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.74 ' CE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.053 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 67' ' ' VAL . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.557 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.891 ' CG1' HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.743 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.546 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.904 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.904 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.604 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.557 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.458 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.458 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.625 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.699 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.654 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.546 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.8 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.743 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.891 HD12 ' CG1' ' A' ' 47' ' ' ILE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.523 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.01 HD23 HG22 ' A' ' 45' ' ' VAL . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.053 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.915 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.911 ' O ' HG22 ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.02 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.599 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.514 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.903 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.8 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 2.5 mttm . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.656 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 120.557 0.218 . . . . 0.0 110.777 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.516 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.534 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.985 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.597 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.744 ' O ' HG11 ' A' ' 95' ' ' VAL . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.534 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.586 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.611 ' N ' HG22 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.727 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.548 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.86 HG23 ' HB2' ' A' ' 8' ' ' ALA . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.097 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.565 ' C ' HG23 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.565 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.589 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.597 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 43' ' ' PHE . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.586 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.097 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.877 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.127 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.649 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.534 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.953 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.953 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.544 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.594 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.594 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.629 HG11 ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.629 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.649 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.469 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.569 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.789 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.732 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.757 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.8 m120 -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.127 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.963 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.702 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.963 ' O ' HG22 ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.723 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 4.0 t-20 -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.985 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.664 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.533 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 13' ' ' LEU . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.789 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.718 ' HB3' HD12 ' A' ' 83' ' ' LEU . 33.3 t0 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.822 0.304 . . . . 0.0 111.822 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.51 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.807 ' HB2' ' CD1' ' A' ' 81' ' ' LEU . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.607 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.692 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.605 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.539 ' N ' HG22 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.718 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.624 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.543 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.671 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.133 ' CD1' HG21 ' A' ' 45' ' ' VAL . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.992 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.642 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.533 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.528 ' O ' ' N ' ' A' ' 43' ' ' PHE . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.992 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.133 HG21 ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.45 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.708 HG12 HG23 ' A' ' 79' ' ' ILE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.654 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.737 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.737 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.43 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.642 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.648 ' O ' HG11 ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.69 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.567 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.504 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.887 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.701 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.712 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.3 m120 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.852 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.766 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.576 ' O ' HG22 ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.656 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' CD2' ' A' ' 81' ' ' LEU . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.737 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.616 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.726 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.887 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.51 -0.181 . . . . 0.0 110.51 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.881 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.707 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.911 HD12 HD13 ' A' ' 79' ' ' ILE . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.664 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.73 ' HA3' HG12 ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.513 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.706 ' N ' HG22 ' A' ' 97' ' ' VAL . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.675 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.45 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.165 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.948 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.602 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.584 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.641 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.996 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.165 HG21 ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.689 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.563 ' O ' HG12 ' A' ' 78' ' ' VAL . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.745 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.745 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.645 HG11 ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.641 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.608 ' HB2' HD12 ' A' ' 26' ' ' ILE . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.66 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.645 ' O ' HG11 ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.689 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.469 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.555 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.672 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.911 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.996 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.97 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.802 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.97 ' O ' HG22 ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.627 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 2.0 m-80 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.64 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.59 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.881 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.666 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.73 HG12 ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.706 HG22 ' N ' ' A' ' 17' ' ' GLU . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.9 mttt . . . . . 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.606 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.725 0.298 . . . . 0.0 110.48 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.606 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.413 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.501 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 1.019 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.616 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.626 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.588 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.697 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.455 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.597 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.093 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.098 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.547 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.637 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.474 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.511 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.162 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.095 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.093 HG21 ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.525 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.861 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.7 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.989 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.989 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.688 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.673 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.673 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.688 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.525 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.522 HG22 ' HA ' ' A' ' 27' ' ' HIS . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.722 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.652 ' O ' HG11 ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.491 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.461 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.522 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.874 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.7 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.861 HD12 HD11 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.162 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.095 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.934 ' O ' HG22 ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.568 HG23 ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.019 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.637 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.551 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.927 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.874 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.595 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 36.0 t0 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 111.513 0.19 . . . . 0.0 111.513 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.912 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.635 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.529 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.973 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.973 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.422 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.703 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.594 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.717 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.462 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.592 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.72 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.977 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.084 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.492 ' CG ' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.492 HG23 ' CG ' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.569 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.084 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.011 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.72 HD12 ' HZ ' ' A' ' 24' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.977 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.977 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.799 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.799 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.654 HG11 ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.453 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.63 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.654 ' O ' HG11 ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.647 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.505 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.513 ' HB1' ' HA ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.898 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.631 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.1 m120 -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.011 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.996 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.736 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.91 ' O ' HG22 ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.62 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.632 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.486 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.912 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.62 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.53 ' HG2' ' N ' ' A' ' 94' ' ' THR . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.703 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.898 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.513 ' HA ' ' HB1' ' A' ' 74' ' ' ALA . 11.1 mttt . . . . . 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.643 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 . . . . . 0 N--CA 1.485 1.307 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.643 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.573 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.978 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.44 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.961 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.961 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.687 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.718 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.709 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.556 ' CE1' ' C ' ' A' ' 72' ' ' LYS . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.571 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.044 HD12 HG21 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 1.071 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.573 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.587 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.574 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.43 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.639 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 15.8 m80 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.587 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.544 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 1.071 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.965 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.044 HG21 HD12 ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.681 HG12 HG23 ' A' ' 79' ' ' ILE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.528 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.02 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.02 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.488 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.62 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.47 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.473 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.473 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.639 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.68 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.463 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.491 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.539 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.912 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.442 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.817 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.508 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.981 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.965 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.718 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.59 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.624 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.978 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.626 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.817 ' O ' HD12 ' A' ' 79' ' ' ILE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.907 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.912 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.652 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 . . . . . 0 N--CA 1.483 1.207 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.476 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.967 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.452 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.624 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.972 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.496 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.689 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.585 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.502 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.616 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.695 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.444 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.84 ' HB2' ' HE1' ' A' ' 43' ' ' PHE . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.469 ' C ' HG23 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.649 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.2 m80 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.58 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.84 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.061 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.083 HG22 HD23 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.673 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.497 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.98 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.98 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.436 HG22 ' H ' ' A' ' 53' ' ' VAL . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.685 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.685 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.469 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.42 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.649 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 45' ' ' VAL . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.633 ' O ' HG11 ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.497 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.477 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.798 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.68 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.783 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 5.1 m120 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 1.083 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.061 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.958 ' O ' HG22 ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.527 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.741 ' CG2' HD12 ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.967 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.569 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.539 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.575 HG23 ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.739 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.798 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 mttm . . . . . 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ASP . . . . . 0.66 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.472 0.177 . . . . 0.0 110.95 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.66 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.425 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.954 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 1.096 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.645 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.686 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.624 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.729 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.607 ' CE1' ' HA ' ' A' ' 72' ' ' LYS . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.42 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.3 OUTLIER -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.529 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 1.142 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.916 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.57 ' OD2' HG21 ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.411 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.57 HG21 ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.632 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.523 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.74 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.916 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 1.142 HG21 ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.647 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLU . . . . . 0.549 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.492 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 56' ' ' VAL . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.627 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.627 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.447 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.632 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PHE . . . . . 0.68 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.452 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 98' ' ' LYS . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.762 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.549 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 1.096 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.546 ' O ' ' N ' ' A' ' 46' ' ' THR . 7.2 m120 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.89 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 42' ' ' GLY . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.703 ' O ' HG22 ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.619 ' HB ' HD22 ' A' ' 81' ' ' LEU . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.628 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.954 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.686 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . 0.544 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.686 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.762 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 1.7 mttm . . . . . 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.566 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.526 0.679 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.713 ' HB3' HD12 ' A' ' 83' ' ' LEU . 34.1 t0 -115.92 47.25 0.53 Allowed Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.437 -0.79 . . . . 0.0 111.667 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.39 1.28 8.92 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 121.33 1.354 . . . . 0.0 108.834 177.193 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -135.1 11.92 3.58 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.481 -0.762 . . . . 0.0 110.866 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.551 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 8.6 tptm -147.58 35.91 0.87 Allowed 'General case' 0 C--N 1.3 -1.582 0 O-C-N 120.78 -1.2 . . . . 0.0 108.388 -179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.486 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 19.9 m -115.41 119.76 37.32 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -179.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.602 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.9 p90 -142.23 143.51 32.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.467 -0.771 . . . . 0.0 110.772 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 1.006 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -124.58 128.81 49.47 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -147.0 142.73 27.8 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.018 -1.051 . . . . 0.0 109.754 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.601 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.67 174.54 39.05 Favored Glycine 0 N--CA 1.481 1.68 0 C-N-CA 119.601 -1.285 . . . . 0.0 110.36 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.61 7.88 4.28 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.56 2.173 . . . . 0.0 108.747 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.983 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.44 157.73 14.95 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.983 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.12 -8.71 0.35 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-N 118.172 0.986 . . . . 0.0 110.169 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.576 ' C ' HG11 ' A' ' 95' ' ' VAL . 3.3 m-20 -67.29 -18.64 65.28 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.02 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.664 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.94 -129.22 10.58 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.15 -58.71 0.16 Allowed Glycine 0 N--CA 1.491 2.329 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.21 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.681 ' N ' HG22 ' A' ' 97' ' ' VAL . 10.7 mt-10 -128.63 142.85 50.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.985 -1.303 . . . . 0.0 111.607 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.783 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.76 -20.93 24.14 Favored 'General case' 0 N--CA 1.502 2.146 0 C-N-CA 120.302 -0.559 . . . . 0.0 109.544 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.94 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 15.0 m-85 -89.02 13.87 11.92 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.952 -1.092 . . . . 0.0 110.02 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.539 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 6.8 tt0 -99.56 143.5 26.55 Favored Pre-proline 0 C--N 1.295 -1.776 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 176.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 29.9 Cg_endo -69.78 129.9 18.38 Favored 'Trans proline' 0 C--N 1.297 -2.163 0 N-CA-C 108.67 -1.319 . . . . 0.0 108.67 -179.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.64 111.52 24.25 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 118.63 -1.228 . . . . 0.0 109.26 -178.339 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 4.9 mttt -150.06 135.56 18.23 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.51 -0.744 . . . . 0.0 110.208 -179.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.654 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.39 42.31 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.292 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -114.14 139.22 49.51 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.932 HD13 HG21 ' A' ' 45' ' ' VAL . 2.6 mt -105.34 142.13 19.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.312 -0.868 . . . . 0.0 109.16 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.519 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.2 m80 -130.6 114.87 15.97 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.553 -0.717 . . . . 0.0 109.785 -179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.087 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.41 148.22 26.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.552 -0.717 . . . . 0.0 110.192 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.551 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 3.7 t -136.48 123.75 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.048 -1.033 . . . . 0.0 108.327 178.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -103.95 -176.37 0.44 Allowed Pre-proline 0 C--N 1.294 -1.845 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.978 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.577 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.1 Cg_endo -77.65 21.58 0.63 Allowed 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.872 1.715 . . . . 0.0 111.507 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.546 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -118.4 11.44 13.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.549 -1.344 . . . . 0.0 109.361 179.464 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.404 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.72 34.17 62.91 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 106.189 -2.765 . . . . 0.0 106.189 -178.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.01 -175.24 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.831 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.602 ' CG ' ' O ' ' A' ' 28' ' ' ALA . 5.7 m-70 -98.2 54.23 1.09 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.216 -0.928 . . . . 0.0 109.072 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.709 ' CD ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 65.02 70.32 0.47 Allowed 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.617 -0.677 . . . . 0.0 109.245 -179.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.451 ' O ' ' OG1' ' A' ' 37' ' ' THR . 12.1 p 43.01 85.0 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.661 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.12 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -42.73 153.21 0.08 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.033 -1.042 . . . . 0.0 110.006 -179.286 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.26 -38.96 3.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.24 46.44 1.12 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.3 m-20 -89.56 122.35 32.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.206 -1.173 . . . . 0.0 109.167 179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.581 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.95 60.4 0.52 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.087 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.22 112.19 24.4 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.563 -0.963 . . . . 0.0 110.027 -178.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.998 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -119.61 113.51 41.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 177.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.061 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -118.43 150.18 20.7 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.22 129.38 5.02 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.415 -179.738 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -120.29 156.2 23.27 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.001 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.529 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.1 OUTLIER -169.17 156.01 6.84 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 117.901 -1.52 . . . . 0.0 110.815 177.305 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.86 -168.15 25.44 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 107.929 -2.068 . . . . 0.0 107.929 -179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.468 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -76.64 72.78 5.49 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.271 1.981 . . . . 0.0 110.277 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.967 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.38 178.28 1.74 Allowed Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.729 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.967 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 36.0 Cg_endo -79.27 -56.94 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.683 2.255 . . . . 0.0 110.249 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.534 HG12 ' CG2' ' A' ' 56' ' ' VAL . 42.6 t -89.65 74.41 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.328 -0.858 . . . . 0.0 108.826 179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.672 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 66.7 m-20 -90.15 -49.91 0.36 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.009 -1.057 . . . . 0.0 111.45 -178.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.672 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.0 Cg_endo -80.42 103.32 1.5 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 121.988 1.792 . . . . 0.0 110.448 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.635 HG11 ' O ' ' A' ' 68' ' ' GLU . 14.5 t -140.5 97.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.846 -1.159 . . . . 0.0 110.715 -179.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -140.12 136.62 33.74 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 118.642 -1.223 . . . . 0.0 110.505 178.807 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.32 155.42 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.615 -0.678 . . . . 0.0 110.0 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.582 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 13.0 t0 -120.24 127.91 52.85 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -88.28 -22.68 23.77 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.052 -1.03 . . . . 0.0 110.753 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.58 23.07 34.73 Favored Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.478 -1.344 . . . . 0.0 111.0 178.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.454 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 57.0 p30 -122.27 26.05 8.65 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.745 -1.444 . . . . 0.0 109.088 179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.28 -10.43 54.35 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.625 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 69.7 p -125.02 127.27 46.71 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.525 -0.985 . . . . 0.0 108.868 179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.582 ' CZ ' ' OD2' ' A' ' 59' ' ' ASP . 11.9 m-85 -117.6 157.32 26.59 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.919 -1.113 . . . . 0.0 109.521 -179.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.6 p-10 -123.6 151.2 43.23 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.945 -1.097 . . . . 0.0 110.852 -177.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.676 HG13 HD11 ' A' ' 26' ' ' ILE . 2.4 m -137.21 143.79 33.6 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.635 ' O ' HG11 ' A' ' 56' ' ' VAL . 8.6 mp0 -151.5 128.61 11.12 Favored 'General case' 0 N--CA 1.503 2.217 0 C-N-CA 118.163 -1.415 . . . . 0.0 113.046 -178.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.8 p90 -131.23 156.37 45.48 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 175.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -150.0 101.77 3.2 Favored Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.592 -1.318 . . . . 0.0 110.472 -178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.494 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.27 171.85 14.46 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 C-N-CA 123.001 2.467 . . . . 0.0 111.137 179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.684 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -132.97 22.56 4.17 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.083 -1.01 . . . . 0.0 111.464 -179.913 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.472 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.2 OUTLIER -152.3 -141.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.579 -1.326 . . . . 0.0 109.011 179.906 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.74 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -99.81 125.96 45.83 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.511 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.35 161.25 33.41 Favored Glycine 0 N--CA 1.486 1.98 0 C-N-CA 118.452 -1.832 . . . . 0.0 111.662 -176.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.513 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 4.7 p30 -113.76 156.46 23.8 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 178.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.78 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.6 m-30 -114.66 140.84 48.51 Favored 'General case' 0 C--N 1.293 -1.866 0 C-N-CA 119.237 -0.985 . . . . 0.0 111.056 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.662 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.56 127.75 75.87 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 176.437 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.779 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -105.32 158.42 5.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 CA-C-O 123.02 1.391 . . . . 0.0 112.482 -176.593 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.487 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 3.8 m120 -149.24 113.67 5.27 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.061 HD23 HG22 ' A' ' 45' ' ' VAL . 1.1 tm? -137.15 118.54 14.7 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 -179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.998 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -133.28 137.9 46.22 Favored 'General case' 0 C--N 1.294 -1.804 0 C-N-CA 118.856 -1.137 . . . . 0.0 112.157 -176.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.713 HD12 ' HB3' ' A' ' 2' ' ' ASP . 3.1 tm? -139.98 74.9 1.48 Allowed 'General case' 0 N--CA 1.501 2.1 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.835 178.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.59 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 29.1 m-20 141.31 -21.5 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.215 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.27 2.34 5.05 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -127.74 175.08 8.58 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.985 -1.303 . . . . 0.0 107.602 179.404 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.568 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.2 p30 -111.95 158.68 19.21 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 120.651 -1.281 . . . . 0.0 110.083 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.811 ' CG2' HD12 ' A' ' 81' ' ' LEU . 5.2 t -66.97 169.57 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 C-N-CA 119.438 -0.905 . . . . 0.0 108.943 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.0 p30 -83.27 24.57 0.79 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.877 -1.14 . . . . 0.0 111.421 -178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.9 13.4 1.13 Allowed Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.006 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -107.09 -41.49 0.14 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.139 -1.213 . . . . 0.0 113.127 -178.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.598 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.15 13.81 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.516 -1.378 . . . . 0.0 108.516 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.517 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.15 170.59 9.29 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 15.3 m -124.89 126.75 46.03 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 119.403 -0.919 . . . . 0.0 110.34 -179.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.664 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.3 t -99.37 155.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 52.7 m -121.58 140.63 51.99 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.587 -1.321 . . . . 0.0 113.528 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.783 HG11 ' SG ' ' A' ' 18' ' ' CYS . 2.8 t -122.25 145.81 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.666 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.55 -173.34 0.34 Allowed Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.471 -0.768 . . . . 0.0 108.971 -178.478 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.74 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 27.9 Cg_endo -69.09 91.06 0.45 Allowed 'Trans proline' 0 C--N 1.32 -0.931 0 C-N-CA 121.246 1.297 . . . . 0.0 110.507 -177.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.94 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.302 -1.487 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.485 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.579 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.655 0.741 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.663 ' HB3' HD12 ' A' ' 83' ' ' LEU . 39.7 t0 -114.01 45.95 0.35 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.552 -0.717 . . . . 0.0 112.099 -178.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.6 Cg_endo -77.73 2.45 7.83 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.433 1.422 . . . . 0.0 108.708 176.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -138.57 11.76 2.73 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.481 -0.762 . . . . 0.0 111.13 -178.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.53 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -145.35 38.16 1.14 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.649 -1.282 . . . . 0.0 108.031 -179.753 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.631 ' O ' HG22 ' A' ' 88' ' ' VAL . 16.2 m -116.23 114.5 24.5 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 23.6 p90 -129.7 144.89 51.5 Favored 'General case' 0 N--CA 1.495 1.793 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.342 -178.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -121.22 125.83 48.1 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 7.5 pt-20 -143.32 140.47 30.57 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.758 -1.214 . . . . 0.0 110.287 -179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.604 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 174.95 39.28 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.259 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.68 9.35 3.53 Favored 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.747 2.298 . . . . 0.0 108.841 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.992 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.02 156.98 15.31 Favored Glycine 0 C--O 1.198 -2.108 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.992 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.32 -6.3 0.33 Allowed 'General case' 0 N--CA 1.503 2.206 0 CA-C-N 118.559 1.179 . . . . 0.0 110.577 179.471 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -67.96 -19.45 64.95 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 178.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.667 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 85.23 -130.82 10.06 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.469 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.772 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.77 -84.75 0.11 Allowed Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.74 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.42 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.7 mp0 -111.57 144.64 40.48 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.076 -1.25 . . . . 0.0 111.915 -177.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.722 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.76 -16.91 32.87 Favored 'General case' 0 N--CA 1.502 2.149 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.93 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 56.1 m-85 -89.26 11.58 18.48 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.567 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 45.3 tt0 -99.07 142.95 25.5 Favored Pre-proline 0 C--N 1.298 -1.658 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 177.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.567 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.15 130.08 21.95 Favored 'Trans proline' 0 C--N 1.299 -2.062 0 C-N-CA 121.214 1.276 . . . . 0.0 109.355 -178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.602 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.86 111.86 24.77 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.029 -1.068 . . . . 0.0 108.884 -178.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 3.2 mttt -151.75 135.42 16.27 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.302 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.95 158.2 44.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.499 -0.751 . . . . 0.0 109.382 179.222 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.6 mtmt -115.45 141.48 48.0 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.956 ' CD1' HG21 ' A' ' 45' ' ' VAL . 9.4 mt -111.47 155.18 12.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 120.967 -1.083 . . . . 0.0 110.874 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.541 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.3 m80 -141.03 120.33 13.02 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 121.565 0.698 . . . . 0.0 110.003 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.898 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -101.87 148.87 24.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.638 -0.664 . . . . 0.0 109.59 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.53 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 11.5 t -133.63 127.88 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.119 -0.988 . . . . 0.0 109.08 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.606 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -113.45 -169.97 0.17 Allowed Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.606 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -80.04 32.34 0.49 Allowed 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.05 1.833 . . . . 0.0 113.046 -177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.63 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -137.59 16.22 2.92 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.298 -1.501 . . . . 0.0 110.036 179.258 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.66 33.66 81.4 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 106.345 -2.702 . . . . 0.0 106.345 -178.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.63 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -147.48 170.59 3.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 -177.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.64 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.1 m-70 -85.41 56.08 3.8 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.606 ' N ' ' HB2' ' A' ' 30' ' ' ASP . 2.5 ttt180 63.0 65.61 0.79 Allowed 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -178.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 3.5 m 46.32 90.22 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.352 -0.939 . . . . 0.0 108.5 -178.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 4.5 t0 -39.48 149.7 0.05 OUTLIER 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 -179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 93.7 -38.86 3.04 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.274 -1.13 . . . . 0.0 110.274 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.47 53.66 0.58 Allowed Glycine 0 N--CA 1.491 2.359 0 O-C-N 120.842 -1.387 . . . . 0.0 110.406 -179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.557 ' O ' ' N ' ' A' ' 43' ' ' PHE . 10.2 m-20 -107.68 111.21 23.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.01 -1.288 . . . . 0.0 109.179 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.539 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -63.17 76.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 178.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.898 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -106.27 123.95 48.84 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.398 -1.06 . . . . 0.0 111.31 -177.702 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.049 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -134.55 112.8 15.99 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 177.458 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.956 HG21 ' CD1' ' A' ' 26' ' ' ILE . 50.1 t -122.04 150.67 25.52 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.802 HG23 ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.06 133.59 7.02 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.907 -1.117 . . . . 0.0 110.821 -179.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.686 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.5 OUTLIER -123.36 156.74 29.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 177.669 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.57 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -167.42 151.37 6.56 Favored 'General case' 0 C--N 1.292 -1.912 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.73 177.724 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -153.98 -168.52 17.69 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.011 -2.036 . . . . 0.0 108.011 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.465 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -76.73 72.57 5.63 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.054 1.836 . . . . 0.0 110.203 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.024 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -161.74 177.9 1.81 Allowed Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.131 -0.981 . . . . 0.0 109.975 -179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.024 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.66 -46.23 0.14 Allowed 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.715 2.277 . . . . 0.0 110.269 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 53' ' ' VAL . 5.1 m -89.14 73.96 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.715 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 51.1 m-20 -90.58 -66.78 0.13 Allowed Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.138 -0.976 . . . . 0.0 111.119 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.715 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.5 Cg_endo -75.77 105.16 2.03 Favored 'Trans proline' 0 C--N 1.318 -1.072 0 C-N-CA 121.936 1.757 . . . . 0.0 110.888 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.649 HG11 ' O ' ' A' ' 68' ' ' GLU . 2.8 t -137.6 93.86 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.867 -1.146 . . . . 0.0 110.637 -179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.802 ' SD ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.85 139.43 36.3 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.845 -1.159 . . . . 0.0 110.505 178.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.93 156.82 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.315 -0.866 . . . . 0.0 109.937 -179.244 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.488 ' HB2' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -116.16 125.46 52.34 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.499 -0.751 . . . . 0.0 109.008 179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -88.95 -9.3 51.97 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.146 -0.971 . . . . 0.0 110.725 -179.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.458 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 75.44 8.43 83.83 Favored Glycine 0 N--CA 1.486 1.994 0 C-N-CA 119.563 -1.303 . . . . 0.0 110.057 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.463 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.5 p30 -100.9 28.11 5.48 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.18 -1.188 . . . . 0.0 109.383 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.64 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.61 1.93 62.8 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 15.6 p -133.65 148.63 51.54 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.552 -0.97 . . . . 0.0 109.125 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.604 ' CE2' ' HB3' ' A' ' 43' ' ' PHE . 11.0 m-85 -119.33 153.95 34.3 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.465 -179.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.3 OUTLIER -124.98 127.49 47.1 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.348 -0.845 . . . . 0.0 109.201 -179.371 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.873 HG11 HG11 ' A' ' 45' ' ' VAL . 1.8 m -122.33 147.54 26.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.649 ' O ' HG11 ' A' ' 56' ' ' VAL . 5.3 mt-10 -156.24 124.53 5.76 Favored 'General case' 0 N--CA 1.5 2.054 0 O-C-N 120.566 -1.334 . . . . 0.0 112.889 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.686 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.8 p90 -130.67 155.32 46.79 Favored 'General case' 0 N--CA 1.497 1.883 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 176.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -150.99 96.08 3.34 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 120.565 -1.335 . . . . 0.0 110.54 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.6 Cg_endo -80.49 -178.22 4.31 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 123.049 2.499 . . . . 0.0 111.63 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.478 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.67 32.0 1.64 Allowed 'General case' 0 N--CA 1.503 2.212 0 O-C-N 121.411 -0.806 . . . . 0.0 110.679 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 3.8 pt-20 -153.12 -162.6 1.51 Allowed 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.367 -1.458 . . . . 0.0 108.386 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.83 118.0 29.09 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 106.482 -1.674 . . . . 0.0 106.482 177.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.582 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.66 163.13 33.43 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.947 -176.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.488 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 28.4 p30 -112.13 158.05 20.09 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.949 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.3 m-85 -112.42 136.86 51.39 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.834 -177.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.679 ' C ' HD13 ' A' ' 79' ' ' ILE . 0.9 OUTLIER -110.34 131.6 60.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 176.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.778 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -109.38 158.24 9.41 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.783 0 CA-C-O 122.957 1.361 . . . . 0.0 112.736 -176.777 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.522 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.4 m120 -154.0 113.66 3.82 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.431 178.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.122 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -139.67 125.98 20.15 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 178.953 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.049 ' OG1' HG13 ' A' ' 44' ' ' VAL . 17.4 p -139.5 136.75 34.86 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.728 -0.789 . . . . 0.0 111.144 -176.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.835 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.8 tm? -135.85 73.71 1.48 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.605 178.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.11 -20.84 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.59 -1.44 5.2 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -178.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.461 ' C ' HG22 ' A' ' 82' ' ' THR . 1.5 p30 -124.65 164.0 20.82 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.632 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -106.75 159.05 16.52 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.598 -1.314 . . . . 0.0 109.452 -179.524 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 1.033 HG21 HD21 ' A' ' 81' ' ' LEU . 79.0 t -65.78 169.02 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 C-N-CA 119.04 -1.064 . . . . 0.0 108.73 -179.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.594 ' N ' HG12 ' A' ' 88' ' ' VAL . 54.1 p30 -83.21 29.06 0.5 Allowed 'General case' 0 N--CA 1.498 1.942 0 O-C-N 120.727 -1.233 . . . . 0.0 111.671 -177.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.93 20.18 1.12 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.165 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.122 ' CE1' HD23 ' A' ' 81' ' ' LEU . 8.4 m-85 -114.99 -38.64 0.08 OUTLIER Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.209 -1.171 . . . . 0.0 114.023 -178.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.628 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.9 Cg_endo -72.48 13.49 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.378 0 N-CA-C 108.429 -1.412 . . . . 0.0 108.429 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.541 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.9 tttm -100.61 177.18 5.08 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 27.5 m -130.76 132.08 45.09 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.1 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.866 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.1 t -97.53 155.09 3.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 178.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 38.0 m -119.75 148.74 43.05 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.539 -1.265 . . . . 0.0 113.298 -176.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.949 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -138.97 131.58 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 177.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.611 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -122.89 -63.84 0.03 OUTLIER Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 120.992 -1.068 . . . . 0.0 112.481 -178.11 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.611 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.8 Cg_endo -75.63 85.71 1.57 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 C-N-CA 121.573 1.515 . . . . 0.0 112.745 -177.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.93 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.606 ' HB1' HH21 ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.542 0.687 . . . . 0.0 109.562 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.598 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 15.5 t0 -113.76 42.79 0.26 Allowed Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.472 -0.767 . . . . 0.0 111.58 -179.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.598 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -77.88 -0.07 10.31 Favored 'Trans proline' 0 C--N 1.312 -1.363 0 C-N-CA 121.125 1.217 . . . . 0.0 108.944 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.1 OUTLIER -128.29 5.27 5.77 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.572 -0.705 . . . . 0.0 111.029 -178.222 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 3.5 mtpt -142.75 36.85 1.44 Allowed 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.825 -1.172 . . . . 0.0 107.951 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 67.6 m -114.38 114.22 25.57 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.6 -0.84 . . . . 0.0 108.853 -179.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.1 OUTLIER -136.37 140.75 43.47 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.952 -179.608 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.942 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.68 122.41 42.45 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -141.99 142.71 32.96 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 118.761 -1.176 . . . . 0.0 110.241 -179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.599 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.77 173.01 38.95 Favored Glycine 0 N--CA 1.481 1.686 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.501 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.1 Cg_endo -79.53 12.11 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.384 2.056 . . . . 0.0 108.603 176.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.998 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.01 157.74 14.89 Favored Glycine 0 C--O 1.202 -1.85 0 N-CA-C 108.196 -1.962 . . . . 0.0 108.196 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.998 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 83.83 -5.81 1.12 Allowed 'General case' 0 N--CA 1.497 1.925 0 CA-C-N 118.574 1.187 . . . . 0.0 110.303 179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -66.66 -19.51 65.78 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 178.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.711 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.21 -134.21 13.23 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.45 -61.18 0.07 OUTLIER Glycine 0 N--CA 1.492 2.389 0 O-C-N 121.913 -0.757 . . . . 0.0 111.81 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 47.4 mt-10 -127.07 142.37 51.55 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 120.887 -1.361 . . . . 0.0 111.798 -177.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.705 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.66 -20.76 24.49 Favored 'General case' 0 N--CA 1.5 2.064 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.717 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.728 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -89.7 13.4 14.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.106 -0.996 . . . . 0.0 109.666 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.3 143.56 26.5 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 105.693 -1.966 . . . . 0.0 105.693 177.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.507 ' HB2' ' HE2' ' A' ' 23' ' ' LYS . 29.9 Cg_endo -69.77 130.92 20.17 Favored 'Trans proline' 0 C--N 1.293 -2.355 0 C-N-CA 121.219 1.279 . . . . 0.0 109.344 -178.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.646 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 3.1 m -103.35 112.21 24.99 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.651 -1.219 . . . . 0.0 108.487 -179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.7 mttm -149.84 132.97 16.31 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 119.582 -0.847 . . . . 0.0 109.071 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.09 158.02 44.72 Favored 'General case' 0 C--N 1.294 -1.809 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.611 179.758 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -114.49 142.9 45.79 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.971 HD12 HG21 ' A' ' 45' ' ' VAL . 3.4 mt -111.63 150.63 13.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.365 -0.834 . . . . 0.0 110.453 -178.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.487 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.59 118.93 12.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.606 -0.684 . . . . 0.0 110.002 -179.51 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.032 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.25 129.2 53.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.662 -0.649 . . . . 0.0 110.797 179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.525 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 3.7 t -116.03 128.72 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 120.454 -1.404 . . . . 0.0 108.44 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.22 -174.93 0.36 Allowed Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.573 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.23 17.88 0.99 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 122.024 1.816 . . . . 0.0 111.786 -178.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.593 ' O ' HG23 ' A' ' 34' ' ' VAL . 51.8 m-20 -116.84 10.33 14.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.546 -1.347 . . . . 0.0 109.105 179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.93 38.75 89.24 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 106.225 -2.75 . . . . 0.0 106.225 -178.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.607 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.09 -161.21 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 122.077 -0.661 . . . . 0.0 109.272 -177.7 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.645 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 20.3 m80 -104.89 60.76 0.69 Allowed 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.676 ' NE ' HD11 ' A' ' 83' ' ' LEU . 0.0 OUTLIER 42.39 68.42 0.48 Allowed 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -178.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.464 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 42.5 82.77 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.559 -0.856 . . . . 0.0 108.745 -179.088 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.446 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 3.8 t0 -41.44 163.03 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.023 -1.048 . . . . 0.0 109.929 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 94.62 -40.1 2.78 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.69 58.65 0.7 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.015 -1.285 . . . . 0.0 110.426 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.539 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.8 m-20 -94.76 119.79 33.93 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.885 -1.362 . . . . 0.0 108.946 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.577 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.4 62.04 0.27 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.032 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.37 116.75 33.07 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.529 -0.983 . . . . 0.0 110.411 -178.781 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -126.23 114.4 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.982 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.002 HG22 HD23 ' A' ' 81' ' ' LEU . 3.4 t -119.13 153.03 21.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.291 -0.88 . . . . 0.0 109.56 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.513 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.69 130.4 4.38 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.863 179.81 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.66 HG12 HG23 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -123.69 156.52 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.542 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.11 152.96 4.41 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.166 -1.413 . . . . 0.0 110.609 176.541 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.407 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.72 -168.59 20.33 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.34 -1.904 . . . . 0.0 108.34 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.539 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.7 Cg_endo -76.55 72.1 5.71 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.326 2.017 . . . . 0.0 110.14 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.936 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.63 176.73 2.33 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.182 -0.949 . . . . 0.0 109.731 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.936 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.08 -45.05 0.17 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.679 2.253 . . . . 0.0 110.449 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 1.4 t -102.28 77.11 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.238 -0.914 . . . . 0.0 108.723 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.6 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.8 m-20 -89.63 -45.0 0.42 Allowed Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.023 -1.048 . . . . 0.0 111.274 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.6 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.7 Cg_endo -82.27 101.33 1.1 Allowed 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 122.25 1.966 . . . . 0.0 110.966 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.655 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.6 t -139.63 95.8 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.743 -1.223 . . . . 0.0 110.777 -179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.558 ' O ' ' HE2' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.98 136.17 33.49 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 118.731 -1.187 . . . . 0.0 110.589 178.865 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.6 156.38 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.6 -0.688 . . . . 0.0 109.562 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.55 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.0 t0 -126.69 125.32 41.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.553 -0.717 . . . . 0.0 109.413 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.426 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 1.2 t-20 -88.85 -16.52 31.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.181 -0.949 . . . . 0.0 110.87 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.98 -2.08 87.45 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 119.511 -1.328 . . . . 0.0 109.984 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 25.0 p-10 -91.69 30.23 1.39 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.225 -1.162 . . . . 0.0 109.759 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.645 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.68 -5.5 45.93 Favored Glycine 0 N--CA 1.495 2.577 0 N-CA-C 110.136 -1.185 . . . . 0.0 110.136 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.504 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 p -124.05 146.55 48.5 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.149 -1.207 . . . . 0.0 109.372 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.575 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.5 m-85 -124.36 155.38 38.87 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.149 -0.97 . . . . 0.0 110.046 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.4 t0 -131.6 133.31 44.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.961 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -126.25 146.48 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.655 ' O ' HG11 ' A' ' 56' ' ' VAL . 2.8 mp0 -151.88 124.88 8.6 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 120.562 -1.336 . . . . 0.0 112.927 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CE1' ' CB ' ' A' ' 22' ' ' SER . 4.9 p90 -131.48 154.83 48.33 Favored 'General case' 0 N--CA 1.5 2.026 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 176.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.513 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.7 OUTLIER -151.81 100.72 2.89 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 120.404 -1.435 . . . . 0.0 110.762 -178.482 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.426 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.0 Cg_endo -82.93 -178.8 4.05 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 C-N-CA 123.054 2.502 . . . . 0.0 111.887 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -142.51 32.67 1.47 Allowed 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.287 -0.883 . . . . 0.0 110.505 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.468 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.0 OUTLIER -152.43 -151.13 0.37 Allowed 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.431 -1.418 . . . . 0.0 108.76 179.538 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.701 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -97.87 122.15 40.63 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.55 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.1 162.24 34.05 Favored Glycine 0 N--CA 1.485 1.936 0 C-N-CA 118.651 -1.737 . . . . 0.0 111.554 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.509 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.8 OUTLIER -113.34 157.04 22.35 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.816 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.7 m-85 -113.17 137.85 50.84 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.03 -1.068 . . . . 0.0 110.639 -177.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.504 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -111.53 129.49 66.8 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 176.563 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.793 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -110.28 158.83 10.39 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-O 122.987 1.375 . . . . 0.0 112.009 -176.822 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.513 ' O ' ' N ' ' A' ' 46' ' ' THR . 5.9 m120 -150.53 113.73 4.85 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.002 HD23 HG22 ' A' ' 45' ' ' VAL . 0.5 OUTLIER -138.44 116.16 11.45 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 6.3 p -130.16 135.86 48.64 Favored 'General case' 0 C--N 1.293 -1.873 0 C-N-CA 119.062 -1.055 . . . . 0.0 112.218 -176.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.756 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.73 74.44 1.47 Allowed 'General case' 0 N--CA 1.5 2.047 0 C-N-CA 119.585 -0.846 . . . . 0.0 109.515 178.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.0 m-20 141.56 -23.07 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.22 2.32 4.63 Favored Glycine 0 N--CA 1.484 1.843 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.612 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -128.2 165.88 19.6 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 121.023 -1.28 . . . . 0.0 108.03 179.469 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.531 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 3.7 m120 -99.63 156.67 16.95 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 120.746 -1.221 . . . . 0.0 109.385 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.718 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.7 t -65.92 171.39 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 C-N-CA 119.24 -0.984 . . . . 0.0 108.396 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.57 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.0 OUTLIER -79.54 22.29 0.46 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.755 -1.216 . . . . 0.0 111.966 -177.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.0 15.83 1.03 Allowed Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.942 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.6 m-85 -109.84 -40.99 0.11 Allowed Pre-proline 0 N--CA 1.486 1.371 0 O-C-N 121.257 -1.143 . . . . 0.0 113.399 -178.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.603 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.29 14.79 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 N-CA-C 108.456 -1.402 . . . . 0.0 108.456 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.793 ' O ' HD12 ' A' ' 79' ' ' ILE . 2.0 tttt -101.71 176.68 5.14 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.521 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 14.1 m -127.78 130.77 49.27 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.509 -0.876 . . . . 0.0 109.743 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.842 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.2 t -97.08 155.11 3.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 54.0 m -120.88 142.91 49.24 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.631 -1.293 . . . . 0.0 113.209 -176.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.816 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.3 t -131.58 143.35 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.696 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.5 mttt -95.69 -170.7 0.23 Allowed Pre-proline 0 N--CA 1.495 1.806 0 O-C-N 121.358 -0.839 . . . . 0.0 109.641 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.701 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.4 Cg_endo -69.04 86.92 0.47 Allowed 'Trans proline' 0 C--N 1.322 -0.818 0 C-N-CA 121.322 1.348 . . . . 0.0 110.253 -178.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.728 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.571 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.509 -179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.561 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.574 0.702 . . . . 0.0 109.812 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.594 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 21.5 t0 -122.54 52.26 3.92 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.693 -0.629 . . . . 0.0 110.931 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -80.53 2.0 8.85 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 121.451 1.434 . . . . 0.0 108.453 177.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -142.0 10.04 1.94 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -177.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.515 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 4.4 mmmp? -139.79 38.03 2.0 Allowed 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.598 -1.313 . . . . 0.0 107.821 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 5.3 m -114.62 115.32 26.95 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.258 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.565 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 8.3 p90 -125.46 135.42 52.31 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.255 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.963 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.11 117.61 27.62 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.39 146.08 33.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.812 -1.18 . . . . 0.0 110.21 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.598 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.25 176.57 39.44 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.503 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.72 10.98 2.88 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.615 2.21 . . . . 0.0 108.686 176.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 1.002 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.32 158.19 14.69 Favored Glycine 0 C--O 1.201 -1.912 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.002 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 86.6 -8.3 0.7 Allowed 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 118.38 1.09 . . . . 0.0 110.342 179.652 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.503 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.3 m-20 -64.8 -21.11 66.71 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 177.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.684 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 77.26 -128.35 8.93 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.21 -1.156 . . . . 0.0 110.21 -179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.5 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.86 -59.63 0.05 OUTLIER Glycine 0 N--CA 1.492 2.394 0 C-N-CA 120.532 -0.842 . . . . 0.0 111.366 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.628 ' N ' HG22 ' A' ' 97' ' ' VAL . 6.5 mp0 -127.64 142.85 51.24 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.874 -1.368 . . . . 0.0 111.325 -178.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.756 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -89.09 -18.62 26.9 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.935 179.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.743 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.0 m-85 -92.61 12.8 21.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.051 -1.031 . . . . 0.0 110.847 -178.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' NE2' ' O ' ' A' ' 15' ' ' GLY . 16.2 pt20 -98.43 154.81 37.41 Favored Pre-proline 0 C--N 1.296 -1.755 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 177.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.425 ' HA ' ' OE1' ' A' ' 70' ' ' GLU . 30.4 Cg_endo -72.0 123.52 9.35 Favored 'Trans proline' 0 C--N 1.297 -2.177 0 C-N-CA 121.502 1.468 . . . . 0.0 108.942 -179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.628 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -103.9 110.38 22.49 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.345 -1.342 . . . . 0.0 108.088 -179.302 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 18.9 mttt -152.76 136.28 15.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.635 -0.665 . . . . 0.0 109.795 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.673 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.17 158.52 43.92 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.478 -0.764 . . . . 0.0 109.343 179.257 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.2 mptp? -114.58 142.77 46.0 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.893 HG23 ' HB2' ' A' ' 8' ' ' ALA . 3.0 mt -114.96 155.33 16.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.281 -0.968 . . . . 0.0 110.297 -178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.565 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.1 m80 -145.78 114.84 7.0 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.417 0.627 . . . . 0.0 110.463 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -89.43 143.15 27.05 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.694 -0.629 . . . . 0.0 109.855 179.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.532 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -127.57 122.84 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.559 -1.338 . . . . 0.0 107.96 178.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.581 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER -102.44 -176.02 0.43 Allowed Pre-proline 0 C--N 1.293 -1.878 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.288 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.57 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -78.26 20.64 0.73 Allowed 'Trans proline' 0 C--N 1.304 -1.782 0 C-N-CA 122.041 1.827 . . . . 0.0 111.652 -179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG23 ' A' ' 34' ' ' VAL . 75.5 m-20 -119.1 10.88 12.24 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.558 -1.339 . . . . 0.0 109.356 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 67.9 37.85 88.5 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 106.076 -2.81 . . . . 0.0 106.076 -178.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.597 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.7 OUTLIER -150.0 -167.0 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -177.695 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.616 ' CD2' ' O ' ' A' ' 28' ' ' ALA . 59.2 m80 -101.1 55.86 0.85 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.581 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 2.4 mtp180 53.25 60.85 3.46 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 38' ' ' ASP . 9.0 m 48.29 93.83 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -178.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.542 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -45.75 177.93 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.913 -1.117 . . . . 0.0 110.716 -178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 48.23 54.18 13.34 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 155.11 61.55 0.01 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 43' ' ' PHE . 57.5 m-20 -124.5 126.06 45.24 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.983 -1.304 . . . . 0.0 109.326 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.71 64.03 0.46 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.45 119.44 38.01 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.694 -0.886 . . . . 0.0 110.757 -178.634 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.047 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.98 114.19 26.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.74 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.1 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.71 152.44 23.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.361 -0.837 . . . . 0.0 109.152 -179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.82 130.82 5.07 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.885 179.681 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.659 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.78 156.29 26.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 177.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.519 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.3 OUTLIER -170.8 155.86 4.88 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 118.085 -1.446 . . . . 0.0 110.883 176.807 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.67 -168.64 22.85 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 107.771 -2.131 . . . . 0.0 107.771 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.533 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.3 Cg_endo -76.56 73.09 5.33 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.139 1.892 . . . . 0.0 110.062 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.975 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.32 178.29 1.74 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 109.451 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.975 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.0 Cg_endo -77.64 -55.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.541 2.161 . . . . 0.0 110.616 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.704 HG12 ' CG2' ' A' ' 56' ' ' VAL . 54.5 t -89.54 75.07 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.629 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 68.1 m-20 -89.76 -48.11 0.39 Allowed Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 120.953 -1.092 . . . . 0.0 111.031 -178.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.629 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -81.16 94.93 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 122.147 1.898 . . . . 0.0 110.968 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.704 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.5 t -132.95 91.6 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.787 -1.196 . . . . 0.0 110.481 -179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -140.0 137.68 34.87 Favored 'General case' 0 C--N 1.295 -1.767 0 C-N-CA 118.913 -1.115 . . . . 0.0 110.08 179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.15 156.75 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.468 -0.77 . . . . 0.0 110.415 -179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 6.1 t0 -110.0 133.67 52.95 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.461 ' OD1' ' O ' ' A' ' 64' ' ' THR . 5.1 m120 -89.23 -33.67 16.91 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.172 -0.955 . . . . 0.0 110.726 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.464 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 101.02 -9.69 58.17 Favored Glycine 0 N--CA 1.486 1.974 0 C-N-CA 119.27 -1.443 . . . . 0.0 109.954 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.505 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 34.7 p30 -100.84 39.55 1.37 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.148 -1.207 . . . . 0.0 109.684 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.57 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.14 -0.12 32.84 Favored Glycine 0 N--CA 1.494 2.566 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.558 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 10.5 p -125.96 148.17 49.32 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.147 -1.208 . . . . 0.0 110.028 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.2 m-85 -127.75 155.21 44.38 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.345 -0.847 . . . . 0.0 109.431 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -128.74 134.09 48.32 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.905 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.673 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -127.25 144.1 38.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 21.2 mp0 -152.61 130.66 11.85 Favored 'General case' 0 N--CA 1.504 2.257 0 O-C-N 120.5 -1.375 . . . . 0.0 112.95 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 47' ' ' ILE . 1.6 p90 -132.92 155.49 48.97 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.425 ' OE1' ' HA ' ' A' ' 21' ' ' PRO . 6.5 tp10 -149.97 97.39 3.43 Favored Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 120.739 -1.226 . . . . 0.0 110.229 -178.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.474 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -81.89 174.84 9.86 Favored 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.895 2.397 . . . . 0.0 111.865 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.563 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -138.34 31.06 2.38 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.462 -0.774 . . . . 0.0 109.681 179.307 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.465 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 12.3 pt-20 -152.5 -151.83 0.4 Allowed 'General case' 0 N--CA 1.484 1.262 0 O-C-N 120.561 -1.337 . . . . 0.0 108.678 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.845 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -98.5 125.58 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 106.833 -1.544 . . . . 0.0 106.833 178.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.88 161.87 33.66 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.562 -1.78 . . . . 0.0 111.588 -176.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 35.3 p-10 -113.07 156.23 23.5 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.731 ' OH ' HG21 ' A' ' 97' ' ' VAL . 6.0 m-30 -114.87 141.03 48.46 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.963 -177.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.673 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -119.48 128.45 75.86 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.159 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 177.004 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.693 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.06 158.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 CA-C-O 122.993 1.377 . . . . 0.0 112.228 -177.327 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.463 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.9 m120 -148.67 113.63 5.45 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.065 -1.458 . . . . 0.0 107.065 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.1 HD23 HG22 ' A' ' 45' ' ' VAL . 1.0 OUTLIER -136.89 120.91 17.69 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.047 ' OG1' HG13 ' A' ' 44' ' ' VAL . 4.3 p -135.01 137.04 42.61 Favored 'General case' 0 N--CA 1.494 1.729 0 C-N-CA 118.777 -1.169 . . . . 0.0 112.335 -176.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.88 74.82 1.48 Allowed 'General case' 0 N--CA 1.499 2.023 0 C-N-CA 119.644 -0.823 . . . . 0.0 109.499 178.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.593 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 17.3 m-20 141.51 -21.97 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.33 2.7 4.94 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 -178.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.85 ' O ' HG22 ' A' ' 82' ' ' THR . 31.6 t0 -128.52 175.78 8.27 Favored 'General case' 0 N--CA 1.483 1.197 0 O-C-N 120.969 -1.313 . . . . 0.0 107.873 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.601 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -110.15 156.47 20.57 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.718 -1.239 . . . . 0.0 109.971 -179.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.771 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.9 t -66.41 169.96 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 C-N-CA 119.306 -0.958 . . . . 0.0 108.656 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.559 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 42.5 p-10 -81.62 23.8 0.63 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.929 -1.107 . . . . 0.0 111.776 -177.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.07 13.99 1.3 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.921 -1.271 . . . . 0.0 109.921 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.963 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.5 m-85 -108.42 -38.83 0.14 Allowed Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.213 -1.169 . . . . 0.0 113.358 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.584 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.8 Cg_endo -73.95 16.19 0.55 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.325 -1.452 . . . . 0.0 108.325 178.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.537 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.43 165.24 11.54 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.256 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 17.1 m -120.71 126.96 51.52 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.781 -0.768 . . . . 0.0 109.737 -179.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.684 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.0 t -98.71 155.11 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 107.232 -1.396 . . . . 0.0 107.232 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 39.7 m -121.58 137.18 54.84 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.531 -1.356 . . . . 0.0 113.408 -176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.756 HG11 ' SG ' ' A' ' 18' ' ' CYS . 3.0 t -120.69 144.24 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 176.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.628 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -95.18 -175.35 0.46 Allowed Pre-proline 0 C--N 1.3 -1.56 0 O-C-N 121.379 -0.825 . . . . 0.0 109.467 -178.139 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.845 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.0 Cg_endo -68.67 86.37 0.45 Allowed 'Trans proline' 0 C--N 1.318 -1.042 0 C-N-CA 121.122 1.215 . . . . 0.0 109.749 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.743 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.392 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.343 -179.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.564 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.653 0.74 . . . . 0.0 109.609 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.627 ' HB3' HD12 ' A' ' 83' ' ' LEU . 24.4 t0 -122.01 51.0 2.72 Favored Pre-proline 0 C--N 1.3 -1.55 0 O-C-N 121.638 -0.664 . . . . 0.0 110.511 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.601 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -78.63 0.77 9.66 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.463 1.442 . . . . 0.0 108.576 177.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -141.57 13.87 2.14 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.578 -0.701 . . . . 0.0 111.124 -178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.553 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -141.23 34.19 1.7 Allowed 'General case' 0 C--N 1.296 -1.718 0 O-C-N 120.81 -1.181 . . . . 0.0 108.064 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 3.6 m -115.61 113.84 24.11 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.554 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.3 p90 -128.74 140.25 51.82 Favored 'General case' 0 N--CA 1.493 1.693 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.857 -179.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.775 ' HB2' HD22 ' A' ' 81' ' ' LEU . . . -119.11 122.29 41.73 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.4 pp20? -141.33 140.18 33.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.899 -1.126 . . . . 0.0 109.98 -179.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.615 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.55 173.76 38.85 Favored Glycine 0 N--CA 1.482 1.754 0 C-N-CA 119.735 -1.221 . . . . 0.0 110.268 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 34.8 Cg_endo -78.87 7.67 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.72 2.28 . . . . 0.0 108.958 177.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.971 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.38 157.39 15.13 Favored Glycine 0 C--O 1.201 -1.916 0 N-CA-C 108.298 -1.921 . . . . 0.0 108.298 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.971 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.01 -6.91 0.36 Allowed 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 118.319 1.06 . . . . 0.0 110.494 179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.523 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.1 m-20 -70.75 -17.5 62.79 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.681 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 76.78 -131.96 11.89 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.525 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.96 -65.7 0.34 Allowed Glycine 0 N--CA 1.492 2.378 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.674 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.601 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.2 mt-10 -123.69 143.84 50.02 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.065 -1.256 . . . . 0.0 111.737 -177.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.73 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.43 -21.08 24.43 Favored 'General case' 0 N--CA 1.5 2.07 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.773 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.887 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 13.6 m-85 -89.29 14.04 12.02 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.929 -1.107 . . . . 0.0 110.214 -178.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.541 ' CG ' ' HD2' ' A' ' 21' ' ' PRO . 55.7 tt0 -99.46 140.56 21.72 Favored Pre-proline 0 C--N 1.294 -1.82 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 176.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 20' ' ' GLN . 28.7 Cg_endo -67.55 130.94 23.29 Favored 'Trans proline' 0 C--N 1.298 -2.083 0 N-CA-C 108.696 -1.309 . . . . 0.0 108.696 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.619 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.54 110.55 22.88 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 118.635 -1.226 . . . . 0.0 108.937 -178.439 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 7.6 mttt -150.31 135.97 18.26 Favored 'General case' 0 C--N 1.301 -1.513 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.847 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.656 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.74 158.32 44.29 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.629 -0.67 . . . . 0.0 109.279 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 mtmt -114.73 139.01 50.04 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.989 HD12 HG21 ' A' ' 45' ' ' VAL . 3.2 mt -108.42 153.83 9.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 C-N-CA 119.297 -0.961 . . . . 0.0 109.795 -178.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.0 m80 -139.21 115.36 10.32 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 121.487 0.66 . . . . 0.0 109.678 -179.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB2' ' HE2' ' A' ' 43' ' ' PHE . . . -96.47 146.18 25.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.468 -0.77 . . . . 0.0 109.522 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.512 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.6 t -134.03 121.58 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 178.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.6 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -102.52 -175.0 0.37 Allowed Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.458 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.6 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 35.2 Cg_endo -79.02 19.65 0.88 Allowed 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.039 1.826 . . . . 0.0 111.465 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.501 ' C ' HG23 ' A' ' 34' ' ' VAL . 30.9 t70 -122.27 12.1 10.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.593 -1.317 . . . . 0.0 109.398 179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.414 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.48 34.69 60.13 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 106.502 -2.639 . . . . 0.0 106.502 -178.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.4 OUTLIER -149.87 171.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 122.08 -0.659 . . . . 0.0 109.333 -177.834 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.604 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.0 m-70 -86.21 55.12 3.4 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 178.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.558 ' HG2' ' CB ' ' A' ' 30' ' ' ASP . 0.1 OUTLIER 63.34 69.07 0.58 Allowed 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.403 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.465 ' O ' ' C ' ' A' ' 38' ' ' ASP . 0.0 OUTLIER 44.01 87.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.648 -179.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 5.7 t0 -39.6 148.51 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.21 -0.931 . . . . 0.0 110.076 -178.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.63 3.19 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.55 51.68 0.69 Allowed Glycine 0 N--CA 1.492 2.373 0 O-C-N 121.054 -1.263 . . . . 0.0 110.187 -179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.54 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -99.92 118.73 36.97 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.054 -1.262 . . . . 0.0 109.271 179.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.503 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.96 69.34 0.31 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 107.237 -2.345 . . . . 0.0 107.237 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.862 ' HE2' ' HB2' ' A' ' 28' ' ' ALA . 0.3 OUTLIER -105.66 130.3 53.71 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.876 0.846 . . . . 0.0 111.369 -177.678 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.06 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -139.38 113.27 6.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 177.704 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.989 HG21 HD12 ' A' ' 26' ' ' ILE . 42.7 t -118.95 151.39 21.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.269 -0.894 . . . . 0.0 108.662 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.543 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -159.36 130.14 5.93 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.183 -1.007 . . . . 0.0 110.808 -178.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.658 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -123.04 156.37 28.74 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 177.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.532 ' HA ' ' HB3' ' A' ' 54' ' ' ASP . 0.0 OUTLIER -171.23 155.82 4.46 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 118.407 -1.317 . . . . 0.0 110.56 176.863 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -158.89 -169.73 22.62 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.425 ' HG2' ' CA ' ' A' ' 75' ' ' GLY . 35.1 Cg_endo -77.48 70.08 6.98 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 C-N-CA 122.324 2.016 . . . . 0.0 110.325 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.2 179.48 1.36 Allowed Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.086 -179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -75.91 -56.04 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.312 2.008 . . . . 0.0 111.196 -179.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.1 t -89.4 80.98 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.044 -1.035 . . . . 0.0 108.911 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.64 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 78.8 m-20 -96.96 -47.83 0.24 Allowed Pre-proline 0 N--CA 1.488 1.456 0 O-C-N 120.858 -1.151 . . . . 0.0 111.771 -178.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.64 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.4 Cg_endo -84.07 105.89 1.16 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 C-N-CA 122.169 1.913 . . . . 0.0 111.337 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 68' ' ' GLU . 16.3 t -144.71 97.23 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 O-C-N 120.807 -1.183 . . . . 0.0 110.788 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.28 138.09 34.71 Favored 'General case' 0 C--N 1.297 -1.696 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.412 178.554 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -137.13 155.85 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.417 -0.802 . . . . 0.0 110.247 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.563 ' CG ' ' CE1' ' A' ' 65' ' ' TYR . 11.6 t0 -118.41 127.36 53.59 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.51 -0.744 . . . . 0.0 109.036 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.36 -21.68 24.21 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.109 -0.994 . . . . 0.0 111.004 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.51 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 88.79 4.46 75.64 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.343 -1.408 . . . . 0.0 110.401 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 30.7 p-10 -102.15 25.4 8.87 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.01 -1.288 . . . . 0.0 109.665 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.604 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.39 -8.82 57.47 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 20.6 p -123.81 137.11 54.72 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.672 -0.899 . . . . 0.0 108.704 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE1' ' CG ' ' A' ' 59' ' ' ASP . 16.3 m-85 -120.41 156.14 32.0 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.974 -1.079 . . . . 0.0 109.465 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.465 ' OD2' ' OE2' ' A' ' 68' ' ' GLU . 25.0 t70 -128.01 138.89 52.77 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 120.974 -1.079 . . . . 0.0 110.371 -178.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.867 HG11 HG11 ' A' ' 45' ' ' VAL . 2.2 m -126.75 148.07 31.57 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.646 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.3 mt-10 -154.89 125.57 6.98 Favored 'General case' 0 N--CA 1.502 2.156 0 O-C-N 120.499 -1.376 . . . . 0.0 112.883 -178.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.658 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.5 p90 -131.63 156.44 45.81 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 176.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -148.15 107.38 3.64 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 120.813 -1.179 . . . . 0.0 109.855 -178.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.34 -157.82 0.08 OUTLIER 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 122.94 2.426 . . . . 0.0 111.655 -179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.605 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -145.57 -59.34 0.33 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.379 -0.826 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.474 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 9.4 pt-20 -94.26 -134.13 0.18 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.694 -1.253 . . . . 0.0 109.959 -178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.878 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -90.46 133.58 34.94 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.757 -1.214 . . . . 0.0 108.831 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.507 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.54 158.29 30.07 Favored Glycine 0 N--CA 1.483 1.81 0 C-N-CA 118.867 -1.635 . . . . 0.0 110.905 -178.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 3.8 p-10 -115.83 156.61 25.78 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.81 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.07 138.45 50.86 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 119.004 -1.078 . . . . 0.0 111.214 -177.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -116.83 126.63 74.37 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.077 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 176.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.748 HG22 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -108.1 158.72 7.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-O 122.891 1.329 . . . . 0.0 112.971 -175.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.543 ' O ' ' N ' ' A' ' 46' ' ' THR . 1.4 m-80 -154.02 113.96 3.86 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.178 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.112 HD23 ' CE1' ' A' ' 91' ' ' PHE . 0.3 OUTLIER -138.24 125.9 22.21 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 106.614 -1.624 . . . . 0.0 106.614 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.06 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.4 p -135.63 137.52 41.96 Favored 'General case' 0 C--N 1.292 -1.919 0 C-N-CA 119.349 -0.941 . . . . 0.0 111.623 -177.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -135.52 74.01 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 C-N-CA 119.278 -0.969 . . . . 0.0 109.452 178.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 14.3 m-20 141.26 -22.58 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.151 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.73 -0.85 4.64 Favored Glycine 0 N--CA 1.484 1.855 0 N-CA-C 108.929 -1.668 . . . . 0.0 108.929 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.805 ' O ' HG22 ' A' ' 82' ' ' THR . 5.1 m-20 -123.88 166.38 15.75 Favored 'General case' 0 N--CA 1.483 1.213 0 O-C-N 121.016 -1.284 . . . . 0.0 107.548 179.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.633 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -106.25 158.31 16.95 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.675 -1.266 . . . . 0.0 109.21 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.957 HG21 HD21 ' A' ' 81' ' ' LEU . 97.4 t -66.14 169.57 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 C-N-CA 118.979 -1.088 . . . . 0.0 108.866 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.613 ' N ' HG12 ' A' ' 88' ' ' VAL . 0.5 OUTLIER -81.63 28.25 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.77 -1.207 . . . . 0.0 111.737 -177.854 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.22 20.99 1.09 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.112 ' CE1' HD23 ' A' ' 81' ' ' LEU . 6.9 m-85 -115.04 -40.08 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.086 -1.244 . . . . 0.0 113.984 -178.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.0 Cg_endo -72.37 15.42 0.42 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 N-CA-C 108.785 -1.275 . . . . 0.0 108.785 178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.679 ' O ' HD12 ' A' ' 79' ' ' ILE . 16.5 tttp -100.12 169.27 9.28 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.574 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 20.1 m -123.79 127.67 48.43 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.156 -179.181 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.681 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.7 t -98.86 155.3 3.9 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.518 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 47.3 m -121.98 142.42 50.32 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.316 -1.354 . . . . 0.0 113.446 -176.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.81 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -124.22 148.24 28.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.62 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -94.47 179.31 1.24 Allowed Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.279 -0.888 . . . . 0.0 110.15 -177.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.878 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 27.1 Cg_endo -65.96 81.05 0.27 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.682 1.588 . . . . 0.0 110.843 -178.098 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.887 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.304 -1.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.615 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.553 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.503 0.668 . . . . 0.0 109.695 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.59 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 24.4 t0 -115.26 44.93 0.38 Allowed Pre-proline 0 C--N 1.3 -1.554 0 O-C-N 121.562 -0.711 . . . . 0.0 111.651 -179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.59 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.8 Cg_endo -77.49 0.69 9.53 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.331 1.354 . . . . 0.0 108.876 177.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -132.91 11.63 4.31 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.397 -0.815 . . . . 0.0 110.947 -178.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -147.98 35.0 0.83 Allowed 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.868 -1.145 . . . . 0.0 108.145 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.505 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 41.4 m -114.83 114.28 25.34 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.3 OUTLIER -137.83 144.61 41.56 Favored 'General case' 0 C--N 1.295 -1.775 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.692 -179.715 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.958 ' HB3' ' CE2' ' A' ' 91' ' ' PHE . . . -118.89 122.39 42.19 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -140.75 141.31 34.88 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.156 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.613 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.9 175.88 39.23 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -79.06 5.41 5.76 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.453 2.102 . . . . 0.0 108.781 177.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.66 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -118.03 156.48 15.62 Favored Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.926 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 94.96 -26.51 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.442 0 CA-C-N 117.488 0.644 . . . . 0.0 110.891 179.036 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.581 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -52.2 -21.09 3.04 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.73 -127.35 8.11 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.579 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 66.04 -62.32 0.14 Allowed Glycine 0 N--CA 1.492 2.415 0 O-C-N 121.816 -0.814 . . . . 0.0 111.604 179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.645 ' N ' HG22 ' A' ' 97' ' ' VAL . 38.9 mp0 -130.62 141.87 50.44 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.811 -1.405 . . . . 0.0 112.03 -178.016 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.716 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.58 -20.19 25.34 Favored 'General case' 0 N--CA 1.504 2.232 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.421 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.04 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.72 10.17 21.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 110.367 -178.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.42 ' OE1' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -99.09 153.21 37.9 Favored Pre-proline 0 C--N 1.295 -1.788 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 177.102 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HD2' ' OE1' ' A' ' 20' ' ' GLN . 30.5 Cg_endo -71.84 128.15 13.82 Favored 'Trans proline' 0 C--N 1.297 -2.181 0 C-N-CA 121.305 1.337 . . . . 0.0 108.656 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.74 110.09 22.28 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.571 -178.866 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.567 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 16.5 mttt -151.91 136.13 16.67 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-O 121.458 0.647 . . . . 0.0 110.011 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.669 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.58 158.97 43.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.443 -0.786 . . . . 0.0 109.479 179.251 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.433 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.0 OUTLIER -114.05 140.67 48.27 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.783 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.854 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -108.17 150.53 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.194 -0.942 . . . . 0.0 110.272 -178.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.486 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.1 OUTLIER -137.09 117.92 14.13 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 120.069 -0.653 . . . . 0.0 110.261 -178.697 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.979 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.45 138.85 40.23 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.579 -0.701 . . . . 0.0 109.497 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.535 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 1.2 t -129.58 129.17 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.952 -1.093 . . . . 0.0 108.366 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -109.66 -173.68 0.27 Allowed Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.598 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.4 Cg_endo -79.14 19.47 0.91 Allowed 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 121.977 1.785 . . . . 0.0 111.549 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.525 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.9 m-20 -118.32 8.93 12.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.706 -1.246 . . . . 0.0 109.362 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.2 32.74 57.93 Favored Glycine 0 N--CA 1.486 2.009 0 N-CA-C 106.425 -2.67 . . . . 0.0 106.425 -178.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.0 OUTLIER -151.13 178.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 122.106 -0.644 . . . . 0.0 109.333 -177.648 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.613 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.6 m-70 -90.37 66.54 6.49 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 178.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.584 ' HD2' HD11 ' A' ' 83' ' ' LEU . 11.7 ptm180 46.99 76.02 0.11 Allowed 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.629 0.728 . . . . 0.0 109.284 -178.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 45.61 84.23 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.174 -179.772 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 1.0 OUTLIER -45.1 164.66 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.8 -1.187 . . . . 0.0 109.672 -179.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 87.04 -39.3 3.1 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -129.67 61.52 0.66 Allowed Glycine 0 N--CA 1.491 2.302 0 O-C-N 120.942 -1.328 . . . . 0.0 109.973 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.518 ' O ' ' N ' ' A' ' 43' ' ' PHE . 38.6 m-20 -96.83 127.1 42.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 109.351 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.525 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.89 63.03 0.49 Allowed Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.349 -1.9 . . . . 0.0 108.349 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.979 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.58 117.64 35.32 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.466 -1.02 . . . . 0.0 110.612 -178.566 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.037 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -127.29 114.22 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 177.768 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.056 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -120.64 153.35 23.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.426 -0.796 . . . . 0.0 109.264 -179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.516 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.05 128.38 4.18 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.596 179.903 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.646 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.09 156.67 24.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.101 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.533 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.51 152.6 3.97 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.551 176.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.464 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.45 -168.49 18.61 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.2 -1.96 . . . . 0.0 108.2 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.509 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.8 Cg_endo -75.56 72.16 5.09 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 122.149 1.899 . . . . 0.0 109.914 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.43 178.07 1.85 Allowed Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.306 -0.871 . . . . 0.0 109.639 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.94 -55.18 0.05 OUTLIER 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.77 2.313 . . . . 0.0 110.591 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.51 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.0 t -89.12 74.22 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.168 -0.957 . . . . 0.0 108.767 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.61 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 81.1 m-20 -89.91 -46.22 0.4 Allowed Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 120.988 -1.07 . . . . 0.0 111.122 -178.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.43 98.03 0.9 Allowed 'Trans proline' 0 C--N 1.314 -1.237 0 C-N-CA 122.203 1.936 . . . . 0.0 111.097 -179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.632 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.4 t -135.81 93.75 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.712 -1.242 . . . . 0.0 110.69 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.48 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.1 OUTLIER -138.32 135.8 35.78 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.789 -1.165 . . . . 0.0 109.978 178.707 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.99 156.51 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.48 -0.763 . . . . 0.0 110.014 -178.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.547 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 3.1 t0 -114.89 128.22 56.16 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -88.39 -16.38 33.06 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.128 -0.982 . . . . 0.0 110.706 -179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.42 15.58 80.72 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.064 179.229 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD2' ' OG1' ' A' ' 64' ' ' THR . 10.2 p-10 -115.11 30.5 7.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.074 -1.251 . . . . 0.0 109.686 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.613 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 78.46 -2.47 66.96 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.508 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 19.0 p -132.05 149.96 52.28 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.462 -1.022 . . . . 0.0 109.384 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.565 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -124.63 155.8 38.55 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.173 -0.954 . . . . 0.0 110.401 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.453 ' OD1' ' N ' ' A' ' 66' ' ' ASP . 0.8 OUTLIER -127.89 130.58 48.77 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.301 -0.874 . . . . 0.0 110.088 -179.101 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.669 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.55 144.42 33.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.632 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.3 mp0 -150.28 127.17 11.07 Favored 'General case' 0 N--CA 1.504 2.251 0 O-C-N 120.513 -1.367 . . . . 0.0 112.823 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.646 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.1 p90 -133.15 154.55 50.51 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 175.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.51 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 0.0 OUTLIER -151.56 96.35 3.2 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 120.655 -1.278 . . . . 0.0 110.766 -178.114 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.483 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.75 178.35 7.07 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 123.059 2.506 . . . . 0.0 111.78 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.536 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.1 OUTLIER -138.43 31.7 2.33 Favored 'General case' 0 N--CA 1.502 2.159 0 O-C-N 121.466 -0.771 . . . . 0.0 110.304 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 100' ' ' ALA . 2.5 pt-20 -152.43 -161.5 1.32 Allowed 'General case' 0 C--N 1.306 -1.312 0 O-C-N 120.457 -1.402 . . . . 0.0 108.028 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.67 123.43 33.7 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.12 162.41 33.17 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 119.065 -1.541 . . . . 0.0 111.263 -176.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' A' ' 76' ' ' ASP . 3.8 p-10 -112.99 157.73 21.15 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.817 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-30 -113.51 139.69 48.76 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.091 -177.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -116.39 127.36 74.02 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.926 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -108.43 158.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-O 123.195 1.474 . . . . 0.0 112.636 -176.465 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.4 m120 -149.05 113.51 5.29 Favored 'General case' 0 C--N 1.291 -1.944 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 178.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.056 HD23 HG22 ' A' ' 45' ' ' VAL . 0.9 OUTLIER -137.49 118.41 14.25 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.358 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.037 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -132.75 135.7 45.9 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.757 -1.177 . . . . 0.0 112.559 -176.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.79 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -140.54 75.25 1.5 Allowed 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.493 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.591 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 13.0 m-20 142.67 -23.66 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.196 0 N-CA-C 108.226 -1.028 . . . . 0.0 108.226 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.61 3.5 4.15 Favored Glycine 0 N--CA 1.483 1.819 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.922 ' O ' HG22 ' A' ' 82' ' ' THR . 0.2 OUTLIER -130.5 173.76 10.54 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.813 -1.404 . . . . 0.0 108.306 179.51 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.591 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 10.8 m120 -104.25 154.76 19.39 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.789 -1.194 . . . . 0.0 109.428 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.758 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.12 171.28 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.19 -0.944 . . . . 0.0 108.634 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.568 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 14.6 t-20 -80.66 22.93 0.55 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.776 -1.202 . . . . 0.0 111.872 -177.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.78 18.56 0.98 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 179.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.958 ' CE2' ' HB3' ' A' ' 8' ' ' ALA . 3.4 m-85 -112.24 -45.79 0.07 OUTLIER Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.088 -1.243 . . . . 0.0 113.661 -177.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.65 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.7 Cg_endo -71.47 14.99 0.36 Allowed 'Trans proline' 0 C--N 1.309 -1.53 0 N-CA-C 108.901 -1.23 . . . . 0.0 108.901 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 9.3 tttt -101.16 176.22 5.33 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.543 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 39.6 m -126.41 129.28 48.43 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.524 -0.871 . . . . 0.0 110.217 -179.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 10.7 t -98.72 156.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.493 ' CG2' ' HD2' ' A' ' 98' ' ' LYS . 73.3 m -120.53 138.04 54.06 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.605 -1.309 . . . . 0.0 113.256 -176.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.817 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -124.69 130.35 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 176.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.61 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -120.2 -67.53 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 120.895 -1.128 . . . . 0.0 112.323 -178.095 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.61 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.4 Cg_endo -73.13 78.63 2.19 Favored 'Trans proline' 0 C--N 1.315 -1.196 0 C-N-CA 121.656 1.571 . . . . 0.0 111.708 -178.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 1.04 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.925 . . . . 0.0 109.749 178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.555 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.556 0.693 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.622 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 22.6 t0 -113.73 41.08 0.24 Allowed Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.479 -0.763 . . . . 0.0 111.65 -179.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.622 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.1 Cg_endo -78.25 0.14 10.17 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 N-CA-C 108.71 -1.304 . . . . 0.0 108.71 177.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.15 9.76 5.29 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.618 -0.676 . . . . 0.0 110.764 -178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.4 OUTLIER -146.59 35.35 0.95 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.904 -1.122 . . . . 0.0 108.054 -179.494 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.483 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.9 m -114.27 114.09 25.5 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.313 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -137.22 142.31 42.07 Favored 'General case' 0 C--N 1.293 -1.85 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.532 -179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.977 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.35 125.69 50.56 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -141.38 141.31 33.8 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.036 -1.065 . . . . 0.0 109.974 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 174.49 39.36 Favored Glycine 0 N--CA 1.481 1.681 0 C-N-CA 119.787 -1.197 . . . . 0.0 110.165 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.0 Cg_endo -79.21 8.55 3.8 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.694 2.263 . . . . 0.0 108.702 176.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.949 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.08 157.19 15.2 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.949 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 88.38 -7.12 0.52 Allowed 'General case' 0 N--CA 1.499 1.985 0 CA-C-N 118.297 1.049 . . . . 0.0 110.271 179.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.425 ' C ' HG11 ' A' ' 95' ' ' VAL . 5.2 m-20 -68.4 -18.94 64.57 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.694 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.73 -129.51 9.19 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.596 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 63.59 -62.09 0.04 OUTLIER Glycine 0 N--CA 1.493 2.469 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.581 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.632 ' N ' HG22 ' A' ' 97' ' ' VAL . 3.2 mp0 -129.05 141.15 51.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.852 -1.381 . . . . 0.0 111.841 -178.161 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.67 -18.75 27.26 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.603 179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.787 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 53.8 m-85 -88.58 9.49 23.8 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.175 -0.953 . . . . 0.0 110.588 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.481 ' HG2' ' O ' ' A' ' 17' ' ' GLU . 3.7 pt20 -98.75 152.36 37.82 Favored Pre-proline 0 C--N 1.294 -1.841 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -71.09 129.93 16.94 Favored 'Trans proline' 0 C--N 1.294 -2.316 0 C-N-CA 121.353 1.368 . . . . 0.0 108.883 -179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.613 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.29 111.29 23.86 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.84 -1.144 . . . . 0.0 108.543 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.571 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.8 mtmp? -151.73 134.38 15.51 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.31 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.637 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.33 159.88 41.29 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.624 -0.672 . . . . 0.0 109.278 179.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.445 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -114.84 140.76 48.68 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.911 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.109 HD13 HG21 ' A' ' 45' ' ' VAL . 3.0 mt -105.4 137.02 36.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 O-C-N 121.205 -0.935 . . . . 0.0 109.653 -178.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.446 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 0.2 OUTLIER -123.14 115.21 21.42 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.606 -0.684 . . . . 0.0 109.727 -179.326 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.11 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.05 134.33 46.66 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.476 -0.765 . . . . 0.0 109.801 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.4 t -126.95 130.84 71.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.861 -1.15 . . . . 0.0 108.504 179.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.592 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.6 OUTLIER -107.49 -172.78 0.25 Allowed Pre-proline 0 C--N 1.295 -1.779 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.592 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 33.9 Cg_endo -78.84 17.89 1.08 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 121.913 1.742 . . . . 0.0 111.664 -178.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 10.9 m-20 -116.04 9.64 14.86 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.598 -1.314 . . . . 0.0 109.106 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.04 33.69 59.3 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 106.272 -2.731 . . . . 0.0 106.272 -178.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 35' ' ' HIS . 0.9 OUTLIER -150.8 -171.96 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 122.178 -0.601 . . . . 0.0 109.404 -177.644 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 5.4 m-70 -98.81 63.06 1.37 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.569 ' CG ' ' O ' ' A' ' 35' ' ' HIS . 10.0 ptm85 47.92 69.53 0.52 Allowed 'General case' 0 N--CA 1.493 1.718 0 CA-C-O 121.65 0.738 . . . . 0.0 109.661 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.448 ' O ' ' O ' ' A' ' 38' ' ' ASP . 0.2 OUTLIER 44.1 86.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.168 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.49 ' OD2' ' N ' ' A' ' 63' ' ' GLY . 0.3 OUTLIER -47.12 174.27 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 95.34 -42.26 2.37 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.3 67.26 0.48 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 1.9 m-20 -91.87 126.91 37.13 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.005 -1.291 . . . . 0.0 109.262 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.554 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.67 60.22 0.92 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.081 -2.008 . . . . 0.0 108.081 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.11 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.0 OUTLIER -100.32 111.18 23.43 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.562 -0.963 . . . . 0.0 109.999 -178.724 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.953 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -118.93 113.58 42.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.35 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.109 HG21 HD13 ' A' ' 26' ' ' ILE . 3.0 t -118.81 149.92 21.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.518 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.35 129.73 5.05 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.171 -1.012 . . . . 0.0 110.508 -179.808 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.674 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -120.77 156.66 24.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 178.107 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.2 155.56 5.43 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 118.056 -1.458 . . . . 0.0 110.866 176.953 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.456 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -163.57 -168.4 25.51 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.023 -2.031 . . . . 0.0 108.023 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.504 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.6 Cg_endo -75.65 73.05 4.82 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.214 1.943 . . . . 0.0 110.212 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -154.55 177.01 2.17 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.289 -0.882 . . . . 0.0 109.675 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.4 Cg_endo -77.8 -48.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.312 -1.39 0 C-N-CA 122.649 2.232 . . . . 0.0 110.315 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.62 HG12 ' CG2' ' A' ' 56' ' ' VAL . 93.0 t -98.34 77.51 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.275 -0.89 . . . . 0.0 108.698 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.681 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.2 m-20 -90.57 -50.06 0.35 Allowed Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 120.943 -1.098 . . . . 0.0 111.566 -178.315 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.681 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -80.94 97.24 0.99 Allowed 'Trans proline' 0 C--N 1.316 -1.168 0 C-N-CA 121.989 1.793 . . . . 0.0 110.652 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.63 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -134.57 92.88 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.836 -1.165 . . . . 0.0 110.624 -179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.44 135.81 35.59 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.673 -1.211 . . . . 0.0 110.321 178.881 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.09 155.8 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.577 -0.702 . . . . 0.0 109.932 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.592 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 18.9 t0 -119.87 133.39 55.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.478 -0.764 . . . . 0.0 109.363 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -88.91 -23.66 22.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.126 -0.984 . . . . 0.0 111.012 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.522 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 89.73 16.01 57.22 Favored Glycine 0 N--CA 1.487 2.049 0 C-N-CA 119.468 -1.349 . . . . 0.0 110.365 179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.424 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 45.8 p-10 -121.52 24.01 10.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.029 -1.277 . . . . 0.0 109.172 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 81.33 -8.29 58.68 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.529 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 16.0 p -121.77 108.86 13.99 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.893 . . . . 0.0 108.729 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.592 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 7.2 m-30 -108.96 157.4 18.69 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.925 -1.109 . . . . 0.0 110.02 -178.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.4 OUTLIER -126.73 155.76 42.23 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.971 -1.08 . . . . 0.0 110.93 -177.533 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.637 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 2.4 m -139.88 144.28 28.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.63 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.0 mp0 -153.31 130.0 10.81 Favored 'General case' 0 N--CA 1.504 2.225 0 O-C-N 120.381 -1.449 . . . . 0.0 112.934 -178.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.674 ' CD1' HG21 ' A' ' 47' ' ' ILE . 3.8 p90 -133.17 155.99 48.31 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 175.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.563 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 9.0 pt-20 -150.62 99.35 3.16 Favored Pre-proline 0 N--CA 1.495 1.795 0 O-C-N 120.348 -1.47 . . . . 0.0 110.865 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.484 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.2 Cg_endo -82.9 179.89 4.94 Favored 'Trans proline' 0 C--N 1.314 -1.249 0 C-N-CA 123.129 2.553 . . . . 0.0 112.062 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.537 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 7.2 mtmt -141.6 31.09 1.68 Allowed 'General case' 0 N--CA 1.502 2.155 0 O-C-N 121.457 -0.777 . . . . 0.0 110.254 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.47 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.4 OUTLIER -153.2 -159.01 0.94 Allowed 'General case' 0 C--N 1.308 -1.2 0 O-C-N 120.267 -1.521 . . . . 0.0 108.538 -179.937 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -92.6 118.47 31.05 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 107.011 -1.478 . . . . 0.0 107.011 178.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.565 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.5 162.11 32.65 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.328 -1.415 . . . . 0.0 110.749 -177.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 12.2 p30 -112.52 157.87 20.61 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.835 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.2 m-85 -113.35 138.44 50.04 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.897 -177.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.512 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.4 p -113.71 129.36 69.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 176.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.611 HD13 HD13 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -107.33 158.24 7.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-O 123.143 1.449 . . . . 0.0 112.601 -176.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.518 ' O ' ' N ' ' A' ' 46' ' ' THR . 10.0 m-80 -149.62 114.27 5.31 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.992 HD23 HG22 ' A' ' 45' ' ' VAL . 0.7 OUTLIER -137.12 116.63 12.84 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -179.484 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.953 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.8 p -130.2 136.56 49.36 Favored 'General case' 0 C--N 1.294 -1.825 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.363 -176.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.1 75.18 1.5 Allowed 'General case' 0 N--CA 1.501 2.12 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.738 178.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 10.7 m-20 141.72 -22.46 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.222 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.78 1.43 4.16 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -130.18 174.81 9.45 Favored 'General case' 0 N--CA 1.483 1.22 0 O-C-N 120.889 -1.359 . . . . 0.0 108.045 179.495 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.581 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.9 OUTLIER -108.37 157.26 18.55 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.826 -179.615 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.75 ' CG2' HD12 ' A' ' 81' ' ' LEU . 4.0 t -66.6 169.11 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.106 -179.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 10.1 m-20 -82.44 24.58 0.68 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.967 -1.083 . . . . 0.0 111.612 -178.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -149.77 13.81 1.02 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.977 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 2.7 m-85 -107.33 -44.44 0.12 Allowed Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.038 -1.272 . . . . 0.0 113.023 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.29 13.23 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 N-CA-C 108.449 -1.404 . . . . 0.0 108.449 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.51 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.1 tptm -95.82 167.58 11.18 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.507 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.8 m -119.98 129.87 54.49 Favored 'General case' 0 C--N 1.292 -1.922 0 C-N-CA 119.189 -1.005 . . . . 0.0 110.395 -178.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.83 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.1 t -97.88 155.02 3.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 178.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 65.6 m -122.23 140.38 52.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.517 -1.364 . . . . 0.0 113.503 -176.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.835 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -128.98 132.38 67.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 176.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.619 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.5 OUTLIER -125.89 -65.61 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 120.938 -1.101 . . . . 0.0 112.215 -178.306 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.619 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.21 73.35 3.86 Favored 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 121.566 1.511 . . . . 0.0 111.791 -178.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.787 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.492 1.628 0 O-C-N 121.13 -0.981 . . . . 0.0 109.341 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.548 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.621 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 27.6 t0 -116.1 43.36 0.37 Allowed Pre-proline 0 C--N 1.3 -1.568 0 O-C-N 121.439 -0.788 . . . . 0.0 111.699 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.621 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.9 Cg_endo -78.51 -1.08 11.28 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 121.323 1.349 . . . . 0.0 108.719 177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.61 7.11 4.82 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.647 -0.658 . . . . 0.0 111.103 -178.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.51 ' C ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -142.71 36.42 1.44 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -179.699 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.485 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 66.1 m -114.62 115.1 26.61 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -132.87 140.1 47.74 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.418 -0.801 . . . . 0.0 110.807 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.827 ' HB2' HD13 ' A' ' 81' ' ' LEU . . . -119.68 125.31 48.39 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -147.75 141.6 25.77 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 118.678 -1.209 . . . . 0.0 110.488 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.63 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.97 175.26 39.34 Favored Glycine 0 N--CA 1.483 1.788 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.8 Cg_endo -80.06 8.72 3.92 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.541 2.16 . . . . 0.0 108.633 176.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.668 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.29 156.79 15.44 Favored Glycine 0 N--CA 1.485 1.926 0 N-CA-C 108.524 -1.83 . . . . 0.0 108.524 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.668 ' CD2' ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.4 -26.53 0.05 Allowed 'General case' 0 N--CA 1.506 2.372 0 CA-C-N 117.956 0.878 . . . . 0.0 110.477 179.188 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.465 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.2 m-20 -49.82 -22.56 1.49 Allowed 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.697 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 87.88 -129.67 9.67 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.354 -0.927 . . . . 0.0 110.892 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.709 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.0 -77.23 0.15 Allowed Glycine 0 N--CA 1.492 2.4 0 O-C-N 121.947 -0.737 . . . . 0.0 111.798 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.513 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.3 mp0 -118.4 143.98 46.27 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.026 -1.279 . . . . 0.0 112.113 -177.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.713 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -18.55 29.07 Favored 'General case' 0 N--CA 1.504 2.236 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.048 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 5.6 m-85 -88.95 10.97 19.49 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.453 -0.78 . . . . 0.0 110.227 -178.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.45 ' OE1' ' HB2' ' A' ' 17' ' ' GLU . 20.6 mt-30 -99.24 152.46 37.8 Favored Pre-proline 0 C--N 1.294 -1.836 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.546 ' HB2' ' CE ' ' A' ' 23' ' ' LYS . 30.9 Cg_endo -71.13 126.8 12.76 Favored 'Trans proline' 0 C--N 1.295 -2.266 0 C-N-CA 121.513 1.475 . . . . 0.0 108.777 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.608 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -105.28 109.11 20.98 Favored 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 118.668 -1.213 . . . . 0.0 109.009 -178.701 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.573 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -150.72 136.87 18.48 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 121.424 0.63 . . . . 0.0 109.87 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.664 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -139.72 159.11 42.93 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.198 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -113.54 141.4 47.2 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.106 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.4 mt -109.27 149.2 12.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.34 -0.85 . . . . 0.0 110.211 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.458 ' ND1' ' C ' ' A' ' 26' ' ' ILE . 0.0 OUTLIER -140.17 118.34 11.98 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.552 -0.717 . . . . 0.0 109.938 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.924 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.77 137.64 44.42 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.49 -0.756 . . . . 0.0 110.051 179.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 0.9 OUTLIER -121.97 132.01 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 178.453 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.579 ' CB ' ' HD2' ' A' ' 31' ' ' PRO . 0.2 OUTLIER -107.16 -176.91 0.44 Allowed Pre-proline 0 C--N 1.295 -1.764 0 O-C-N 121.299 -0.876 . . . . 0.0 109.082 -179.198 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.579 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.0 Cg_endo -77.31 18.24 0.81 Allowed 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.143 1.895 . . . . 0.0 112.035 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.508 ' C ' HG23 ' A' ' 34' ' ' VAL . 8.8 m-20 -117.31 9.16 13.32 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.551 -1.343 . . . . 0.0 109.191 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.446 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 72.16 37.73 59.58 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 106.361 -2.696 . . . . 0.0 106.361 -178.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -151.34 -175.38 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.587 ' CB ' ' HA3' ' A' ' 63' ' ' GLY . 2.1 m-70 -94.66 56.63 2.08 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.556 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.3 ttp85 55.87 67.03 1.06 Allowed 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.459 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 41.72 82.38 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.7 OUTLIER -40.68 159.9 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.146 -0.971 . . . . 0.0 110.169 -178.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.91 -44.17 1.53 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -138.44 64.53 0.55 Allowed Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.331 -1.414 . . . . 0.0 110.766 -179.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.562 ' O ' ' N ' ' A' ' 43' ' ' PHE . 93.5 m-20 -89.7 127.81 35.99 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.866 -1.373 . . . . 0.0 108.714 178.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.724 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -66.54 65.75 0.17 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.924 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.37 117.88 35.13 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.525 -0.985 . . . . 0.0 110.812 -178.264 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.084 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -126.9 113.51 33.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 177.786 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.106 HG21 ' CD1' ' A' ' 26' ' ' ILE . 16.5 t -121.68 148.85 24.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.303 -0.873 . . . . 0.0 108.87 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.534 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -157.67 126.5 5.71 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.956 -178.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.666 HD11 HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.46 157.31 20.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.099 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.525 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.84 153.97 4.14 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.564 -1.254 . . . . 0.0 110.382 177.609 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.411 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.68 -168.35 22.45 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.511 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -75.52 72.99 4.77 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.209 1.939 . . . . 0.0 110.05 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.988 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.57 178.94 1.49 Allowed Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.281 -0.887 . . . . 0.0 109.376 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.988 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.1 Cg_endo -78.28 -56.69 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.426 0 C-N-CA 122.507 2.138 . . . . 0.0 110.688 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.497 HG12 HG22 ' A' ' 56' ' ' VAL . 1.7 t -89.47 74.89 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.324 -0.86 . . . . 0.0 108.89 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.593 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 75.4 m-20 -89.21 -45.6 0.43 Allowed Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 120.966 -1.084 . . . . 0.0 110.933 -178.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.593 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -81.57 93.88 0.96 Allowed 'Trans proline' 0 C--N 1.316 -1.179 0 C-N-CA 122.079 1.853 . . . . 0.0 110.641 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.653 HG11 ' O ' ' A' ' 68' ' ' GLU . 3.6 t -133.63 89.77 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.883 -1.135 . . . . 0.0 110.921 -179.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.456 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -138.71 135.92 35.26 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.979 -1.089 . . . . 0.0 109.716 178.562 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.46 156.44 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.459 -0.775 . . . . 0.0 110.273 -178.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.553 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 10.0 t0 -108.57 130.56 55.3 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.52 -2.76 58.46 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.118 -0.989 . . . . 0.0 110.613 -179.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 65.49 9.87 46.04 Favored Glycine 0 N--CA 1.485 1.931 0 C-N-CA 119.523 -1.322 . . . . 0.0 109.909 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.448 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 49.0 p-10 -111.51 35.45 3.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.206 -1.173 . . . . 0.0 109.38 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.587 ' HA3' ' CB ' ' A' ' 35' ' ' HIS . . . 66.91 7.77 44.83 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.53 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 27.8 p -136.83 150.27 48.21 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.401 -1.058 . . . . 0.0 109.119 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE1' ' CD2' ' A' ' 43' ' ' PHE . 4.3 m-85 -126.14 154.78 42.69 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 110.534 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 22.4 t0 -126.23 124.83 41.29 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.503 -0.748 . . . . 0.0 109.217 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.681 HG11 HG11 ' A' ' 45' ' ' VAL . 2.0 m -119.86 142.46 35.29 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.653 ' O ' HG11 ' A' ' 56' ' ' VAL . 4.4 mp0 -151.1 127.41 10.61 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 120.531 -1.355 . . . . 0.0 113.051 -177.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.635 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.3 p90 -132.49 155.68 48.13 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -150.45 96.08 3.46 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 120.54 -1.35 . . . . 0.0 110.24 -178.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.487 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -80.59 176.8 8.75 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 123.096 2.53 . . . . 0.0 111.697 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 1.2 mptt -139.14 32.05 2.15 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.414 -0.803 . . . . 0.0 110.269 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.464 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 3.6 pt-20 -152.85 -164.07 1.85 Allowed 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.529 -1.357 . . . . 0.0 108.353 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.28 119.61 29.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.566 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.44 163.33 33.42 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.123 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 15.7 p30 -112.0 158.17 19.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.841 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.4 m-85 -112.71 138.25 49.79 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 122.068 0.937 . . . . 0.0 110.751 -177.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.424 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -113.35 127.43 70.66 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 N-CA-C 104.223 -2.51 . . . . 0.0 104.223 175.702 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.743 ' CG1' ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -118.51 157.73 19.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.184 0 C-N-CA 117.691 -1.604 . . . . 0.0 111.461 -175.089 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.563 ' N ' HG13 ' A' ' 79' ' ' ILE . 7.2 m-80 -152.05 114.25 4.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.115 -0.99 . . . . 0.0 110.385 -176.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.097 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -132.3 133.64 44.3 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 178.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.084 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.7 p -143.61 136.32 27.34 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.3 -178.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.73 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -138.27 74.99 1.5 Allowed 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 119.578 -0.849 . . . . 0.0 109.75 179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.601 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 12.7 m-20 141.45 -20.76 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.247 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.18 0.39 5.08 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.66 -1.776 . . . . 0.0 108.66 -178.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.866 ' O ' HG22 ' A' ' 82' ' ' THR . 30.7 p-10 -128.33 175.37 8.53 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.642 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.06 162.32 17.16 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.815 -1.178 . . . . 0.0 109.77 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.876 HG23 ' CD2' ' A' ' 81' ' ' LEU . 4.6 t -66.56 169.93 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 119.266 -0.973 . . . . 0.0 109.168 -179.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 1.6 t30 -83.2 25.67 0.69 Allowed 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.917 -1.115 . . . . 0.0 111.356 -178.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.72 28.28 1.04 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 107.8 -2.12 . . . . 0.0 107.8 179.081 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.743 ' CD2' ' CG1' ' A' ' 79' ' ' ILE . 4.8 m-85 -120.29 -48.07 0.04 OUTLIER Pre-proline 0 C--N 1.305 -1.344 0 O-C-N 121.71 -0.877 . . . . 0.0 113.289 -177.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.684 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.5 Cg_endo -70.36 18.09 0.22 Allowed 'Trans proline' 0 C--N 1.304 -1.78 0 CA-C-N 120.031 1.047 . . . . 0.0 109.473 179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.527 ' H ' ' C ' ' A' ' 91' ' ' PHE . 1.4 ttpt -103.41 175.28 5.53 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-O 121.946 0.879 . . . . 0.0 108.865 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.541 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 55.4 m -127.19 129.78 48.49 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.399 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.697 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 6.2 t -99.05 154.72 4.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 4.3 m -118.2 145.07 45.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.563 -1.335 . . . . 0.0 113.402 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.841 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -132.78 128.54 57.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.612 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -118.78 -65.69 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.86 0 O-C-N 120.887 -1.133 . . . . 0.0 112.553 -178.097 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.612 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.9 Cg_endo -74.07 80.66 2.11 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 C-N-CA 121.604 1.536 . . . . 0.0 111.732 -178.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 1.048 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.604 0 O-C-N 121.171 -0.955 . . . . 0.0 109.831 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.391 0.615 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.647 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 41.4 t0 45.16 51.8 9.54 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.434 -0.791 . . . . 0.0 110.288 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.647 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.1 2.87 8.1 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 121.817 1.678 . . . . 0.0 108.656 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.449 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -145.06 4.29 1.08 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.484 -0.76 . . . . 0.0 112.147 -177.431 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 4.4 mmpt? -135.2 42.72 2.72 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.433 -1.417 . . . . 0.0 108.062 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.547 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.5 m -115.44 114.17 24.69 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.595 -0.842 . . . . 0.0 108.971 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.611 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.7 p90 -138.45 144.17 39.98 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.27 -0.893 . . . . 0.0 110.966 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.874 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.06 119.43 31.36 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -139.86 142.73 36.54 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.909 -1.119 . . . . 0.0 110.111 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.589 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.88 175.51 39.24 Favored Glycine 0 N--CA 1.483 1.781 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.236 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.52 9.68 3.36 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.654 2.236 . . . . 0.0 109.006 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.995 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.25 158.18 14.69 Favored Glycine 0 C--O 1.201 -1.959 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.995 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.6 -4.08 0.59 Allowed 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 118.418 1.109 . . . . 0.0 110.385 179.627 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.5 OUTLIER -69.69 -17.47 63.48 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.281 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.699 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 79.22 -132.99 11.92 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.628 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.35 -71.22 0.23 Allowed Glycine 0 N--CA 1.492 2.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.77 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.565 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.2 mt-10 -121.41 143.83 49.01 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 120.964 -1.315 . . . . 0.0 111.944 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.701 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.03 -19.47 27.1 Favored 'General case' 0 N--CA 1.502 2.137 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.669 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 33.8 m-85 -88.64 11.18 18.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.068 -1.02 . . . . 0.0 110.383 -178.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -99.39 147.65 33.61 Favored Pre-proline 0 C--N 1.296 -1.743 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 176.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -70.7 131.18 19.42 Favored 'Trans proline' 0 C--N 1.295 -2.251 0 C-N-CA 121.288 1.325 . . . . 0.0 109.34 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.617 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.63 110.87 23.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.055 -1.058 . . . . 0.0 108.379 -179.219 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.6 mtmt -150.32 135.49 17.86 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.346 -0.846 . . . . 0.0 110.227 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.651 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.91 158.75 43.51 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.529 -0.732 . . . . 0.0 109.586 179.624 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.11 144.22 44.0 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.968 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -116.62 156.09 17.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.563 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -144.58 122.7 12.15 Favored 'General case' 0 N--CA 1.49 1.531 0 CA-C-O 121.418 0.628 . . . . 0.0 109.987 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.007 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . -107.65 131.3 54.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.492 -0.755 . . . . 0.0 110.415 179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.555 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.3 t -116.33 128.42 73.66 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.58 -1.325 . . . . 0.0 108.21 178.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.72 -174.62 0.38 Allowed Pre-proline 0 C--N 1.298 -1.669 0 O-C-N 121.61 -0.681 . . . . 0.0 109.307 -178.858 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.36 15.48 1.38 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.003 1.802 . . . . 0.0 112.045 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.468 ' C ' HG23 ' A' ' 34' ' ' VAL . 4.3 t70 -113.63 5.63 16.59 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.473 -1.392 . . . . 0.0 109.241 179.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.76 39.12 48.8 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.31 -2.716 . . . . 0.0 106.31 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.628 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.3 t -150.8 -159.89 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -177.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.637 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 7.2 m80 -107.51 65.28 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 1.007 ' CZ ' ' HB3' ' A' ' 28' ' ' ALA . 0.0 OUTLIER 40.86 61.71 1.62 Allowed 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.505 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER 37.68 81.03 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 -178.523 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.2 OUTLIER -39.37 159.0 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.041 -1.037 . . . . 0.0 110.735 -178.195 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 113.38 -50.27 0.78 Allowed Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -132.07 64.77 0.6 Allowed Glycine 0 N--CA 1.491 2.345 0 O-C-N 120.903 -1.351 . . . . 0.0 109.745 -179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.57 ' CB ' ' NH2' ' A' ' 36' ' ' ARG . 1.0 OUTLIER -90.03 128.44 36.28 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -1.229 . . . . 0.0 109.617 -179.932 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 68.85 0.49 Allowed Glycine 0 N--CA 1.491 2.312 0 N-CA-C 107.404 -2.278 . . . . 0.0 107.404 178.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.807 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -109.47 127.88 54.75 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.512 -0.993 . . . . 0.0 111.592 -177.5 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.056 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -140.58 113.49 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.72 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.968 HG21 HD12 ' A' ' 26' ' ' ILE . 17.9 t -118.74 150.7 20.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.536 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.81 127.67 4.14 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 118.943 -1.103 . . . . 0.0 110.941 -178.976 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.9 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -119.7 156.26 22.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 177.49 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.544 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.99 152.66 3.58 Favored 'General case' 0 C--N 1.295 -1.797 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.34 176.752 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.444 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.06 -169.21 20.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 108.364 -1.894 . . . . 0.0 108.364 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.554 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.3 Cg_endo -77.29 70.83 6.6 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 122.295 1.996 . . . . 0.0 110.038 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.24 178.88 1.5 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.398 -0.813 . . . . 0.0 109.28 -179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -76.81 -55.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.399 2.066 . . . . 0.0 110.791 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.573 ' O ' HG12 ' A' ' 53' ' ' VAL . 53.1 t -89.23 76.72 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.06 -1.025 . . . . 0.0 109.28 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -93.67 -45.86 0.3 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 120.872 -1.142 . . . . 0.0 111.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.607 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.0 Cg_endo -83.53 102.21 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.357 2.038 . . . . 0.0 111.485 -179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.692 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.1 t -142.83 92.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 120.765 -1.209 . . . . 0.0 110.764 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.13 135.87 31.32 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.736 -1.228 . . . . 0.0 110.46 179.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.18 154.99 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 CA-C-O 121.669 0.747 . . . . 0.0 110.081 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.602 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 0.5 OUTLIER -121.8 124.59 44.54 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 179.886 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.12 -23.66 23.6 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.955 -1.09 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.469 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 89.14 6.07 72.11 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.079 -1.534 . . . . 0.0 110.114 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.444 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 38.5 p-10 -102.2 22.38 13.35 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.089 -1.242 . . . . 0.0 109.179 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.637 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 85.08 -13.16 55.87 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 58.1 p -120.11 136.59 54.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 108.878 179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.602 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 39.6 m-85 -124.19 157.11 35.52 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.994 -1.066 . . . . 0.0 109.217 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -128.67 149.59 50.61 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.931 -1.105 . . . . 0.0 110.396 -178.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.734 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.95 144.57 30.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.692 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.8 mp0 -152.28 122.73 7.28 Favored 'General case' 0 N--CA 1.504 2.259 0 O-C-N 120.456 -1.402 . . . . 0.0 112.8 -177.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.671 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.5 p90 -129.98 155.61 45.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.471 -1.393 . . . . 0.0 107.716 176.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -147.18 106.33 3.87 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 120.823 -1.173 . . . . 0.0 109.228 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HG2' ' CA ' ' A' ' 18' ' ' CYS . 36.7 Cg_endo -77.61 -159.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 122.886 2.39 . . . . 0.0 111.953 -179.068 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.669 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -144.89 -61.98 0.36 Allowed 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.496 -0.752 . . . . 0.0 110.279 -179.394 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -87.71 -143.76 0.13 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.137 -1.602 . . . . 0.0 109.178 -179.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HB2' ' O ' ' A' ' 98' ' ' LYS . . . -89.22 130.35 35.65 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.997 -1.065 . . . . 0.0 108.339 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.554 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -158.86 159.96 30.72 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.524 -177.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 20.1 p30 -113.43 156.15 24.01 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 179.059 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.91 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -115.1 130.78 57.01 Favored 'General case' 0 C--N 1.294 -1.814 0 C-N-CA 118.891 -1.124 . . . . 0.0 111.139 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -104.8 131.02 54.88 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 104.047 -2.575 . . . . 0.0 104.047 175.299 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.9 HD12 HD11 ' A' ' 47' ' ' ILE . 0.5 OUTLIER -114.11 156.07 15.16 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 C-N-CA 117.883 -1.527 . . . . 0.0 111.417 -175.412 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' A' ' 46' ' ' THR . 0.9 OUTLIER -150.09 114.59 5.22 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 121.898 0.856 . . . . 0.0 110.239 -178.111 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.92 HD23 HG22 ' A' ' 45' ' ' VAL . 0.0 OUTLIER -135.0 118.24 16.61 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 179.445 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.056 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.1 p -128.57 134.98 48.77 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.99 -176.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.803 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -139.82 75.55 1.52 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.574 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.2 m-20 143.02 -25.57 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.029 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 133.87 1.57 3.69 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.973 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -131.92 174.34 10.27 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.708 -1.466 . . . . 0.0 108.986 179.808 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.1 m-80 -97.66 149.63 22.05 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.909 -1.119 . . . . 0.0 109.558 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.818 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.1 t -67.24 174.23 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.155 -0.966 . . . . 0.0 108.834 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.581 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 37.6 p-10 -76.72 23.15 0.17 Allowed 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.93 -1.106 . . . . 0.0 112.307 -178.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.09 23.72 1.42 Allowed Glycine 0 N--CA 1.496 2.661 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 178.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.874 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 11.5 m-85 -122.59 -28.33 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.612 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 -177.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.663 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 32.6 Cg_endo -77.94 17.64 0.98 Allowed 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 107.695 -1.694 . . . . 0.0 107.695 177.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.497 ' H ' ' C ' ' A' ' 91' ' ' PHE . 56.6 tttm -104.1 168.95 8.78 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 122.271 1.034 . . . . 0.0 110.458 -179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 86.0 m -127.5 129.61 47.72 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.958 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.6 t -98.31 153.49 4.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 179.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 16.0 m -121.4 140.82 51.63 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 118.542 -1.263 . . . . 0.0 113.084 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.91 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -130.47 131.22 65.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 177.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.621 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -124.41 -65.71 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.696 0 C-N-CA 118.863 -1.135 . . . . 0.0 112.426 -178.134 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.1 Cg_endo -74.71 71.96 4.61 Favored 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 121.564 1.51 . . . . 0.0 112.038 -178.065 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 120.97 -1.081 . . . . 0.0 108.648 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.681 ' HB1' ' OD1' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.804 0.812 . . . . 0.0 109.582 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.632 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 44.9 t0 41.89 53.89 8.09 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.52 -0.737 . . . . 0.0 110.794 179.712 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.632 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -82.28 3.6 7.7 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 121.66 1.573 . . . . 0.0 108.148 177.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.32 19.0 0.85 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.626 -0.671 . . . . 0.0 111.055 -177.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.536 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.1 OUTLIER -145.63 36.98 1.08 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.837 -1.164 . . . . 0.0 108.076 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.506 ' O ' HG22 ' A' ' 88' ' ' VAL . 3.0 m -115.17 114.78 25.73 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.516 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 40.7 p90 -134.76 138.91 44.74 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.003 -179.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.971 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.13 118.57 32.23 Favored 'General case' 0 N--CA 1.493 1.69 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 0.4 OUTLIER -140.03 141.87 36.26 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.829 -1.148 . . . . 0.0 110.173 -179.098 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.638 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.4 175.36 38.85 Favored Glycine 0 N--CA 1.481 1.699 0 N-CA-C 110.121 -1.192 . . . . 0.0 110.121 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.5 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.8 Cg_endo -79.21 9.07 3.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.771 2.314 . . . . 0.0 108.898 177.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.981 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.17 157.45 15.07 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 108.669 -1.773 . . . . 0.0 108.669 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.981 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.1 OUTLIER 85.53 -3.81 0.85 Allowed 'General case' 0 N--CA 1.5 2.061 0 CA-C-N 118.41 1.105 . . . . 0.0 110.682 179.291 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -67.99 -19.64 64.95 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.661 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 86.89 -134.38 12.46 Favored Glycine 0 N--CA 1.494 2.503 0 C-N-CA 120.071 -1.061 . . . . 0.0 110.678 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.683 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.22 -73.27 0.09 OUTLIER Glycine 0 N--CA 1.495 2.577 0 O-C-N 122.033 -0.687 . . . . 0.0 112.018 179.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.501 ' N ' HG22 ' A' ' 97' ' ' VAL . 24.0 mt-10 -118.79 142.61 47.55 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.839 -1.389 . . . . 0.0 112.19 -177.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.682 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.4 -19.16 26.95 Favored 'General case' 0 N--CA 1.504 2.24 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.368 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.899 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 57.6 m-85 -88.62 9.49 23.9 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.17 -0.956 . . . . 0.0 110.417 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -98.23 148.44 34.51 Favored Pre-proline 0 C--N 1.294 -1.818 0 N-CA-C 105.599 -2.0 . . . . 0.0 105.599 177.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.79 132.81 22.39 Favored 'Trans proline' 0 C--N 1.292 -2.399 0 C-N-CA 121.203 1.268 . . . . 0.0 109.613 -178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.604 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.0 m -103.47 111.89 24.54 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.265 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.577 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 1.0 OUTLIER -148.65 133.3 17.81 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.447 -0.901 . . . . 0.0 109.571 179.701 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.666 ' CD2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.45 158.66 43.67 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.443 ' HD3' ' N ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -113.94 142.4 46.19 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.673 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.128 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.6 mt -109.7 149.72 12.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.196 -0.94 . . . . 0.0 109.922 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.525 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -140.76 114.05 8.6 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.511 0.672 . . . . 0.0 109.741 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.951 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -99.05 143.26 29.53 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.529 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 11.9 t -131.75 116.45 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.142 -0.974 . . . . 0.0 109.359 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.681 ' OD1' ' HB1' ' A' ' 1' ' ' ALA . 0.1 OUTLIER -102.08 -173.39 0.29 Allowed Pre-proline 0 N--CA 1.493 1.693 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.258 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.63 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.64 35.28 0.56 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 C-N-CA 121.741 1.628 . . . . 0.0 112.805 -178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.571 ' O ' HG23 ' A' ' 34' ' ' VAL . 1.2 m-20 -131.64 12.61 4.9 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.253 -1.529 . . . . 0.0 109.895 179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.48 31.82 68.14 Favored Glycine 0 N--CA 1.486 2.026 0 N-CA-C 106.146 -2.782 . . . . 0.0 106.146 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -150.8 -173.24 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 -177.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.607 ' CD2' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -99.88 54.94 0.93 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.164 -0.96 . . . . 0.0 108.707 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.699 ' C ' HG23 ' A' ' 37' ' ' THR . 0.0 OUTLIER 74.06 37.58 0.61 Allowed 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.699 HG23 ' C ' ' A' ' 36' ' ' ARG . 1.1 p 69.1 98.38 0.06 Allowed 'General case' 0 N--CA 1.491 1.619 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 -178.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.4 OUTLIER -44.73 169.62 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.395 -1.44 . . . . 0.0 110.111 -178.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 66.36 71.06 0.96 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' ' HD2' ' A' ' 36' ' ' ARG . . . 121.46 61.45 0.23 Allowed Glycine 0 N--CA 1.493 2.456 0 O-C-N 120.721 -1.458 . . . . 0.0 110.825 179.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.4 OUTLIER -110.58 131.92 54.63 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.89 -1.359 . . . . 0.0 108.674 179.117 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -72.91 58.2 1.78 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 107.765 -2.134 . . . . 0.0 107.765 178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.951 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -103.91 101.21 11.01 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.63 -0.924 . . . . 0.0 110.299 -178.306 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.8 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -109.36 113.46 44.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.401 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.128 HG21 ' CD1' ' A' ' 26' ' ' ILE . 97.8 t -125.93 143.41 39.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.089 -1.007 . . . . 0.0 109.597 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.448 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.3 OUTLIER -159.88 139.44 11.26 Favored 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.36 -179.61 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.8 OUTLIER -118.85 157.18 20.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 178.214 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.644 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -164.73 148.74 9.09 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 118.269 -1.372 . . . . 0.0 110.473 177.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.449 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -157.57 -168.12 19.55 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.449 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -75.83 73.48 4.77 Favored 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.084 1.856 . . . . 0.0 110.434 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.983 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -158.6 177.88 1.92 Allowed Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.118 -0.989 . . . . 0.0 109.563 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.983 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.6 Cg_endo -76.86 -56.0 0.05 OUTLIER 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 122.608 2.205 . . . . 0.0 110.464 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.478 HG12 ' CG2' ' A' ' 56' ' ' VAL . 2.7 t -88.76 79.1 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.716 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 35.4 m-20 -89.84 -65.72 0.16 Allowed Pre-proline 0 N--CA 1.486 1.367 0 O-C-N 121.19 -0.944 . . . . 0.0 111.229 -177.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.716 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.1 Cg_endo -74.38 110.38 3.09 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.883 1.722 . . . . 0.0 110.604 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.626 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -142.81 101.06 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.903 -1.123 . . . . 0.0 110.983 -179.103 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.416 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -139.82 135.95 33.53 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.038 -1.038 . . . . 0.0 110.347 178.432 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.98 155.06 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.632 -0.668 . . . . 0.0 109.804 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.57 ' OD2' ' CE1' ' A' ' 65' ' ' TYR . 3.5 t0 -118.96 122.86 43.2 Favored 'General case' 0 N--CA 1.49 1.571 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -88.45 -19.95 25.83 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.167 -0.958 . . . . 0.0 110.479 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 83.92 25.87 43.62 Favored Glycine 0 N--CA 1.486 2.019 0 C-N-CA 119.633 -1.27 . . . . 0.0 110.53 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.425 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 43.8 p-10 -124.29 33.68 5.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.021 -1.282 . . . . 0.0 109.78 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.607 ' HA3' ' CD2' ' A' ' 35' ' ' HIS . . . 74.1 -1.35 48.91 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.181 -1.167 . . . . 0.0 110.181 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 73.4 p -133.7 145.98 50.39 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 108.461 179.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.57 ' CE1' ' OD2' ' A' ' 59' ' ' ASP . 27.6 m-85 -128.03 156.38 42.83 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.087 -1.008 . . . . 0.0 110.09 -178.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -123.16 140.31 53.16 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.165 -0.959 . . . . 0.0 109.853 -178.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 45' ' ' VAL . 1.6 m -131.72 143.13 41.28 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.626 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.2 mp0 -152.86 130.56 11.58 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 120.536 -1.353 . . . . 0.0 112.873 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.681 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.8 p90 -133.23 156.15 48.06 Favored 'General case' 0 N--CA 1.502 2.14 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 176.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.568 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 7.2 pt-20 -150.76 101.72 3.06 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 120.259 -1.526 . . . . 0.0 110.712 -179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.478 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.0 Cg_endo -80.98 178.21 7.14 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 123.158 2.572 . . . . 0.0 111.837 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.488 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 2.4 mtmp? -139.16 27.77 2.33 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.397 -0.814 . . . . 0.0 111.021 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 2.8 pt-20 -153.3 -159.66 1.02 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.231 -1.543 . . . . 0.0 108.263 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.04 118.51 29.64 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.542 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.56 33.21 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.363 -1.399 . . . . 0.0 110.844 -176.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.438 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.0 OUTLIER -112.22 157.74 20.53 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 179.543 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.925 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.9 m-85 -113.19 139.82 48.44 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.048 0.928 . . . . 0.0 111.054 -177.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.644 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -114.25 127.34 71.73 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 176.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.707 HD13 HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -104.2 157.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 CA-C-O 122.832 1.301 . . . . 0.0 111.988 -177.057 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.544 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.0 m120 -150.16 113.38 4.89 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.047 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -143.02 126.9 17.19 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.129 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.8 ' OG1' HG13 ' A' ' 44' ' ' VAL . 16.4 p -138.85 138.37 37.43 Favored 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.489 -177.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.779 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.7 tm? -136.09 73.18 1.45 Allowed 'General case' 0 N--CA 1.5 2.028 0 C-N-CA 119.44 -0.904 . . . . 0.0 109.176 178.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.583 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 23.6 m-20 142.12 -23.82 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 136.94 -4.89 3.6 Favored Glycine 0 N--CA 1.482 1.76 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.755 ' O ' HG22 ' A' ' 82' ' ' THR . 0.7 OUTLIER -124.08 175.12 7.19 Favored 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 179.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.678 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.2 OUTLIER -110.53 160.99 16.14 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.795 -1.191 . . . . 0.0 109.189 179.941 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.61 HG23 ' CD2' ' A' ' 81' ' ' LEU . 3.3 t -66.55 170.78 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 C-N-CA 119.245 -0.982 . . . . 0.0 108.941 -179.365 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.556 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 t30 -80.09 22.78 0.5 Allowed 'General case' 0 N--CA 1.497 1.903 0 O-C-N 120.885 -1.134 . . . . 0.0 111.947 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.584 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -148.99 18.78 1.22 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.971 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.0 m-85 -110.79 -44.93 0.09 OUTLIER Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 0.0 113.261 -178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.642 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.1 Cg_endo -73.17 16.28 0.46 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 N-CA-C 108.674 -1.318 . . . . 0.0 108.674 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.532 ' H ' ' C ' ' A' ' 91' ' ' PHE . 11.1 tttp -100.29 174.51 6.09 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -126.57 129.92 49.52 Favored 'General case' 0 C--N 1.293 -1.885 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.322 -179.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.84 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -97.57 154.84 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 178.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 76.9 m -119.57 146.7 45.26 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.779 -1.201 . . . . 0.0 113.125 -176.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.925 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -138.74 132.96 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 177.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.59 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.1 OUTLIER -125.37 -63.9 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.815 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.447 -178.502 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.59 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.3 Cg_endo -74.38 72.95 4.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 121.548 1.498 . . . . 0.0 112.041 -178.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.899 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.141 -0.974 . . . . 0.0 109.452 178.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.539 ' HB1' ' HD2' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.673 0.749 . . . . 0.0 109.485 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.625 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 39.3 t0 43.53 53.09 9.45 Favored Pre-proline 0 C--N 1.3 -1.58 0 O-C-N 121.366 -0.834 . . . . 0.0 110.564 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.625 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.44 1.99 8.88 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 121.755 1.637 . . . . 0.0 108.283 177.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -144.52 14.15 1.58 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.574 -0.704 . . . . 0.0 111.251 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.559 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -142.74 36.74 1.44 Allowed 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.766 -1.209 . . . . 0.0 107.85 -179.586 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 4.4 m -114.83 113.56 24.39 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.133 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 10.7 p90 -141.64 143.07 33.44 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.953 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.937 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -119.71 121.33 38.97 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -140.27 141.39 35.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.88 -1.137 . . . . 0.0 110.069 -179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.89 174.75 39.26 Favored Glycine 0 N--CA 1.482 1.724 0 C-N-CA 119.781 -1.199 . . . . 0.0 110.183 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.57 8.77 3.77 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.71 2.274 . . . . 0.0 108.8 176.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.969 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.14 157.77 14.89 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.969 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.86 -7.13 0.37 Allowed 'General case' 0 N--CA 1.503 2.179 0 CA-C-N 118.4 1.1 . . . . 0.0 110.335 179.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -69.45 -16.31 63.45 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 74.44 -132.41 14.53 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.526 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.87 -59.83 0.14 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.931 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.682 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.5 mp0 -128.95 141.87 51.12 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.788 -1.419 . . . . 0.0 112.07 -177.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.773 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.8 -21.44 23.76 Favored 'General case' 0 N--CA 1.501 2.117 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.707 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.927 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 14.4 m-85 -88.88 12.37 15.4 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.004 -1.06 . . . . 0.0 110.413 -178.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.27 149.96 36.29 Favored Pre-proline 0 C--N 1.294 -1.824 0 N-CA-C 106.125 -1.806 . . . . 0.0 106.125 176.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -70.93 128.14 14.58 Favored 'Trans proline' 0 C--N 1.294 -2.299 0 C-N-CA 121.346 1.364 . . . . 0.0 108.766 -179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.623 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.58 109.05 20.8 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 118.506 -1.278 . . . . 0.0 108.308 -179.248 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.576 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 20.7 mtmt -151.1 137.09 18.21 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.892 -0.723 . . . . 0.0 110.076 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.641 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.33 158.49 43.95 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.913 -0.715 . . . . 0.0 109.412 179.18 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.9 mtmp? -114.78 141.75 47.45 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.898 HD12 HG21 ' A' ' 45' ' ' VAL . 1.5 mt -113.31 148.44 16.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.331 -178.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.556 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -135.84 118.57 16.09 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.679 0.752 . . . . 0.0 110.358 -179.501 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.081 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.27 137.66 42.7 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.559 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.8 t -125.75 124.42 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.949 -1.095 . . . . 0.0 108.716 179.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.585 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -101.18 -174.22 0.34 Allowed Pre-proline 0 C--N 1.299 -1.587 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.585 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.3 Cg_endo -79.73 21.26 0.8 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 121.891 1.728 . . . . 0.0 111.589 -179.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.555 ' O ' HG23 ' A' ' 34' ' ' VAL . 43.1 t0 -123.53 13.39 9.41 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.634 -1.291 . . . . 0.0 109.697 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.81 33.39 66.34 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 106.086 -2.805 . . . . 0.0 106.086 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.555 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -150.49 164.77 2.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 -177.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.643 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 3.8 m-70 -82.96 57.26 3.8 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.55 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 19.0 ttt180 64.78 62.06 0.78 Allowed 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -178.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.463 ' O ' ' O ' ' A' ' 36' ' ' ARG . 73.1 m 49.08 92.62 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.413 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.47 ' OD2' ' HA ' ' A' ' 62' ' ' ASP . 2.5 t0 -39.25 153.71 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.242 -0.911 . . . . 0.0 109.996 -179.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.67 -37.44 3.17 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 36' ' ' ARG . . . -113.02 44.43 1.5 Allowed Glycine 0 N--CA 1.491 2.34 0 O-C-N 120.895 -1.356 . . . . 0.0 110.279 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.538 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.0 OUTLIER -95.97 113.0 24.58 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.032 -1.275 . . . . 0.0 109.028 179.474 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.28 61.42 0.41 Allowed Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.081 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.87 108.46 21.18 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.501 -0.999 . . . . 0.0 110.341 -178.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.907 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.69 114.39 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.128 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.015 HG22 HD23 ' A' ' 81' ' ' LEU . 2.6 t -119.78 151.97 22.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 109.031 -179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.511 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.5 130.97 5.36 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 119.254 -0.979 . . . . 0.0 110.413 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.66 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.3 OUTLIER -123.94 156.68 31.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.583 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.8 OUTLIER -169.85 151.8 4.27 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.163 -1.415 . . . . 0.0 110.558 176.717 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -154.9 -169.3 19.35 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.545 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 35.2 Cg_endo -77.02 70.89 6.47 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 122.209 1.94 . . . . 0.0 110.345 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.999 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.49 178.52 1.63 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.35 -0.844 . . . . 0.0 109.27 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.999 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.7 Cg_endo -77.52 -50.38 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.501 0 C-N-CA 122.515 2.143 . . . . 0.0 110.672 -179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -94.56 76.05 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.235 -0.915 . . . . 0.0 109.003 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.591 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 77.4 m-20 -91.34 -44.97 0.37 Allowed Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 120.883 -1.135 . . . . 0.0 111.505 -178.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -82.77 99.87 0.94 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 122.232 1.955 . . . . 0.0 111.107 -179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.669 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.5 t -140.12 94.67 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 O-C-N 120.796 -1.19 . . . . 0.0 110.967 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.448 ' HG3' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.47 135.79 32.33 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.861 -1.15 . . . . 0.0 110.165 178.614 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.96 156.99 42.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.537 -0.727 . . . . 0.0 110.285 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.576 ' OD2' ' CE2' ' A' ' 65' ' ' TYR . 0.3 OUTLIER -110.83 129.64 55.8 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.361 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -89.23 -5.03 57.97 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.031 -1.043 . . . . 0.0 110.469 -179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.431 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 65.22 9.44 42.13 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.47 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 22.2 p-10 -108.98 30.09 6.88 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.124 -1.221 . . . . 0.0 109.322 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.643 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.66 4.43 75.78 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.51 HG22 ' HA ' ' A' ' 27' ' ' HIS . 7.6 p -135.41 151.43 50.43 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.425 -1.044 . . . . 0.0 109.5 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' ' OD2' ' A' ' 59' ' ' ASP . 5.9 m-85 -122.88 155.13 37.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.292 -0.88 . . . . 0.0 110.543 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -131.59 124.29 29.68 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -179.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.641 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.9 m -115.71 148.12 18.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.669 ' O ' HG11 ' A' ' 56' ' ' VAL . 1.0 OUTLIER -149.81 120.09 7.32 Favored 'General case' 0 N--CA 1.504 2.265 0 O-C-N 120.579 -1.326 . . . . 0.0 112.728 -177.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.66 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.3 p90 -132.17 155.98 47.24 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.313 -1.492 . . . . 0.0 107.242 176.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.547 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.3 pt-20 -150.69 102.03 3.07 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 120.602 -1.311 . . . . 0.0 110.737 -178.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.508 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.2 Cg_endo -78.76 171.15 17.06 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.121 2.548 . . . . 0.0 111.397 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.656 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 5.3 mttt -129.47 18.34 5.84 Favored 'General case' 0 N--CA 1.502 2.147 0 O-C-N 121.093 -1.004 . . . . 0.0 111.985 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.473 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 4.9 pt-20 -152.41 -137.74 0.07 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.09 -1.631 . . . . 0.0 109.525 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.708 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -99.11 124.82 44.41 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.545 ' HA3' ' HG2' ' A' ' 50' ' ' PRO . . . -161.82 160.63 32.59 Favored Glycine 0 N--CA 1.484 1.858 0 C-N-CA 118.435 -1.841 . . . . 0.0 111.563 -176.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 23.9 p-10 -115.08 156.62 24.84 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 178.272 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.858 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.8 m-85 -114.13 138.83 49.91 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 121.071 -1.018 . . . . 0.0 110.899 -177.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.583 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -115.24 129.35 71.63 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 176.551 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.607 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.94 158.76 7.72 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 CA-C-O 123.214 1.483 . . . . 0.0 112.892 -176.501 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 46' ' ' THR . 2.2 m120 -149.34 113.92 5.31 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.015 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -137.86 122.51 18.61 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.612 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.93 HG22 ' O ' ' A' ' 86' ' ' ASP . 3.2 p -135.99 136.94 40.74 Favored 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 118.855 -1.138 . . . . 0.0 112.476 -176.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.76 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.99 75.74 1.52 Allowed 'General case' 0 N--CA 1.502 2.137 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.493 178.197 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.598 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 141.48 -21.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.95 4.17 5.66 Favored Glycine 0 N--CA 1.483 1.827 0 N-CA-C 108.876 -1.69 . . . . 0.0 108.876 -178.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.93 ' O ' HG22 ' A' ' 82' ' ' THR . 0.5 OUTLIER -129.91 178.14 6.75 Favored 'General case' 0 N--CA 1.483 1.201 0 O-C-N 121.082 -1.246 . . . . 0.0 107.781 179.4 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 8.1 m-80 -111.42 156.49 21.54 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 120.76 -1.212 . . . . 0.0 109.797 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.649 ' CG2' HD12 ' A' ' 81' ' ' LEU . 3.0 t -67.0 170.1 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.281 -0.968 . . . . 0.0 108.434 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.564 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.4 m120 -81.53 25.43 0.52 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.802 -1.186 . . . . 0.0 111.825 -177.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.526 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -150.03 16.05 1.04 Allowed Glycine 0 N--CA 1.495 2.605 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.207 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.4 m-85 -109.6 -38.39 0.12 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.115 -1.227 . . . . 0.0 113.482 -178.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.592 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.6 Cg_endo -74.28 16.05 0.6 Allowed 'Trans proline' 0 C--N 1.311 -1.406 0 N-CA-C 108.323 -1.453 . . . . 0.0 108.323 178.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.534 ' H ' ' C ' ' A' ' 91' ' ' PHE . 13.0 ttpt -100.46 167.79 10.15 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.55 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.0 m -122.93 128.66 50.57 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.125 -179.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.771 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.3 t -98.15 155.67 3.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 8.9 m -121.17 144.99 48.29 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.549 -1.344 . . . . 0.0 113.345 -176.49 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.858 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -129.0 146.25 34.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.63 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.2 OUTLIER -94.88 -176.57 0.57 Allowed Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.533 -0.729 . . . . 0.0 109.837 -177.657 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.708 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 26.7 Cg_endo -66.64 85.92 0.29 Allowed 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.315 1.343 . . . . 0.0 110.299 -178.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.927 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.3 -1.556 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.29 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.584 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 121.601 0.715 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.578 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 28.9 t0 -117.06 48.9 0.76 Allowed Pre-proline 0 C--N 1.3 -1.553 0 O-C-N 121.572 -0.705 . . . . 0.0 111.102 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.584 ' HD3' ' C ' ' A' ' 1' ' ' ALA . 36.4 Cg_endo -77.23 0.99 9.19 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 121.406 1.404 . . . . 0.0 108.817 177.416 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.97 15.32 2.47 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.468 -0.77 . . . . 0.0 111.118 -178.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.537 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.56 32.93 1.17 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.912 -1.118 . . . . 0.0 108.394 -179.753 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.533 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.9 m -115.99 114.42 24.59 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.508 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 3.4 p90 -133.08 145.85 51.12 Favored 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.324 -0.95 . . . . 0.0 111.127 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 1.02 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.52 124.44 43.57 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 23.1 pt-20 -144.87 142.7 30.13 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.913 -1.117 . . . . 0.0 109.928 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.584 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.81 173.76 39.07 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.05 10.91 2.98 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.796 2.331 . . . . 0.0 108.637 176.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.986 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 157.8 14.94 Favored Glycine 0 C--O 1.201 -1.944 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.986 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 85.67 -6.18 0.84 Allowed 'General case' 0 N--CA 1.5 2.042 0 CA-C-N 118.575 1.188 . . . . 0.0 110.449 179.315 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.409 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.0 m-20 -65.48 -20.56 66.4 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.707 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 81.27 -132.27 11.06 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.54 -63.18 0.11 Allowed Glycine 0 N--CA 1.492 2.389 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.587 179.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.612 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.0 OUTLIER -125.82 143.45 51.06 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.909 -1.348 . . . . 0.0 111.513 -178.084 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.72 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.31 -19.31 26.9 Favored 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.312 -0.555 . . . . 0.0 109.65 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.725 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 6.5 m-85 -89.71 12.11 17.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.007 -1.058 . . . . 0.0 110.141 -178.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 17' ' ' GLU . 2.4 mm-40 -99.17 140.82 21.97 Favored Pre-proline 0 C--N 1.295 -1.762 0 N-CA-C 105.533 -2.025 . . . . 0.0 105.533 176.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -68.67 133.71 28.37 Favored 'Trans proline' 0 C--N 1.294 -2.295 0 C-N-CA 121.206 1.271 . . . . 0.0 109.382 -178.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.654 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 2.8 m -103.3 112.04 24.74 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.679 -179.293 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 30.3 mtmt -148.21 132.39 17.38 Favored 'General case' 0 C--N 1.294 -1.841 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.287 179.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.653 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.46 157.99 44.68 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.334 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 14.4 mtmt -115.37 142.13 47.11 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.958 HD12 HG21 ' A' ' 45' ' ' VAL . 1.6 mt -113.7 152.63 15.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.88 -178.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -139.27 118.62 12.82 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.652 0.739 . . . . 0.0 110.141 -179.561 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.74 ' HB2' ' CE1' ' A' ' 43' ' ' PHE . . . -98.77 142.4 30.36 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.531 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -130.64 120.9 49.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.894 -1.129 . . . . 0.0 108.453 178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB2' ' HD2' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -104.67 -178.36 0.61 Allowed Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' HD2' ' HB2' ' A' ' 30' ' ' ASP . 34.2 Cg_endo -77.0 24.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.891 1.727 . . . . 0.0 111.933 -179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.544 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -121.65 10.85 10.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.571 -1.331 . . . . 0.0 109.24 179.206 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.424 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.08 32.3 60.71 Favored Glycine 0 N--CA 1.486 1.996 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -178.317 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.6 OUTLIER -150.66 -178.73 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.662 ' HB3' ' HB3' ' A' ' 28' ' ' ALA . 2.3 m-70 -94.46 55.62 1.99 Allowed 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.57 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 65.01 65.91 0.58 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.692 -0.63 . . . . 0.0 109.458 -179.579 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.453 ' O ' ' O ' ' A' ' 36' ' ' ARG . 7.1 m 46.46 91.1 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.182 -0.949 . . . . 0.0 108.855 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.7 t0 -39.77 147.72 0.08 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.158 -0.964 . . . . 0.0 109.741 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.76 -39.63 3.11 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.03 49.06 0.89 Allowed Glycine 0 N--CA 1.492 2.384 0 O-C-N 121.059 -1.259 . . . . 0.0 110.01 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.55 ' HB2' ' OH ' ' A' ' 65' ' ' TYR . 14.2 m-20 -105.49 115.84 30.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.153 -1.204 . . . . 0.0 109.149 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.04 67.73 0.2 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 107.773 -2.131 . . . . 0.0 107.773 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.74 ' CE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -98.49 124.27 43.12 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.569 -0.96 . . . . 0.0 111.19 -178.01 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.053 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -136.57 113.4 13.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.7 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 67' ' ' VAL . 93.5 t -118.79 152.42 21.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.308 -0.87 . . . . 0.0 109.233 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.557 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -160.51 125.54 3.81 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.97 -179.438 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.891 ' CG1' HD12 ' A' ' 79' ' ' ILE . 0.3 OUTLIER -118.64 157.47 20.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 177.594 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.743 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -166.93 148.82 6.11 Favored 'General case' 0 C--N 1.296 -1.743 0 C-N-CA 117.806 -1.557 . . . . 0.0 110.915 177.023 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -155.93 -169.35 20.08 Favored Glycine 0 N--CA 1.487 2.066 0 N-CA-C 107.893 -2.083 . . . . 0.0 107.893 179.705 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.546 ' CG ' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.46 72.19 6.1 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.222 1.948 . . . . 0.0 110.388 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.904 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -155.42 174.75 3.64 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.158 -0.964 . . . . 0.0 109.591 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.904 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.3 Cg_endo -78.13 -34.84 1.49 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.625 2.217 . . . . 0.0 110.585 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.86 72.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.265 -0.897 . . . . 0.0 109.0 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.604 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.7 m-20 -90.38 -45.96 0.39 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.043 -1.036 . . . . 0.0 111.14 -178.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.11 96.55 0.89 Allowed 'Trans proline' 0 C--N 1.315 -1.211 0 C-N-CA 122.167 1.912 . . . . 0.0 110.578 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 6.6 t -138.25 93.57 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 O-C-N 120.722 -1.236 . . . . 0.0 111.287 -179.348 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.557 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -140.15 136.07 33.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.898 -1.126 . . . . 0.0 110.01 178.371 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.03 156.41 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.504 -0.748 . . . . 0.0 109.916 -178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.544 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -115.28 129.47 56.63 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.522 -0.736 . . . . 0.0 109.151 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.458 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 2.9 m120 -88.92 -11.86 43.31 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.032 -1.042 . . . . 0.0 110.697 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 76.52 12.31 84.45 Favored Glycine 0 N--CA 1.486 2.015 0 C-N-CA 119.461 -1.352 . . . . 0.0 109.952 179.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.458 ' HA ' ' OD2' ' A' ' 38' ' ' ASP . 8.8 p30 -112.12 31.55 6.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.089 -1.242 . . . . 0.0 109.703 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.625 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 73.68 1.18 57.84 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.473 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 28.9 p -132.03 146.24 51.95 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 121.456 -1.026 . . . . 0.0 109.211 179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.585 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 7.4 m-85 -122.97 155.66 36.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.11 -0.994 . . . . 0.0 110.46 -179.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -126.72 128.87 47.34 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.409 -0.807 . . . . 0.0 109.354 -179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 1.024 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -122.95 148.22 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 3.0 mt-10 -155.1 123.64 6.03 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.45 -1.406 . . . . 0.0 113.355 -177.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.699 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.0 p90 -131.51 153.63 49.61 Favored 'General case' 0 N--CA 1.504 2.238 0 O-C-N 120.629 -1.295 . . . . 0.0 107.889 175.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.541 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 2.1 pt-20 -151.98 101.59 2.84 Favored Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 120.362 -1.461 . . . . 0.0 111.198 -178.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.654 ' HB3' ' HB2' ' A' ' 51' ' ' ALA . 37.2 Cg_endo -83.57 -177.9 3.4 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 C-N-CA 123.059 2.506 . . . . 0.0 111.794 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -142.62 32.89 1.44 Allowed 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.409 -0.807 . . . . 0.0 110.454 179.847 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.466 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.7 OUTLIER -152.38 -150.06 0.32 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.407 -1.433 . . . . 0.0 108.653 179.632 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.747 ' HB2' ' HA ' ' A' ' 99' ' ' PRO . . . -98.59 123.95 43.08 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 178.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.546 ' HA3' ' CG ' ' A' ' 50' ' ' PRO . . . -162.4 161.77 33.84 Favored Glycine 0 N--CA 1.484 1.867 0 C-N-CA 118.607 -1.758 . . . . 0.0 111.575 -176.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 5.1 p-10 -113.56 156.41 23.68 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 178.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.8 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.3 m-85 -114.45 135.33 54.22 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.005 -1.078 . . . . 0.0 110.966 -177.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.743 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.3 p -108.84 131.67 58.89 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 104.127 -2.546 . . . . 0.0 104.127 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.891 HD12 ' CG1' ' A' ' 47' ' ' ILE . 0.4 OUTLIER -117.6 156.71 19.05 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.023 0 C-N-CA 117.651 -1.619 . . . . 0.0 111.658 -175.489 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.523 ' N ' HG13 ' A' ' 79' ' ' ILE . 6.9 m-80 -150.5 114.52 5.06 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-O 121.652 0.739 . . . . 0.0 110.174 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.01 HD23 HG22 ' A' ' 45' ' ' VAL . 0.2 OUTLIER -135.07 115.87 13.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.164 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.053 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.3 p -127.02 136.19 51.86 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.662 -0.649 . . . . 0.0 111.518 -176.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.915 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.3 tm? -140.64 76.46 1.55 Allowed 'General case' 0 N--CA 1.501 2.115 0 C-N-CA 119.478 -0.889 . . . . 0.0 109.636 178.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 45.8 m-20 142.65 -23.47 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 131.91 3.11 4.12 Favored Glycine 0 N--CA 1.483 1.792 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -179.009 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.911 ' O ' HG22 ' A' ' 82' ' ' THR . 7.8 m-20 -130.64 172.03 12.41 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.773 -1.428 . . . . 0.0 108.823 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.574 ' ND2' ' CG2' ' A' ' 82' ' ' THR . 2.8 m-80 -102.87 150.39 23.56 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.829 -1.17 . . . . 0.0 108.833 179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.565 ' CG1' ' N ' ' A' ' 89' ' ' ASN . 4.9 t -67.41 171.15 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.012 -1.055 . . . . 0.0 109.239 -179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 29.2 m120 -78.14 19.24 0.45 Allowed 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.784 -1.198 . . . . 0.0 112.197 -177.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.91 15.55 3.07 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.02 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 10.1 m-85 -114.09 -32.09 0.11 Allowed Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.727 1.01 . . . . 0.0 113.727 -177.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.599 ' CD ' ' H ' ' A' ' 91' ' ' PHE . 31.7 Cg_endo -75.78 16.43 0.78 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 108.131 -1.527 . . . . 0.0 108.131 177.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.514 ' H ' ' C ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -103.85 168.67 8.98 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 122.182 0.992 . . . . 0.0 109.782 -179.77 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.522 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.2 m -126.35 131.19 51.85 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.903 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.5 t -98.11 155.68 3.72 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 3.9 m -121.41 140.06 52.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.663 -1.273 . . . . 0.0 113.253 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.8 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.2 t -128.29 142.41 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 176.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.686 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 2.5 mttm -95.02 -170.81 0.23 Allowed Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.435 -0.791 . . . . 0.0 109.253 -177.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HA ' ' HB2' ' A' ' 74' ' ' ALA . 29.2 Cg_endo -69.42 88.79 0.49 Allowed 'Trans proline' 0 C--N 1.321 -0.906 0 C-N-CA 121.135 1.223 . . . . 0.0 110.376 -178.294 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.725 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.408 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CZ ' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.652 0.739 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.656 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 51.4 t0 47.85 51.38 10.5 Favored Pre-proline 0 C--N 1.299 -1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 110.777 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.6 Cg_endo -81.56 0.98 9.58 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.649 1.566 . . . . 0.0 108.067 177.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -146.46 13.15 1.21 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.706 -0.621 . . . . 0.0 111.34 -177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER -139.02 37.43 2.14 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.625 -1.297 . . . . 0.0 108.004 -179.498 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.516 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.8 m -114.71 114.72 26.0 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.534 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 15.8 p90 -139.92 142.74 36.42 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.486 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.985 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.36 125.56 46.18 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.0 pp20? -142.86 141.35 31.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.865 -1.147 . . . . 0.0 110.321 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.597 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.42 175.08 39.71 Favored Glycine 0 N--CA 1.484 1.87 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 179.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -78.84 8.55 3.69 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.473 2.116 . . . . 0.0 108.852 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.656 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.27 157.12 15.26 Favored Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.744 ' O ' HG11 ' A' ' 95' ' ' VAL . 0.0 OUTLIER 89.13 -27.67 0.05 Allowed 'General case' 0 N--CA 1.503 2.202 0 CA-C-N 117.931 0.865 . . . . 0.0 110.096 179.599 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.534 ' C ' HG11 ' A' ' 95' ' ' VAL . 2.9 m-20 -49.95 -22.06 1.41 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.675 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 83.76 -129.01 8.87 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.586 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.59 -64.51 0.11 Allowed Glycine 0 N--CA 1.49 2.246 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.594 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.611 ' N ' HG22 ' A' ' 97' ' ' VAL . 50.5 mt-10 -128.87 142.64 50.89 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.786 -1.42 . . . . 0.0 111.93 -178.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.727 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.5 m -88.38 -20.27 25.51 Favored 'General case' 0 N--CA 1.501 2.08 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.326 179.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' ' HB1' ' A' ' 100' ' ' ALA . 6.6 m-85 -88.32 10.19 20.65 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.27 -0.894 . . . . 0.0 110.109 -178.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -99.13 150.59 36.84 Favored Pre-proline 0 C--N 1.294 -1.807 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 177.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -70.93 129.16 15.94 Favored 'Trans proline' 0 C--N 1.295 -2.271 0 C-N-CA 121.356 1.37 . . . . 0.0 108.641 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.617 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.8 111.28 23.96 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 118.7 -1.2 . . . . 0.0 108.838 -178.751 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.579 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 28.5 mttt -151.52 135.58 16.62 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.534 -0.729 . . . . 0.0 109.657 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.683 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.55 158.66 43.67 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.6 mttp -114.23 141.08 48.01 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.86 HG23 ' HB2' ' A' ' 8' ' ' ALA . 1.2 mt -110.98 152.04 13.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 119.306 -0.958 . . . . 0.0 110.494 -178.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.548 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.2 m80 -140.61 118.35 11.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.548 0.689 . . . . 0.0 109.87 -179.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.097 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.27 139.52 39.16 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.651 -0.656 . . . . 0.0 109.607 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.534 ' O ' ' CB ' ' A' ' 2' ' ' ASP . 2.4 t -129.35 128.68 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.596 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.8 OUTLIER -105.58 -171.68 0.23 Allowed Pre-proline 0 C--N 1.299 -1.59 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.417 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.596 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.5 Cg_endo -78.74 17.97 1.06 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 121.728 1.619 . . . . 0.0 111.599 -179.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.565 ' C ' HG23 ' A' ' 34' ' ' VAL . 77.0 m-20 -117.99 11.34 13.36 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.555 -1.341 . . . . 0.0 109.315 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.43 33.21 67.97 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 106.267 -2.733 . . . . 0.0 106.267 -178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.565 HG23 ' C ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -148.59 178.53 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 122.187 -0.596 . . . . 0.0 109.412 -177.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.589 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.7 m-70 -91.05 66.17 5.73 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.743 ' CZ ' ' HB3' ' A' ' 1' ' ' ALA . 11.7 ptm180 46.11 70.7 0.35 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -178.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.47 ' O ' ' O ' ' A' ' 38' ' ' ASP . 7.0 m 46.68 86.85 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 7.3 t0 -46.13 173.01 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.887 -1.133 . . . . 0.0 109.706 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 88.0 -38.01 3.21 Favored Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -140.46 62.67 0.54 Allowed Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.628 -1.273 . . . . 0.0 110.311 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 43' ' ' PHE . 15.2 m-20 -89.65 124.66 34.78 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.323 . . . . 0.0 109.068 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.586 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -67.89 62.45 0.34 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 108.464 -1.854 . . . . 0.0 108.464 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.097 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -101.41 110.01 21.93 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.406 -1.055 . . . . 0.0 110.203 -178.785 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.877 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -116.78 114.04 44.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.265 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.127 HG22 HD23 ' A' ' 81' ' ' LEU . 2.5 t -118.98 152.76 21.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.253 -0.904 . . . . 0.0 109.141 -179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.17 127.14 4.4 Favored 'General case' 0 C--N 1.3 -1.573 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.725 179.977 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.649 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.42 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.437 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.534 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -170.26 155.24 5.21 Favored 'General case' 0 C--N 1.297 -1.674 0 C-N-CA 118.21 -1.396 . . . . 0.0 110.77 176.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -160.51 -168.92 23.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.178 -1.969 . . . . 0.0 108.178 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.534 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -78.11 71.13 6.82 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 C-N-CA 122.396 2.064 . . . . 0.0 110.262 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.953 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -153.98 178.03 1.76 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.04 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.953 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.89 -49.65 0.09 OUTLIER 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.422 2.081 . . . . 0.0 110.378 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.544 HG12 ' CG2' ' A' ' 56' ' ' VAL . 3.5 t -95.42 76.4 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.321 -0.862 . . . . 0.0 109.166 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.594 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 72.3 m-20 -91.59 -45.34 0.36 Allowed Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 120.975 -1.078 . . . . 0.0 111.504 -178.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.594 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -82.27 95.25 0.88 Allowed 'Trans proline' 0 C--N 1.314 -1.252 0 C-N-CA 122.223 1.949 . . . . 0.0 110.797 -179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.629 HG11 ' O ' ' A' ' 68' ' ' GLU . 11.5 t -135.4 94.46 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 O-C-N 120.836 -1.165 . . . . 0.0 110.764 -179.308 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.446 ' O ' ' SD ' ' A' ' 57' ' ' MET . 4.1 ppp? -140.13 135.0 32.06 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.497 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -132.17 156.6 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.487 -0.758 . . . . 0.0 109.907 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.549 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.6 t0 -113.57 130.84 56.29 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.587 -0.695 . . . . 0.0 109.425 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' HB3' ' OD1' ' A' ' 62' ' ' ASP . 0.7 OUTLIER -89.18 -13.67 37.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 110.987 -179.472 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 78.87 -5.86 56.89 Favored Glycine 0 N--CA 1.488 2.128 0 O-C-N 120.622 -1.299 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 60' ' ' ASN . 44.6 p-10 -95.93 34.22 1.57 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.073 -1.251 . . . . 0.0 109.608 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.589 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 71.83 -0.28 37.62 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 -179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.519 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 71.0 p -128.1 150.5 49.94 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.233 -1.157 . . . . 0.0 109.609 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 4.9 m-85 -125.24 155.2 40.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.852 -179.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -127.91 124.81 38.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.433 -0.792 . . . . 0.0 109.353 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.683 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.5 m -119.53 148.86 22.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.629 ' O ' HG11 ' A' ' 56' ' ' VAL . 10.4 mt-10 -154.82 126.95 7.72 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.489 -1.382 . . . . 0.0 112.993 -177.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.649 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.4 p90 -133.78 156.21 48.42 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 176.111 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.549 ' O ' ' CG ' ' A' ' 70' ' ' GLU . 4.4 pt-20 -150.52 99.65 3.17 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 120.418 -1.426 . . . . 0.0 110.552 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.9 Cg_endo -81.02 175.1 10.21 Favored 'Trans proline' 0 C--N 1.314 -1.272 0 C-N-CA 123.116 2.544 . . . . 0.0 112.032 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.548 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -137.32 29.54 2.72 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.536 -0.727 . . . . 0.0 110.5 179.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.596 ' O ' ' HB2' ' A' ' 100' ' ' ALA . 0.3 OUTLIER -153.49 -159.6 1.01 Allowed 'General case' 0 C--N 1.305 -1.329 0 O-C-N 120.443 -1.41 . . . . 0.0 108.109 179.223 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -90.65 122.78 33.73 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.569 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.99 162.59 33.24 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.244 -1.455 . . . . 0.0 111.284 -176.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.5 OUTLIER -112.69 157.58 21.09 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.386 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.789 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.0 m-85 -113.62 139.9 48.64 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.712 -177.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.732 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.71 128.35 74.1 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.025 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 176.442 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.757 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -110.09 158.72 10.18 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 123.264 1.507 . . . . 0.0 112.524 -176.594 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 2.8 m120 -149.97 114.18 5.16 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 178.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.127 HD23 HG22 ' A' ' 45' ' ' VAL . 0.8 OUTLIER -136.6 116.71 13.4 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.405 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.963 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.3 p -130.69 136.9 49.25 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 118.745 -1.182 . . . . 0.0 113.134 -176.103 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.702 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -140.73 74.68 1.47 Allowed 'General case' 0 N--CA 1.503 2.198 0 C-N-CA 119.933 -0.707 . . . . 0.0 109.67 178.143 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.594 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 53.8 m-20 141.87 -21.88 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.355 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.8 3.52 4.5 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.092 -1.603 . . . . 0.0 109.092 -178.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.963 ' O ' HG22 ' A' ' 82' ' ' THR . 52.4 m-20 -131.17 173.39 11.08 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 120.878 -1.366 . . . . 0.0 108.176 179.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.587 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -105.58 156.1 18.57 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 120.808 -1.183 . . . . 0.0 109.444 -179.988 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.723 ' CG2' HD12 ' A' ' 81' ' ' LEU . 2.9 t -66.94 170.77 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 O-C-N 121.22 -0.925 . . . . 0.0 109.296 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.56 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 4.0 t-20 -80.59 23.72 0.5 Allowed 'General case' 0 N--CA 1.499 1.991 0 O-C-N 120.824 -1.172 . . . . 0.0 111.821 -177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -150.64 18.45 0.99 Allowed Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.985 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.7 m-85 -114.41 -45.61 0.06 OUTLIER Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.264 -1.139 . . . . 0.0 113.776 -177.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.664 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.1 Cg_endo -71.76 15.17 0.38 Allowed 'Trans proline' 0 C--N 1.309 -1.521 0 N-CA-C 108.801 -1.269 . . . . 0.0 108.801 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.533 ' H ' ' C ' ' A' ' 91' ' ' PHE . 2.5 tmtt? -100.85 172.95 6.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 36.3 m -123.1 127.77 49.17 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.931 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 13' ' ' LEU . 6.7 t -98.99 152.67 4.34 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 12.2 m -118.69 141.03 48.99 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.583 -1.323 . . . . 0.0 113.242 -176.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.789 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.6 t -126.31 130.99 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 176.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.601 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 3.0 mtmt -121.41 -64.35 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.771 0 O-C-N 120.932 -1.105 . . . . 0.0 112.509 -178.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.601 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.7 Cg_endo -74.83 76.69 3.25 Favored 'Trans proline' 0 C--N 1.315 -1.209 0 C-N-CA 121.495 1.464 . . . . 0.0 111.596 -178.075 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 1.045 ' HB1' ' CE1' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 110.026 179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.546 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 121.527 0.68 . . . . 0.0 109.624 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.718 ' HB3' HD12 ' A' ' 83' ' ' LEU . 33.3 t0 -116.09 44.43 0.41 Allowed Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.807 . . . . 0.0 111.822 -179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.609 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.0 Cg_endo -77.62 1.44 8.81 Favored 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 121.369 1.38 . . . . 0.0 108.753 177.313 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 1.6 mt-10 -133.53 9.78 4.0 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.539 -0.726 . . . . 0.0 111.031 -178.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -147.23 37.3 0.93 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.83 -1.169 . . . . 0.0 108.349 -179.503 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.51 ' OG ' ' OD2' ' A' ' 2' ' ' ASP . 49.0 m -114.93 125.1 53.25 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 -179.326 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.614 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 1.1 p90 -143.08 144.29 32.19 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.197 -0.939 . . . . 0.0 111.374 -179.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.807 ' HB2' ' CD1' ' A' ' 81' ' ' LEU . . . -126.58 127.12 44.76 Favored 'General case' 0 N--CA 1.498 1.945 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -149.0 143.68 26.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.895 -1.128 . . . . 0.0 109.783 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.607 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.22 176.11 38.64 Favored Glycine 0 N--CA 1.481 1.648 0 C-N-CA 119.682 -1.247 . . . . 0.0 110.256 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.497 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.5 Cg_endo -79.91 11.24 2.84 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.715 2.277 . . . . 0.0 108.793 176.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.58 158.26 14.7 Favored Glycine 0 C--O 1.202 -1.905 0 N-CA-C 108.545 -1.822 . . . . 0.0 108.545 -179.454 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 84.25 -3.48 1.05 Allowed 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 118.609 1.205 . . . . 0.0 110.596 179.375 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -68.73 -17.01 63.98 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.692 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.39 -136.05 15.99 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.605 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 68.49 -72.36 0.34 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.794 179.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.539 ' N ' HG22 ' A' ' 97' ' ' VAL . 68.1 mt-10 -119.44 144.57 46.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.088 -1.242 . . . . 0.0 111.632 -177.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.718 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.73 -19.95 26.88 Favored 'General case' 0 N--CA 1.5 2.063 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.915 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 15.2 m-85 -88.64 12.83 13.65 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.459 -179.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 12.8 tt0 -98.44 134.31 21.96 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 176.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.543 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 28.5 Cg_endo -67.55 136.46 39.53 Favored 'Trans proline' 0 C--N 1.294 -2.292 0 C-N-CA 121.191 1.261 . . . . 0.0 109.537 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.668 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 4.5 m -104.15 111.55 24.19 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.751 -1.179 . . . . 0.0 108.756 -179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.586 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -145.67 133.66 21.4 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 178.846 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.671 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -140.5 158.28 44.23 Favored 'General case' 0 C--N 1.29 -2.007 0 C-N-CA 119.758 -0.777 . . . . 0.0 109.188 179.545 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.3 mmtp -113.62 139.61 48.88 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.133 ' CD1' HG21 ' A' ' 45' ' ' VAL . 15.6 mt -108.47 151.15 10.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.365 -0.835 . . . . 0.0 109.819 -178.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.53 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.6 m80 -143.25 114.47 7.86 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 121.549 0.69 . . . . 0.0 109.63 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.992 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.07 147.18 26.51 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.643 -0.661 . . . . 0.0 110.062 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.55 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.1 t -132.49 118.7 36.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.894 -1.129 . . . . 0.0 107.968 178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.593 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -98.34 -173.75 0.33 Allowed Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.593 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.49 20.55 0.84 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.908 1.738 . . . . 0.0 111.468 -179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 34' ' ' VAL . 31.2 m-20 -124.24 14.27 9.0 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.592 -1.318 . . . . 0.0 109.659 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.33 33.02 72.4 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 106.297 -2.721 . . . . 0.0 106.297 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -147.42 161.9 7.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.027 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.642 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.3 m-70 -79.84 55.85 2.17 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.533 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 7.0 ttp85 66.42 63.07 0.54 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.466 ' O ' ' C ' ' A' ' 38' ' ' ASP . 11.2 p 46.04 90.59 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 108.702 -179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.466 ' C ' ' O ' ' A' ' 37' ' ' THR . 1.0 OUTLIER -39.81 156.22 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.212 -0.93 . . . . 0.0 109.868 -179.404 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.42 -36.26 3.24 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.76 59.65 0.63 Allowed Glycine 0 N--CA 1.492 2.416 0 O-C-N 120.999 -1.295 . . . . 0.0 110.295 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.528 ' O ' ' N ' ' A' ' 43' ' ' PHE . 0.9 OUTLIER -105.12 120.51 41.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.045 -1.268 . . . . 0.0 108.985 179.231 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -68.68 61.17 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 108.241 -1.944 . . . . 0.0 108.241 179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.992 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -99.74 112.47 24.71 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 110.466 -178.667 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -123.37 113.0 35.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 177.871 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.133 HG21 ' CD1' ' A' ' 26' ' ' ILE . 89.2 t -125.03 147.9 29.59 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.161 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.45 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -159.91 136.99 9.42 Favored 'General case' 0 C--N 1.295 -1.761 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.455 -179.476 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.708 HG12 HG23 ' A' ' 79' ' ' ILE . 0.7 OUTLIER -118.9 157.52 20.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.172 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.654 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.2 OUTLIER -169.79 146.52 3.23 Favored 'General case' 0 C--N 1.293 -1.861 0 C-N-CA 118.288 -1.365 . . . . 0.0 110.545 177.634 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -151.23 -169.2 16.64 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.401 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 35.0 Cg_endo -77.32 70.36 6.8 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 122.313 2.009 . . . . 0.0 110.353 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.06 -179.51 1.12 Allowed Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.248 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.1 Cg_endo -76.08 -55.58 0.06 OUTLIER 'Trans proline' 0 C--N 1.311 -1.404 0 C-N-CA 122.429 2.086 . . . . 0.0 110.904 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 62.5 t -89.3 84.87 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.034 -1.041 . . . . 0.0 108.545 179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.737 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 69.8 m-20 -98.69 -56.27 0.18 Allowed Pre-proline 0 N--CA 1.487 1.377 0 O-C-N 120.821 -1.174 . . . . 0.0 111.686 -178.332 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.737 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 38.1 Cg_endo -81.58 115.77 2.85 Favored 'Trans proline' 0 C--N 1.32 -0.952 0 C-N-CA 122.013 1.808 . . . . 0.0 111.536 -179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.648 HG11 ' O ' ' A' ' 68' ' ' GLU . 15.1 t -149.97 101.37 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 O-C-N 120.737 -1.227 . . . . 0.0 110.744 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.43 ' N ' ' SD ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.9 135.2 31.05 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.825 -1.172 . . . . 0.0 110.861 178.666 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.41 156.3 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.717 -0.615 . . . . 0.0 109.511 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.548 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 9.1 t0 -113.13 133.43 55.03 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.397 -0.815 . . . . 0.0 109.869 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -89.35 -12.01 41.68 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.265 -0.897 . . . . 0.0 110.429 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.14 6.15 78.61 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 119.621 -1.276 . . . . 0.0 110.106 179.225 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 28.4 p-10 -109.33 30.77 6.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.075 -1.25 . . . . 0.0 109.804 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.642 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 75.81 -0.36 61.96 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 11.2 p -128.48 145.28 51.15 Favored 'General case' 0 C--N 1.308 -1.206 0 O-C-N 121.601 -0.941 . . . . 0.0 109.049 179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.629 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.1 m-85 -123.29 154.16 39.22 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.076 -1.015 . . . . 0.0 110.39 -179.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 24' ' ' PHE . 40.9 t0 -125.1 125.36 43.64 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.45 -0.781 . . . . 0.0 109.058 -179.245 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.663 ' CG2' ' CD2' ' A' ' 24' ' ' PHE . 1.8 m -119.65 144.74 27.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.648 ' O ' HG11 ' A' ' 56' ' ' VAL . 16.2 mp0 -151.98 126.71 9.55 Favored 'General case' 0 N--CA 1.502 2.146 0 O-C-N 120.575 -1.328 . . . . 0.0 113.009 -178.101 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.69 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.1 p90 -129.8 156.48 44.27 Favored 'General case' 0 N--CA 1.502 2.145 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 176.177 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -148.04 107.83 3.68 Favored Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 120.439 -1.413 . . . . 0.0 110.133 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.465 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.8 Cg_endo -79.32 -159.52 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 122.884 2.389 . . . . 0.0 111.504 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.624 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -141.73 -61.96 0.46 Allowed 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.297 -0.877 . . . . 0.0 110.835 -179.555 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.476 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.4 pt-20 -92.69 -134.18 0.15 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.833 -1.167 . . . . 0.0 110.123 -178.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -89.71 132.87 34.96 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.79 -1.194 . . . . 0.0 108.75 179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.504 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -162.06 158.91 30.97 Favored Glycine 0 N--CA 1.483 1.827 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.579 -178.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.1 p30 -115.16 155.6 26.83 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.887 ' OH ' HG21 ' A' ' 97' ' ' VAL . 3.0 m-85 -115.23 136.25 53.3 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 118.941 -1.103 . . . . 0.0 111.025 -177.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.701 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -114.41 128.46 71.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 105.784 -1.932 . . . . 0.0 105.784 176.412 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.712 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.5 OUTLIER -104.8 158.14 5.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 122.913 1.339 . . . . 0.0 112.143 -176.974 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.503 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 3.3 m120 -150.36 112.87 4.7 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.852 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -140.72 128.1 21.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.611 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 18.5 p -141.83 138.73 32.4 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.762 -0.775 . . . . 0.0 111.279 -177.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.766 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.0 tm? -136.08 73.15 1.45 Allowed 'General case' 0 N--CA 1.499 1.999 0 C-N-CA 119.279 -0.968 . . . . 0.0 109.579 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.596 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.7 m-20 141.19 -22.38 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.195 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.68 -4.31 3.97 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -178.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.576 ' O ' HG22 ' A' ' 82' ' ' THR . 16.6 m-20 -123.96 170.7 10.36 Favored 'General case' 0 N--CA 1.482 1.139 0 O-C-N 120.863 -1.375 . . . . 0.0 107.375 179.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.656 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -111.92 161.29 16.56 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.669 -1.269 . . . . 0.0 109.485 -179.941 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.764 HG23 ' CD2' ' A' ' 81' ' ' LEU . 10.3 t -66.32 169.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 119.053 -1.059 . . . . 0.0 109.034 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.554 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 57.6 t30 -82.78 24.68 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.885 -1.134 . . . . 0.0 111.454 -178.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.21 18.74 1.91 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 179.117 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.737 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.6 m-85 -113.05 -39.99 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.364 -1.08 . . . . 0.0 113.779 -177.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.616 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.7 Cg_endo -73.93 15.39 0.59 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 N-CA-C 108.516 -1.379 . . . . 0.0 108.516 178.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 91' ' ' PHE . 4.2 ttmt -100.36 171.54 7.7 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.535 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 49.4 m -126.95 130.0 49.23 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 119.453 -0.899 . . . . 0.0 110.514 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.726 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.0 t -99.03 155.13 3.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 37.8 m -122.16 147.72 45.81 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.593 -1.317 . . . . 0.0 113.214 -176.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.887 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -132.86 147.13 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.696 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.3 OUTLIER -94.76 -175.42 0.47 Allowed Pre-proline 0 N--CA 1.499 1.981 0 O-C-N 121.455 -0.778 . . . . 0.0 109.663 -177.905 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.696 ' HD2' ' CB ' ' A' ' 98' ' ' LYS . 27.1 Cg_endo -66.42 84.62 0.28 Allowed 'Trans proline' 0 C--N 1.322 -0.863 0 C-N-CA 121.565 1.51 . . . . 0.0 110.904 -177.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.915 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.301 -1.526 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.505 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.581 ' HB1' ' OD1' ' A' ' 30' ' ' ASP . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.766 0.793 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.631 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 49.5 t0 44.01 52.77 9.65 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.191 -0.943 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.631 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.7 Cg_endo -81.79 3.94 7.42 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 121.563 1.509 . . . . 0.0 108.226 177.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 15.38 1.3 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.534 -0.729 . . . . 0.0 111.304 -177.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' CG ' ' HB ' ' A' ' 29' ' ' VAL . 4.7 tptm -147.0 37.98 0.97 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.79 -1.194 . . . . 0.0 108.29 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.52 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 m -115.59 114.03 24.39 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' HIS . 0.9 OUTLIER -144.32 145.91 32.27 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.831 -179.586 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.881 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -122.44 125.22 45.38 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 8' ' ' ALA . 5.3 mt-10 -142.28 142.57 32.57 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.369 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.6 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.46 175.02 39.75 Favored Glycine 0 N--CA 1.482 1.728 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 179.43 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.489 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -79.38 8.0 4.15 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.322 2.015 . . . . 0.0 108.845 177.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.707 ' O ' ' HB3' ' A' ' 13' ' ' LEU . . . -118.08 144.45 18.12 Favored Glycine 0 N--CA 1.483 1.799 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.911 HD12 HD13 ' A' ' 79' ' ' ILE . 0.2 OUTLIER 105.35 -21.08 0.01 OUTLIER 'General case' 0 N--CA 1.513 2.699 0 C-N-CA 123.151 0.581 . . . . 0.0 110.748 178.919 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.664 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.4 OUTLIER -52.04 -20.68 2.58 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 121.268 -0.895 . . . . 0.0 108.632 178.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.73 ' HA3' HG12 ' A' ' 95' ' ' VAL . . . 78.33 -128.8 8.94 Favored Glycine 0 N--CA 1.496 2.693 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.513 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.82 -55.66 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.218 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.706 ' N ' HG22 ' A' ' 97' ' ' VAL . 21.7 mt-10 -130.97 143.16 50.52 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.898 -1.354 . . . . 0.0 111.559 -178.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.675 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -87.81 -20.34 26.22 Favored 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.417 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.851 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 49.7 m-85 -88.78 12.98 13.51 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.191 -0.943 . . . . 0.0 109.755 -179.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -99.17 136.38 20.52 Favored Pre-proline 0 C--N 1.296 -1.737 0 N-CA-C 105.237 -2.135 . . . . 0.0 105.237 176.674 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.45 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.7 Cg_endo -69.68 135.28 30.24 Favored 'Trans proline' 0 C--N 1.295 -2.276 0 C-N-CA 121.205 1.27 . . . . 0.0 109.112 -178.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.665 ' CB ' ' CE1' ' A' ' 69' ' ' PHE . 1.9 m -104.38 110.56 22.85 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 118.358 -1.337 . . . . 0.0 109.184 -179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.572 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -146.21 129.59 16.79 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.379 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.657 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.07 158.62 43.77 Favored 'General case' 0 C--N 1.288 -2.076 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.741 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 34.8 mttm -114.28 142.81 45.82 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.165 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.7 mt -104.49 149.73 7.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 O-C-N 121.388 -0.82 . . . . 0.0 109.205 -178.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.502 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 2.4 m80 -139.64 114.29 9.3 Favored 'General case' 0 C--N 1.295 -1.793 0 O-C-N 121.574 -0.704 . . . . 0.0 109.526 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.948 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -105.53 143.93 33.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.622 -0.674 . . . . 0.0 110.008 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.562 ' HB ' ' CG ' ' A' ' 5' ' ' LYS . 2.9 t -133.52 120.23 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.078 -1.014 . . . . 0.0 108.828 179.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.602 ' HB2' ' N ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER -104.23 -176.32 0.43 Allowed Pre-proline 0 N--CA 1.493 1.709 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.584 ' HD2' ' HB3' ' A' ' 30' ' ' ASP . 35.7 Cg_endo -78.36 34.13 0.49 Allowed 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.051 1.834 . . . . 0.0 113.245 -178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.526 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -132.56 13.21 4.51 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.166 -1.584 . . . . 0.0 109.856 179.143 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.42 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.58 34.05 63.39 Favored Glycine 0 N--CA 1.483 1.817 0 N-CA-C 106.393 -2.683 . . . . 0.0 106.393 -178.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.93 179.33 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.074 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.641 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 6.1 m170 -93.13 53.2 1.92 Allowed 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.142 -0.974 . . . . 0.0 108.763 179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.712 ' CG ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 67.48 73.45 0.32 Allowed 'General case' 0 N--CA 1.485 1.317 0 CA-C-O 122.74 1.257 . . . . 0.0 109.025 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.472 ' C ' ' O ' ' A' ' 36' ' ' ARG . 16.8 p 39.58 83.6 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.617 -1.302 . . . . 0.0 109.876 -179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.463 ' O ' ' O ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -43.84 167.59 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.867 -1.146 . . . . 0.0 109.811 -179.641 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.59 -43.03 2.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -141.03 67.39 0.48 Allowed Glycine 0 N--CA 1.491 2.322 0 O-C-N 121.001 -1.293 . . . . 0.0 109.972 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.55 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.2 OUTLIER -90.7 136.05 33.32 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.927 -1.337 . . . . 0.0 108.873 179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -77.75 54.48 3.75 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.468 -1.853 . . . . 0.0 108.468 179.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.996 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -94.28 98.09 10.68 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.52 -0.988 . . . . 0.0 110.152 -179.066 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.91 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -104.43 113.32 41.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.069 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.165 HG21 ' CD1' ' A' ' 26' ' ' ILE . 8.4 t -121.05 147.78 24.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.34 -0.85 . . . . 0.0 108.92 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.44 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.46 131.72 5.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.043 -1.063 . . . . 0.0 110.642 -179.928 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.689 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -120.57 155.99 23.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.563 ' O ' HG12 ' A' ' 78' ' ' VAL . 3.2 pt-20 -170.74 152.77 3.82 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 117.966 -1.494 . . . . 0.0 110.831 176.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.442 ' O ' ' CG ' ' A' ' 54' ' ' ASP . . . -157.52 -168.8 20.48 Favored Glycine 0 N--CA 1.488 2.106 0 N-CA-C 107.957 -2.057 . . . . 0.0 107.957 179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -77.36 72.2 6.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.075 1.85 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.97 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -157.52 177.13 2.22 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.094 -1.004 . . . . 0.0 109.504 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.97 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.7 Cg_endo -75.76 -51.21 0.11 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 122.533 2.156 . . . . 0.0 110.622 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 70' ' ' GLU . 4.5 m -89.39 80.43 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.745 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 32.2 m-20 -95.11 -62.95 0.14 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.054 -1.028 . . . . 0.0 111.47 -177.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.745 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.4 Cg_endo -77.8 106.27 2.16 Favored 'Trans proline' 0 C--N 1.317 -1.109 0 C-N-CA 122.058 1.839 . . . . 0.0 111.432 -179.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.645 HG11 ' O ' ' A' ' 68' ' ' GLU . 7.2 t -141.31 95.98 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 O-C-N 120.717 -1.24 . . . . 0.0 110.966 -179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.23 136.69 33.62 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.775 -1.203 . . . . 0.0 110.652 178.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -135.61 156.69 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 CA-C-O 121.67 0.747 . . . . 0.0 110.273 -179.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.586 ' OD2' ' CZ ' ' A' ' 65' ' ' TYR . 10.1 t0 -122.11 129.69 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -88.63 -26.31 21.96 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.04 -1.037 . . . . 0.0 111.016 -179.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 59' ' ' ASP . . . 95.42 36.38 5.4 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.365 -1.397 . . . . 0.0 110.848 179.112 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 5.1 p30 -140.28 27.26 2.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.836 -1.391 . . . . 0.0 109.571 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.641 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 82.05 -11.47 48.47 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 61.0 p -122.72 125.69 46.06 Favored 'General case' 0 N--CA 1.485 1.31 0 O-C-N 121.594 -0.945 . . . . 0.0 108.962 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.608 ' HB2' HD12 ' A' ' 26' ' ' ILE . 13.4 m-85 -120.24 157.42 29.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.858 -1.151 . . . . 0.0 109.064 -179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -125.42 154.48 41.88 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.702 -1.249 . . . . 0.0 110.555 -177.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.66 HG11 HG11 ' A' ' 45' ' ' VAL . 2.3 m -137.9 147.78 25.8 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.645 ' O ' HG11 ' A' ' 56' ' ' VAL . 13.1 mt-10 -155.64 126.21 6.84 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.042 -1.463 . . . . 0.0 112.876 -178.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.689 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.9 p90 -134.04 154.86 50.88 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.214 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 53' ' ' VAL . 0.0 OUTLIER -151.33 108.3 2.97 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 120.408 -1.433 . . . . 0.0 110.064 -179.416 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.469 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -78.94 -161.3 0.14 Allowed 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 122.96 2.44 . . . . 0.0 112.57 -178.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.636 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -142.69 -58.75 0.44 Allowed 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.772 -0.58 . . . . 0.0 110.392 -179.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.467 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 0.6 OUTLIER -87.23 -142.36 0.11 Allowed 'General case' 0 C--N 1.308 -1.237 0 O-C-N 120.224 -1.548 . . . . 0.0 108.998 -179.082 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -91.26 134.83 34.24 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.838 -1.164 . . . . 0.0 108.184 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.555 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.98 160.94 32.03 Favored Glycine 0 N--CA 1.486 1.97 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.681 -177.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 11.9 p30 -113.34 156.17 23.87 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.149 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.672 ' OH ' HG21 ' A' ' 97' ' ' VAL . 5.1 m-30 -114.93 132.93 56.39 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.873 -177.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -112.22 128.12 69.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 176.573 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.911 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -105.9 157.04 6.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 122.948 1.356 . . . . 0.0 112.309 -176.912 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 1.6 m120 -149.13 113.6 5.29 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 178.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.996 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.58 120.86 17.97 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.135 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.97 HG22 ' O ' ' A' ' 86' ' ' ASP . 2.6 p -136.51 135.1 38.26 Favored 'General case' 0 C--N 1.294 -1.829 0 C-N-CA 118.602 -1.239 . . . . 0.0 112.327 -176.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.802 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.5 tm? -137.44 73.9 1.46 Allowed 'General case' 0 N--CA 1.502 2.161 0 C-N-CA 119.721 -0.791 . . . . 0.0 109.192 178.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.566 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.8 m-20 142.42 -24.73 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.164 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 132.04 2.76 4.15 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -178.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.97 ' O ' HG22 ' A' ' 82' ' ' THR . 2.0 p30 -125.34 172.16 9.83 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.865 -1.373 . . . . 0.0 108.118 179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.627 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 2.0 m-80 -105.16 151.55 23.92 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.707 -1.245 . . . . 0.0 109.696 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.64 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.24 170.88 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 C-N-CA 119.065 -1.054 . . . . 0.0 108.784 -179.594 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 8.8 p-10 -81.72 26.29 0.5 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.797 -1.189 . . . . 0.0 111.769 -177.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.59 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.9 20.91 1.13 Allowed Glycine 0 N--CA 1.493 2.466 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.881 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 5.7 m-85 -119.28 -43.28 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.481 0 N-CA-C 114.14 1.163 . . . . 0.0 114.14 -177.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.666 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.5 Cg_endo -72.69 15.79 0.43 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.932 -1.219 . . . . 0.0 108.932 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.523 ' H ' ' C ' ' A' ' 91' ' ' PHE . 32.9 ttpt -100.33 168.46 9.76 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 30.4 m -122.67 128.47 50.65 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 119.563 -0.855 . . . . 0.0 109.79 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.73 HG12 ' HA3' ' A' ' 15' ' ' GLY . 47.0 t -99.56 151.25 4.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 178.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 48.5 m -118.9 137.88 53.14 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.557 -1.339 . . . . 0.0 113.149 -176.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.706 HG22 ' N ' ' A' ' 17' ' ' GLU . 3.1 t -122.73 130.69 74.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 176.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.663 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 15.9 mttt -123.12 -66.74 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 120.693 -1.254 . . . . 0.0 112.393 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.663 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 36.8 Cg_endo -77.15 73.42 5.48 Favored 'Trans proline' 0 C--N 1.317 -1.126 0 C-N-CA 121.683 1.589 . . . . 0.0 112.468 -177.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.851 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.493 1.717 0 O-C-N 120.742 -1.224 . . . . 0.0 108.273 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.707 ' HB3' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.485 0.66 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.606 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 40.0 t0 47.84 56.98 18.01 Favored Pre-proline 0 C--N 1.301 -1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 110.48 179.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.606 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.4 Cg_endo -82.45 3.69 7.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 121.938 1.759 . . . . 0.0 108.273 177.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.413 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 2.2 tt0 -149.1 15.56 0.92 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.535 -0.728 . . . . 0.0 111.472 -177.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.552 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 32.7 mttt -145.62 40.09 1.18 Allowed 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.728 -1.233 . . . . 0.0 107.806 -179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.501 ' O ' HG22 ' A' ' 88' ' ' VAL . 1.7 m -115.51 115.74 27.0 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.587 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 2.3 p90 -138.08 142.58 40.24 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.165 -179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 1.019 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -123.1 120.4 33.14 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -140.35 143.98 36.05 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.828 -1.17 . . . . 0.0 110.039 -179.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.616 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.48 175.52 38.9 Favored Glycine 0 N--CA 1.481 1.669 0 C-N-CA 119.833 -1.175 . . . . 0.0 110.257 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.481 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.9 Cg_endo -79.16 7.97 4.1 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.66 2.24 . . . . 0.0 108.83 177.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.987 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.4 156.78 15.45 Favored Glycine 0 C--O 1.2 -2.018 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.987 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 90.34 -6.23 0.33 Allowed 'General case' 0 N--CA 1.503 2.204 0 CA-C-N 118.179 0.989 . . . . 0.0 110.573 179.351 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.9 OUTLIER -68.29 -17.4 64.26 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.223 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.69 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.19 -131.74 10.76 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.626 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 65.33 -66.87 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.862 179.75 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.588 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.6 mt-10 -125.95 141.68 51.86 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.762 -1.434 . . . . 0.0 111.888 -177.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.697 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.26 -18.66 28.12 Favored 'General case' 0 N--CA 1.503 2.201 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.878 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 54.6 m-85 -87.98 10.49 18.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.345 -0.847 . . . . 0.0 110.4 -178.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -99.18 151.94 37.6 Favored Pre-proline 0 C--N 1.295 -1.771 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 177.014 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.84 130.15 16.44 Favored 'Trans proline' 0 C--N 1.294 -2.306 0 C-N-CA 121.32 1.346 . . . . 0.0 108.976 -179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.597 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.62 111.71 24.5 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.788 -1.165 . . . . 0.0 108.487 -179.096 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.574 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 9.1 mtmt -152.18 136.01 16.33 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.422 -0.799 . . . . 0.0 110.191 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.658 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.97 159.23 42.66 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.508 -0.745 . . . . 0.0 109.31 179.207 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 35.2 mtpt -114.13 140.94 48.1 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.553 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.093 ' CD1' HG21 ' A' ' 45' ' ' VAL . 3.1 mt -108.99 145.05 16.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.954 -178.176 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.564 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -138.14 115.07 10.79 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.923 -179.513 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.098 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -98.24 160.73 14.1 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.557 179.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.547 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 1.8 t -142.14 111.02 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.583 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -87.81 -175.89 0.64 Allowed Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 108.553 -179.801 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 34.8 Cg_endo -79.11 20.94 0.77 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.041 1.827 . . . . 0.0 111.637 -178.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 0.9 OUTLIER -122.15 14.27 10.54 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.642 -1.286 . . . . 0.0 109.41 179.434 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 73.03 30.33 63.39 Favored Glycine 0 N--CA 1.486 2.029 0 N-CA-C 105.965 -2.854 . . . . 0.0 105.965 -178.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 0.3 OUTLIER -151.57 138.32 12.8 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.007 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.637 ' HA ' ' O ' ' A' ' 28' ' ' ALA . 22.2 m-70 -34.51 -44.59 0.2 Allowed 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.465 -0.772 . . . . 0.0 110.904 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 30' ' ' ASP . 8.0 ttt-85 160.8 71.99 0.0 OUTLIER 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 38' ' ' ASP . 72.6 p 45.59 86.58 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -177.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 37' ' ' THR . 2.2 t0 -46.26 176.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.956 -1.09 . . . . 0.0 110.515 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.2 -41.84 2.08 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.08 79.36 0.15 Allowed Glycine 0 N--CA 1.488 2.116 0 O-C-N 120.937 -1.331 . . . . 0.0 109.995 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.474 ' OD2' ' HB3' ' A' ' 36' ' ' ARG . 1.2 m-20 -88.32 138.99 30.95 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.823 -1.398 . . . . 0.0 108.618 179.322 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.511 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -70.34 58.48 0.86 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.162 ' CE1' HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -100.15 94.76 6.4 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.443 -1.033 . . . . 0.0 110.074 -179.327 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.095 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -100.26 114.23 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 178.047 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.093 HG21 ' CD1' ' A' ' 26' ' ' ILE . 18.9 t -121.47 149.43 24.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.371 -0.83 . . . . 0.0 109.574 -179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.525 HG23 ' CE ' ' A' ' 57' ' ' MET . 0.2 OUTLIER -160.39 133.04 6.39 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.807 179.695 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.861 HD11 HD12 ' A' ' 79' ' ' ILE . 0.4 OUTLIER -122.26 157.42 26.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 178.002 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.7 ' HG3' HG13 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.32 155.4 5.22 Favored 'General case' 0 C--N 1.295 -1.799 0 C-N-CA 118.212 -1.395 . . . . 0.0 110.521 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.446 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -164.28 -168.31 26.16 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.065 -2.014 . . . . 0.0 108.065 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.471 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 33.0 Cg_endo -74.95 73.34 4.32 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 C-N-CA 122.209 1.939 . . . . 0.0 110.123 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.989 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.1 177.4 2.08 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.989 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.16 -56.06 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.524 2.149 . . . . 0.0 110.172 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.688 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.1 t -90.9 77.39 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.279 -0.888 . . . . 0.0 108.896 179.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.673 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 73.5 m-20 -89.57 -49.72 0.38 Allowed Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 120.844 -1.16 . . . . 0.0 111.209 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.673 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.3 Cg_endo -81.25 97.47 0.98 Allowed 'Trans proline' 0 C--N 1.316 -1.14 0 C-N-CA 122.137 1.891 . . . . 0.0 110.581 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.688 ' CG2' HG12 ' A' ' 53' ' ' VAL . 10.4 t -134.75 93.49 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.819 -1.176 . . . . 0.0 110.85 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.525 ' CE ' HG23 ' A' ' 46' ' ' THR . 0.0 OUTLIER -139.18 138.2 36.71 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 118.909 -1.116 . . . . 0.0 110.013 178.71 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.31 155.73 37.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 110.07 -178.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.543 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 23.4 t0 -114.27 128.46 56.37 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.441 -0.787 . . . . 0.0 109.481 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.43 -5.93 56.97 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.107 -0.996 . . . . 0.0 110.714 -179.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 73.23 13.63 79.53 Favored Glycine 0 N--CA 1.488 2.111 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.114 179.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' A' ' 62' ' ' ASP . 30.7 p-10 -115.28 41.16 2.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.077 -1.249 . . . . 0.0 109.551 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.62 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 60.32 11.62 21.23 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.522 HG22 ' HA ' ' A' ' 27' ' ' HIS . 31.8 p -139.37 149.99 44.79 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.451 -1.029 . . . . 0.0 109.102 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' ' CG ' ' A' ' 59' ' ' ASP . 5.3 m-85 -126.83 155.46 42.87 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.102 -0.999 . . . . 0.0 111.132 -178.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.43 ' N ' ' OD1' ' A' ' 66' ' ' ASP . 0.7 OUTLIER -124.85 122.67 38.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.511 -0.743 . . . . 0.0 109.124 179.831 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.722 HG11 HG11 ' A' ' 45' ' ' VAL . 1.7 m -120.52 143.02 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.193 -0.942 . . . . 0.0 108.656 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.652 ' O ' HG11 ' A' ' 56' ' ' VAL . 14.6 mp0 -153.37 129.88 10.68 Favored 'General case' 0 N--CA 1.505 2.292 0 O-C-N 120.534 -1.354 . . . . 0.0 113.006 -178.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 5.4 p90 -131.78 156.05 46.67 Favored 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 175.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -150.24 96.7 3.44 Favored Pre-proline 0 N--CA 1.496 1.845 0 O-C-N 120.424 -1.422 . . . . 0.0 110.597 -178.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.491 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.09 176.49 9.28 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 123.063 2.509 . . . . 0.0 111.628 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.455 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 7.9 mttt -138.18 30.46 2.45 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.317 -0.865 . . . . 0.0 110.49 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.461 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.7 pt-20 -153.05 -160.02 1.07 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 120.469 -1.394 . . . . 0.0 108.482 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.36 120.47 30.73 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 178.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.522 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -160.05 161.47 32.46 Favored Glycine 0 N--CA 1.486 2.032 0 C-N-CA 119.098 -1.525 . . . . 0.0 111.006 -177.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 0.3 OUTLIER -112.95 157.52 21.37 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.139 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.874 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.27 138.16 50.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.084 -1.01 . . . . 0.0 111.376 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.7 HG13 ' HG3' ' A' ' 48' ' ' GLU . 0.8 OUTLIER -111.03 128.92 67.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.056 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 175.26 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.861 HD12 HD11 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -116.61 157.03 17.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.077 -1.449 . . . . 0.0 111.047 -175.635 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 14.3 m-80 -152.42 114.42 4.41 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.495 -0.753 . . . . 0.0 110.114 -177.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.162 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -133.48 117.49 17.23 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 179.138 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.095 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.2 p -126.87 137.49 53.17 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.591 -0.693 . . . . 0.0 111.402 -176.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD13 ' O ' ' A' ' 83' ' ' LEU . 2.9 tm? -136.99 73.59 1.45 Allowed 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.01 179.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.707 ' OD1' ' HB3' ' A' ' 1' ' ' ALA . 28.8 m-20 141.55 -24.4 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.23 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.79 1.55 3.33 Favored Glycine 0 N--CA 1.484 1.871 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.934 ' O ' HG22 ' A' ' 82' ' ' THR . 5.3 p30 -125.49 172.78 9.39 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 120.736 -1.449 . . . . 0.0 108.282 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -104.77 153.44 21.3 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 120.934 -1.104 . . . . 0.0 109.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.568 HG23 ' CD1' ' A' ' 81' ' ' LEU . 2.7 t -67.36 172.12 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.173 -0.955 . . . . 0.0 108.856 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.566 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 31.2 t-20 -80.83 22.74 0.58 Allowed 'General case' 0 N--CA 1.499 2.007 0 O-C-N 120.845 -1.159 . . . . 0.0 112.077 -177.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -148.42 18.67 1.32 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 178.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.019 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 3.5 m-85 -114.3 -42.1 0.07 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -177.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.637 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 29.4 Cg_endo -72.15 19.72 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.668 0 N-CA-C 109.053 -1.172 . . . . 0.0 109.053 178.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.551 ' H ' ' C ' ' A' ' 91' ' ' PHE . 19.9 ttmt -103.38 172.24 6.92 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.911 0.862 . . . . 0.0 109.254 179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 21.9 m -126.08 130.79 51.79 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.927 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.8 t -98.5 154.5 3.94 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.719 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 7.7 m -121.24 142.3 50.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.671 -1.268 . . . . 0.0 112.991 -176.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.874 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.8 t -132.05 131.94 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.266 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.574 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -123.1 -63.24 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 120.897 -1.127 . . . . 0.0 112.643 -177.872 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.574 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.8 Cg_endo -75.5 72.96 4.77 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 C-N-CA 121.535 1.49 . . . . 0.0 112.345 -177.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.878 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.053 -1.029 . . . . 0.0 109.221 178.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.568 ' C ' ' HD3' ' A' ' 3' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.442 0.639 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.595 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 36.0 t0 -116.68 47.12 0.59 Allowed Pre-proline 0 C--N 1.301 -1.538 0 O-C-N 121.529 -0.732 . . . . 0.0 111.513 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.595 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 36.7 Cg_endo -77.6 0.62 9.62 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 121.353 1.369 . . . . 0.0 108.696 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -138.15 13.67 2.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.578 -0.701 . . . . 0.0 110.936 -178.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.528 ' N ' ' OD1' ' A' ' 2' ' ' ASP . 0.0 OUTLIER -144.02 34.63 1.23 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.808 -1.183 . . . . 0.0 107.95 -179.497 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.511 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 16.2 m -115.72 114.63 25.09 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -179.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.434 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -134.46 146.07 49.43 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.63 -178.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.912 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -121.64 130.92 53.81 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -148.61 139.36 22.86 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 120.97 -1.081 . . . . 0.0 110.192 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.635 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.66 173.95 39.8 Favored Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.529 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 35.0 Cg_endo -77.16 7.85 3.5 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.595 2.197 . . . . 0.0 109.112 176.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.973 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.56 157.24 15.22 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.622 -1.791 . . . . 0.0 108.622 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.973 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 89.11 -8.27 0.44 Allowed 'General case' 0 N--CA 1.504 2.27 0 CA-C-N 118.252 1.026 . . . . 0.0 110.698 179.258 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.422 ' C ' HG11 ' A' ' 95' ' ' VAL . 0.7 OUTLIER -68.56 -17.45 64.14 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.8 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.703 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 78.66 -130.49 10.03 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.587 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 64.97 -65.88 0.07 OUTLIER Glycine 0 N--CA 1.492 2.398 0 O-C-N 121.874 -0.78 . . . . 0.0 111.488 179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.594 ' N ' HG22 ' A' ' 97' ' ' VAL . 1.8 mp0 -125.62 143.0 51.22 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.851 -1.382 . . . . 0.0 111.925 -177.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.717 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.4 m -88.07 -19.86 26.52 Favored 'General case' 0 N--CA 1.499 2.002 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.673 ' CZ ' ' O ' ' A' ' 72' ' ' LYS . 23.1 m-85 -89.41 11.75 18.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 110.287 -178.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.462 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -98.85 144.8 28.84 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 106.018 -1.845 . . . . 0.0 106.018 177.204 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HD2' ' HG2' ' A' ' 20' ' ' GLN . 29.7 Cg_endo -69.24 128.21 16.16 Favored 'Trans proline' 0 C--N 1.297 -2.164 0 N-CA-C 108.667 -1.32 . . . . 0.0 108.667 -179.337 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.592 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.02 111.7 24.38 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 118.588 -1.245 . . . . 0.0 108.868 -178.583 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.575 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 15.9 mtmm -149.89 133.77 16.94 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.587 -0.695 . . . . 0.0 109.588 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.72 ' HZ ' HD12 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -141.94 158.99 43.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.4 -0.812 . . . . 0.0 109.011 179.41 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.521 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -114.86 140.57 48.85 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 179.512 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.977 ' CD1' HG21 ' A' ' 45' ' ' VAL . 4.1 mt -104.87 136.55 38.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.3 -0.875 . . . . 0.0 108.951 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.521 ' CE1' ' O ' ' A' ' 25' ' ' LYS . 0.1 OUTLIER -124.06 117.42 24.66 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.395 -0.816 . . . . 0.0 110.107 -178.669 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.084 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -101.35 146.17 27.94 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.539 -0.726 . . . . 0.0 110.041 179.486 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.513 ' N ' ' OD2' ' A' ' 2' ' ' ASP . 2.5 t -134.09 126.28 49.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.577 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.3 OUTLIER -107.12 -175.78 0.38 Allowed Pre-proline 0 C--N 1.295 -1.782 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 -179.567 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.577 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.0 Cg_endo -78.59 20.86 0.74 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 C-N-CA 122.054 1.836 . . . . 0.0 111.818 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.492 ' CG ' HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -126.08 10.65 7.56 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 120.31 -1.494 . . . . 0.0 110.393 179.667 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.47 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 80.48 32.21 34.92 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 107.682 -2.167 . . . . 0.0 107.682 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.492 HG23 ' CG ' ' A' ' 32' ' ' ASP . 2.2 t -151.43 172.23 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 O-C-N 121.871 -0.782 . . . . 0.0 109.243 -178.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.63 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 4.6 m-70 -85.25 52.82 2.55 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.569 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 0.0 OUTLIER 67.69 70.66 0.34 Allowed 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -179.64 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.0 OUTLIER 42.55 89.32 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.367 -0.833 . . . . 0.0 109.248 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 1.2 t0 -39.59 146.58 0.1 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.261 -0.9 . . . . 0.0 110.014 -179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 89.49 -38.79 3.17 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.869 -1.292 . . . . 0.0 109.869 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.31 34.17 5.77 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.4 m-20 -89.91 112.28 23.6 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -1.163 . . . . 0.0 109.25 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.442 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -67.52 63.42 0.28 Allowed Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.115 -1.994 . . . . 0.0 108.115 179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.084 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -97.94 114.15 26.18 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.566 -0.961 . . . . 0.0 110.548 -178.455 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.996 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -123.94 113.29 36.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 178.111 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.011 HG22 HD23 ' A' ' 81' ' ' LEU . 2.7 t -122.39 148.68 25.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.386 -0.821 . . . . 0.0 108.998 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.424 ' O ' ' OD1' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.78 135.14 7.24 Favored 'General case' 0 C--N 1.298 -1.639 0 C-N-CA 119.232 -0.987 . . . . 0.0 110.533 -179.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.72 HD12 ' HZ ' ' A' ' 24' ' ' PHE . 0.4 OUTLIER -121.74 155.88 26.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 178.258 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.568 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -170.44 153.53 4.34 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.802 -1.159 . . . . 0.0 110.143 177.124 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.455 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -155.34 -168.98 19.28 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -76.66 70.4 6.42 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.549 2.166 . . . . 0.0 110.458 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.977 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -159.18 179.5 1.35 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.045 -1.034 . . . . 0.0 109.341 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.977 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 32.8 Cg_endo -75.97 -51.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.409 2.073 . . . . 0.0 110.5 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.4 t -89.64 85.85 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.112 -0.992 . . . . 0.0 108.496 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.799 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 76.0 m-20 -102.59 -60.12 0.08 OUTLIER Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.761 -1.212 . . . . 0.0 112.093 -177.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.799 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.1 Cg_endo -78.4 108.57 2.49 Favored 'Trans proline' 0 C--N 1.32 -0.971 0 C-N-CA 121.867 1.711 . . . . 0.0 111.565 -179.187 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.654 HG11 ' O ' ' A' ' 68' ' ' GLU . 5.8 t -141.63 95.47 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 O-C-N 120.882 -1.136 . . . . 0.0 110.339 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.453 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.62 137.41 33.62 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.686 -1.259 . . . . 0.0 110.706 179.241 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.9 156.11 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.596 -0.69 . . . . 0.0 109.808 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.542 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 3.8 t0 -114.63 128.96 56.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.532 -0.73 . . . . 0.0 109.513 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -88.97 -21.97 23.27 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.342 -0.849 . . . . 0.0 110.714 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.33 14.57 76.2 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.254 179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.454 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 18.8 p-10 -114.94 32.79 5.79 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.899 -1.353 . . . . 0.0 109.807 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.63 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 76.93 -3.65 56.26 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 3.1 p -131.34 147.69 52.6 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.497 -1.002 . . . . 0.0 108.554 179.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 3.0 m-85 -125.99 155.9 40.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.16 -0.962 . . . . 0.0 109.762 -179.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -121.53 140.13 52.61 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.163 -0.961 . . . . 0.0 109.981 -179.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.651 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.0 m -136.21 147.53 27.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.654 ' O ' HG11 ' A' ' 56' ' ' VAL . 53.0 mt-10 -158.06 128.74 6.33 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 120.444 -1.41 . . . . 0.0 112.691 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.647 ' CD1' HG21 ' A' ' 47' ' ' ILE . 4.1 p90 -131.13 156.17 45.73 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 176.38 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -149.49 101.48 3.3 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 120.768 -1.207 . . . . 0.0 109.928 -178.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.505 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 35.5 Cg_endo -77.77 -164.41 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.82 2.347 . . . . 0.0 111.51 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.673 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -136.02 -62.78 0.67 Allowed 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.35 -0.844 . . . . 0.0 110.602 -179.304 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.457 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 1.0 OUTLIER -87.57 -141.03 0.11 Allowed 'General case' 0 C--N 1.307 -1.271 0 O-C-N 120.219 -1.55 . . . . 0.0 109.45 -178.687 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.513 ' HB1' ' HA ' ' A' ' 98' ' ' LYS . . . -89.48 132.88 34.82 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 120.977 -1.077 . . . . 0.0 108.345 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.518 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.46 160.35 31.29 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 119.628 -1.272 . . . . 0.0 110.319 -178.097 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.452 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 2.3 p30 -113.79 156.06 24.54 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.898 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.1 m-85 -114.98 143.89 44.45 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.017 -177.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.568 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -122.36 127.58 75.17 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.075 0 N-CA-C 105.666 -1.976 . . . . 0.0 105.666 176.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.631 HG22 ' CE2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -105.44 158.58 5.93 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 CA-C-O 122.986 1.374 . . . . 0.0 112.884 -176.324 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 45' ' ' VAL . 2.1 m120 -147.46 114.15 6.05 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.011 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.09 124.79 22.38 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 106.955 -1.498 . . . . 0.0 106.955 -179.07 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.996 ' OG1' HG13 ' A' ' 44' ' ' VAL . 3.0 p -139.79 137.14 34.77 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 118.778 -1.169 . . . . 0.0 112.184 -176.633 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.736 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.1 tm? -140.88 74.98 1.48 Allowed 'General case' 0 N--CA 1.501 2.099 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.576 178.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.592 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 11.3 m-20 141.45 -20.39 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.329 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 127.38 4.55 5.82 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.91 ' O ' HG22 ' A' ' 82' ' ' THR . 20.2 t0 -127.8 173.97 9.52 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 121.124 -1.221 . . . . 0.0 107.772 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.62 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 4.7 m-80 -110.44 152.67 26.02 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 120.648 -1.283 . . . . 0.0 109.629 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.632 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.5 t -67.3 162.03 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.415 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 2.9 m-80 -79.34 25.32 0.31 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 120.661 -1.275 . . . . 0.0 112.019 -177.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.486 ' H ' HG12 ' A' ' 88' ' ' VAL . . . -142.94 14.78 2.38 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 178.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.912 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.0 m-85 -113.01 -39.19 0.1 OUTLIER Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.368 -1.078 . . . . 0.0 113.727 -177.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.62 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -74.26 14.92 0.67 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 N-CA-C 108.317 -1.455 . . . . 0.0 108.317 178.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.53 ' HG2' ' N ' ' A' ' 94' ' ' THR . 10.7 ttpt -98.51 166.93 11.12 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 25.4 m -121.08 127.85 52.05 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.661 -0.816 . . . . 0.0 109.952 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.703 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 5.4 t -98.56 153.33 4.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 29.2 m -121.34 143.67 49.07 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.51 -1.276 . . . . 0.0 113.318 -176.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.898 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -129.5 133.67 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 177.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.612 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 11.1 mttt -127.74 -65.76 0.02 OUTLIER Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 120.834 -1.166 . . . . 0.0 112.118 -178.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.612 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 34.4 Cg_endo -75.12 68.73 5.8 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.521 1.481 . . . . 0.0 111.78 -178.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.49 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 120.908 -1.12 . . . . 0.0 108.768 178.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB1' ' HG3' ' A' ' 36' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.499 0.666 . . . . 0.0 109.534 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.643 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.3 t0 43.24 51.77 7.51 Favored Pre-proline 0 C--N 1.303 -1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 110.168 -179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.643 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.5 Cg_endo -81.84 3.89 7.46 Favored 'Trans proline' 0 C--N 1.309 -1.524 0 C-N-CA 121.581 1.521 . . . . 0.0 108.472 178.065 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.415 ' C ' ' HG2' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -144.06 7.28 1.39 Allowed 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.508 -0.745 . . . . 0.0 111.839 -177.4 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.573 ' CB ' ' HB ' ' A' ' 29' ' ' VAL . 5.7 mmtm -140.53 41.11 1.88 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.468 -1.395 . . . . 0.0 108.192 -179.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.7 m -115.49 114.09 24.56 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.508 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -140.27 141.7 35.78 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.396 -0.921 . . . . 0.0 110.687 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.978 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.71 119.86 35.7 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 178.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.44 ' HG2' ' C ' ' A' ' 8' ' ' ALA . 3.0 mt-10 -139.92 143.88 36.85 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.759 -1.213 . . . . 0.0 110.308 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.595 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.65 174.87 39.07 Favored Glycine 0 N--CA 1.48 1.6 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.3 Cg_endo -79.55 10.29 3.12 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.61 2.207 . . . . 0.0 108.468 176.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.961 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -116.65 157.32 15.12 Favored Glycine 0 C--O 1.203 -1.82 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.961 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 87.59 -7.3 0.6 Allowed 'General case' 0 N--CA 1.498 1.951 0 CA-C-N 118.363 1.082 . . . . 0.0 110.15 179.508 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 14' ' ' ASP . 0.4 OUTLIER -66.33 -20.5 66.1 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.375 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.687 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 84.81 -132.29 10.99 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.273 -0.965 . . . . 0.0 110.736 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.718 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 69.27 -87.13 0.24 Allowed Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.591 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -108.41 147.11 32.08 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.243 -1.151 . . . . 0.0 111.883 -177.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.709 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.2 m -87.14 -17.22 33.27 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.774 -0.579 . . . . 0.0 109.554 179.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.734 ' CD1' ' CB ' ' A' ' 100' ' ' ALA . 5.9 m-85 -90.67 13.16 16.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -0.904 . . . . 0.0 110.027 -178.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.77 144.54 28.17 Favored Pre-proline 0 C--N 1.294 -1.808 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 177.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -68.44 128.36 17.15 Favored 'Trans proline' 0 C--N 1.295 -2.264 0 C-N-CA 121.387 1.391 . . . . 0.0 108.91 -179.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.571 ' OG ' ' CE1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -104.06 111.83 24.57 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 118.951 -1.1 . . . . 0.0 108.479 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.584 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 14.7 mtpt -152.11 135.52 16.01 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.087 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.672 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.87 158.12 44.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.462 -0.774 . . . . 0.0 109.179 179.072 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -115.12 143.39 45.28 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.044 HD12 HG21 ' A' ' 45' ' ' VAL . 1.7 mt -112.7 152.31 14.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.75 -177.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.552 ' N ' ' ND1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -142.74 118.82 10.7 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.454 0.645 . . . . 0.0 109.952 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 1.071 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -104.61 130.24 52.63 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.68 -0.637 . . . . 0.0 110.38 179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.573 ' HB ' ' CB ' ' A' ' 5' ' ' LYS . 2.3 t -115.88 124.34 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 120.77 -1.206 . . . . 0.0 108.152 178.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.587 ' HB3' ' CA ' ' A' ' 36' ' ' ARG . 0.3 OUTLIER -94.25 -176.71 0.59 Allowed Pre-proline 0 C--N 1.296 -1.741 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.165 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.574 ' HD2' ' CB ' ' A' ' 30' ' ' ASP . 34.3 Cg_endo -77.69 17.35 0.97 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.158 1.905 . . . . 0.0 111.969 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.551 ' O ' HG23 ' A' ' 34' ' ' VAL . 22.1 t70 -118.2 9.32 12.55 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.553 -1.342 . . . . 0.0 109.282 179.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.43 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 70.94 38.21 64.72 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 106.084 -2.807 . . . . 0.0 106.084 -178.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 32' ' ' ASP . 1.4 t -150.57 177.12 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 -177.622 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.639 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 15.8 m80 -85.49 54.76 3.23 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 178.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.798 ' HG3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER 50.38 66.08 1.26 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 -178.414 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.475 ' C ' ' O ' ' A' ' 36' ' ' ARG . 0.2 OUTLIER 41.8 81.76 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.7 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -42.08 168.54 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.065 -1.022 . . . . 0.0 110.837 -178.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 111.21 -46.75 1.13 Allowed Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -150.36 74.86 0.26 Allowed Glycine 0 N--CA 1.489 2.172 0 O-C-N 120.844 -1.386 . . . . 0.0 109.84 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 43' ' ' PHE . 8.3 m-20 -88.59 134.77 33.78 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.921 -1.34 . . . . 0.0 109.006 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.544 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.19 59.4 0.58 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.328 -1.909 . . . . 0.0 108.328 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 1.071 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -100.43 112.55 24.91 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.402 -1.058 . . . . 0.0 110.183 -178.802 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.965 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -120.83 114.33 43.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.326 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.044 HG21 HD12 ' A' ' 26' ' ' ILE . 4.8 t -121.79 149.68 25.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.459 ' O ' ' ND2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.65 134.65 7.07 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.788 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.681 HG12 HG23 ' A' ' 79' ' ' ILE . 0.5 OUTLIER -125.18 157.2 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.471 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.552 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -168.9 153.62 5.85 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.297 -1.361 . . . . 0.0 110.736 176.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.467 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.55 -168.8 19.81 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.528 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 34.6 Cg_endo -76.41 71.74 5.76 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.325 2.017 . . . . 0.0 110.215 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.02 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.6 179.27 1.4 Allowed Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.252 -0.905 . . . . 0.0 109.365 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.02 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 34.9 Cg_endo -77.78 -56.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.311 -1.417 0 C-N-CA 122.535 2.157 . . . . 0.0 110.439 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.488 HG12 ' CG2' ' A' ' 56' ' ' VAL . 4.0 t -89.97 75.11 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.164 -0.96 . . . . 0.0 108.991 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.62 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 79.0 m-20 -90.11 -45.98 0.4 Allowed Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.118 . . . . 0.0 111.303 -178.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.5 Cg_endo -82.19 98.9 0.95 Allowed 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.14 1.893 . . . . 0.0 110.832 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.657 HG11 ' O ' ' A' ' 68' ' ' GLU . 4.9 t -136.44 93.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.858 -1.151 . . . . 0.0 110.719 -179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.47 ' O ' ' HG3' ' A' ' 57' ' ' MET . 0.2 OUTLIER -140.08 135.18 32.32 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.859 -1.137 . . . . 0.0 110.096 178.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.84 155.7 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.512 -0.743 . . . . 0.0 109.73 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.535 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 5.3 t0 -121.5 126.97 50.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.531 -0.731 . . . . 0.0 109.099 179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.473 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 85.2 m-20 -89.13 -9.15 52.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.107 -0.996 . . . . 0.0 110.734 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 71.82 14.63 75.7 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.473 ' OD1' ' HB2' ' A' ' 60' ' ' ASN . 36.7 p-10 -112.74 36.98 3.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.339 -1.095 . . . . 0.0 108.922 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.639 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 67.33 2.62 20.85 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.498 ' C ' ' CD1' ' A' ' 65' ' ' TYR . 3.3 p -131.31 145.49 51.89 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.02 -1.282 . . . . 0.0 109.341 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 5.7 m-85 -124.67 153.7 41.9 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -0.987 . . . . 0.0 110.354 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -128.36 129.1 45.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.364 -0.835 . . . . 0.0 109.579 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.672 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 1.8 m -124.53 144.63 33.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' O ' HG11 ' A' ' 56' ' ' VAL . 9.1 mp0 -152.99 126.28 8.62 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 120.589 -1.319 . . . . 0.0 112.768 -178.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.68 ' CD1' HG21 ' A' ' 47' ' ' ILE . 6.2 p90 -132.69 153.99 50.59 Favored 'General case' 0 N--CA 1.498 1.937 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 175.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.469 ' HG3' ' O ' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -152.34 97.4 2.96 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 120.435 -1.415 . . . . 0.0 110.897 -178.372 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.463 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 37.1 Cg_endo -81.27 178.86 6.35 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 C-N-CA 122.909 2.406 . . . . 0.0 111.724 -179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.556 ' C ' ' CE1' ' A' ' 19' ' ' PHE . 0.5 OUTLIER -139.07 32.46 2.16 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.39 -0.818 . . . . 0.0 110.266 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.491 ' O ' ' HB2' ' A' ' 18' ' ' CYS . 12.0 pt-20 -152.19 -150.25 0.33 Allowed 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.487 -1.383 . . . . 0.0 108.291 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.731 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -96.66 126.15 41.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 178.27 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.539 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.93 160.93 32.94 Favored Glycine 0 N--CA 1.485 1.953 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.968 -176.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 1.4 p30 -114.64 156.28 25.01 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 178.178 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.912 ' OH ' HG21 ' A' ' 97' ' ' VAL . 2.4 m-85 -114.96 137.33 52.12 Favored 'General case' 0 C--N 1.295 -1.765 0 C-N-CA 118.868 -1.133 . . . . 0.0 110.918 -178.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.442 HG13 ' HG3' ' A' ' 48' ' ' GLU . 1.0 OUTLIER -113.62 129.81 68.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 176.208 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.817 HD12 ' O ' ' A' ' 93' ' ' LYS . 0.2 OUTLIER -108.97 158.16 8.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.88 1.324 . . . . 0.0 112.274 -176.564 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.508 ' N ' ' HD2' ' A' ' 91' ' ' PHE . 5.3 m-80 -148.47 114.79 5.88 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.981 HD21 ' CE1' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -136.83 121.99 19.14 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 106.965 -1.495 . . . . 0.0 106.965 -179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.965 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.9 p -134.72 134.39 40.98 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 118.646 -1.221 . . . . 0.0 112.493 -176.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.718 HD13 ' O ' ' A' ' 83' ' ' LEU . 3.2 tm? -140.88 75.71 1.52 Allowed 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.158 178.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.588 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 54.2 m-20 142.67 -23.57 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.168 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 130.68 4.67 4.24 Favored Glycine 0 N--CA 1.485 1.961 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -178.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.932 ' O ' HG22 ' A' ' 82' ' ' THR . 0.1 OUTLIER -132.24 175.2 9.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.868 -1.372 . . . . 0.0 108.527 179.643 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.59 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 16.8 m-80 -102.86 150.92 23.02 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.781 -1.199 . . . . 0.0 109.274 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.624 ' HB ' HD12 ' A' ' 81' ' ' LEU . 2.6 t -67.18 170.57 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 120.908 -1.12 . . . . 0.0 108.557 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.565 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 0.7 OUTLIER -80.27 23.9 0.46 Allowed 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.842 -1.161 . . . . 0.0 111.994 -177.786 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.38 17.19 1.68 Allowed Glycine 0 N--CA 1.496 2.655 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.978 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.3 m-85 -115.79 -38.39 0.07 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.408 -1.054 . . . . 0.0 113.776 -177.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.626 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.2 Cg_endo -73.71 16.59 0.5 Allowed 'Trans proline' 0 C--N 1.312 -1.363 0 N-CA-C 108.361 -1.438 . . . . 0.0 108.361 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.817 ' O ' HD12 ' A' ' 79' ' ' ILE . 0.1 OUTLIER -101.02 170.75 8.07 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.2 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.513 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 41.3 m -127.14 129.22 47.48 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 119.755 -0.778 . . . . 0.0 109.41 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.907 HG21 ' O ' ' A' ' 13' ' ' LEU . 4.5 t -98.32 154.88 3.85 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.782 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.7 m -122.73 141.31 51.93 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.448 -1.301 . . . . 0.0 113.225 -176.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.912 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.9 t -128.03 142.87 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.682 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 0.0 OUTLIER -94.81 -171.19 0.24 Allowed Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.326 -0.859 . . . . 0.0 109.399 -177.903 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.731 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 29.1 Cg_endo -70.11 89.33 0.56 Allowed 'Trans proline' 0 C--N 1.32 -0.947 0 C-N-CA 121.205 1.27 . . . . 0.0 110.629 -178.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.734 ' CB ' ' CD1' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.303 -1.452 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.88 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.47 ' O ' ' OD1' ' A' ' 84' ' ' ASP . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.693 0.758 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.652 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 38.9 t0 49.95 48.18 5.7 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.462 -0.774 . . . . 0.0 110.378 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.652 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.8 Cg_endo -81.09 3.55 7.71 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.459 1.439 . . . . 0.0 108.578 178.191 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.476 ' O ' ' HG2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -141.7 5.77 1.8 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.593 -0.692 . . . . 0.0 111.886 -177.343 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.8 OUTLIER -140.71 41.32 1.85 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.391 -1.443 . . . . 0.0 108.418 -179.561 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.519 ' OG ' ' O ' ' A' ' 2' ' ' ASP . 1.6 m -114.72 113.48 24.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -134.73 142.73 46.85 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.087 -1.045 . . . . 0.0 111.187 -178.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.967 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -118.67 117.9 30.19 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.452 ' HA ' ' OE1' ' A' ' 9' ' ' GLU . 6.0 mm-40 -138.69 142.72 38.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 120.842 -1.161 . . . . 0.0 110.109 -179.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.624 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -162.72 175.79 39.08 Favored Glycine 0 N--CA 1.481 1.655 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.4 Cg_endo -80.12 7.06 4.89 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.462 2.108 . . . . 0.0 108.71 177.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.972 ' O ' HD23 ' A' ' 13' ' ' LEU . . . -117.81 157.17 15.28 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.551 -1.82 . . . . 0.0 108.551 -179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.972 HD23 ' O ' ' A' ' 12' ' ' GLY . 0.0 OUTLIER 91.49 -8.35 0.25 Allowed 'General case' 0 N--CA 1.503 2.195 0 CA-C-N 118.087 0.943 . . . . 0.0 110.476 179.572 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.496 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.0 OUTLIER -67.12 -19.34 65.61 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 178.395 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.689 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 82.94 -126.89 7.69 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.585 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 62.87 -60.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.4 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.523 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.617 ' N ' HG22 ' A' ' 97' ' ' VAL . 44.7 mt-10 -131.44 140.23 49.56 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.747 -1.443 . . . . 0.0 111.959 -178.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.723 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.7 m -88.88 -19.54 25.73 Favored 'General case' 0 N--CA 1.501 2.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.338 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.886 ' CE2' ' HB1' ' A' ' 100' ' ' ALA . 53.1 m-85 -88.74 8.1 30.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 110.699 -178.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -99.21 157.2 34.47 Favored Pre-proline 0 C--N 1.296 -1.719 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 177.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.502 ' HB2' ' HD2' ' A' ' 23' ' ' LYS . 30.7 Cg_endo -71.77 126.54 12.09 Favored 'Trans proline' 0 C--N 1.296 -2.188 0 C-N-CA 121.559 1.506 . . . . 0.0 109.36 -179.42 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.616 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -105.25 109.73 21.83 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 120.904 -1.123 . . . . 0.0 108.679 -179.211 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.585 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -149.86 138.29 20.65 Favored 'General case' 0 N--CA 1.487 1.408 0 CA-C-O 121.481 0.658 . . . . 0.0 110.217 -179.823 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.67 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -141.08 157.9 44.66 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.453 -0.779 . . . . 0.0 109.334 178.731 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -114.93 140.97 48.58 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.695 HD12 HG21 ' A' ' 45' ' ' VAL . 2.3 mt -112.24 155.43 13.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.72 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.444 ' ND1' ' N ' ' A' ' 27' ' ' HIS . 1.9 m80 -143.67 115.42 8.21 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-O 121.648 0.737 . . . . 0.0 110.051 179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.84 ' HB2' ' HE1' ' A' ' 43' ' ' PHE . . . -99.03 134.28 42.1 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.76 -0.587 . . . . 0.0 110.033 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.544 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.9 t -119.64 119.11 59.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 120.54 -1.35 . . . . 0.0 108.5 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -91.42 -174.8 0.45 Allowed Pre-proline 0 C--N 1.296 -1.744 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.389 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.598 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 36.2 Cg_endo -80.2 19.72 1.02 Allowed 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.18 1.92 . . . . 0.0 111.632 -178.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.469 ' C ' HG23 ' A' ' 34' ' ' VAL . 2.3 m-20 -116.97 6.51 13.0 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.585 -1.322 . . . . 0.0 109.334 179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 74.44 36.01 50.65 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 106.202 -2.759 . . . . 0.0 106.202 -178.074 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' H ' ' A' ' 35' ' ' HIS . 1.2 t -150.43 -166.2 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -177.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.649 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 57.2 m80 -101.19 55.97 0.84 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 108.872 178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.58 ' CA ' ' HB3' ' A' ' 30' ' ' ASP . 1.9 mtp-105 54.65 57.2 5.93 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 36' ' ' ARG . 8.5 m 46.52 91.07 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 107.907 -1.145 . . . . 0.0 107.907 -178.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.53 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.5 OUTLIER -38.23 152.19 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.06 -1.025 . . . . 0.0 110.411 -178.389 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 85.95 -29.13 4.74 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.413 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -119.46 55.32 0.61 Allowed Glycine 0 N--CA 1.492 2.382 0 O-C-N 120.7 -1.471 . . . . 0.0 111.21 -179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 43' ' ' PHE . 1.5 m-20 -113.48 122.3 46.89 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.819 -1.4 . . . . 0.0 108.677 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 83' ' ' LEU . . . -68.37 63.8 0.41 Allowed Glycine 0 N--CA 1.493 2.44 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 179.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.84 ' HE1' ' HB2' ' A' ' 28' ' ' ALA . 0.2 OUTLIER -93.68 118.63 31.64 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.479 -1.012 . . . . 0.0 111.557 -177.944 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.061 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.2 OUTLIER -132.96 113.57 20.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 177.163 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.083 HG22 HD23 ' A' ' 81' ' ' LEU . 5.5 t -118.45 153.5 20.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.27 -0.894 . . . . 0.0 109.267 -179.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -161.47 128.66 4.02 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.572 179.978 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.673 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.2 OUTLIER -121.02 156.56 24.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.888 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.535 ' N ' ' CG2' ' A' ' 47' ' ' ILE . 0.0 OUTLIER -169.66 153.29 4.95 Favored 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 118.009 -1.476 . . . . 0.0 110.832 176.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.476 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -156.95 -168.61 19.8 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 107.674 -2.17 . . . . 0.0 107.674 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.497 ' HG2' ' HA3' ' A' ' 75' ' ' GLY . 36.1 Cg_endo -77.69 72.41 6.09 Favored 'Trans proline' 0 C--N 1.302 -1.895 0 C-N-CA 122.254 1.969 . . . . 0.0 110.674 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.98 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -160.29 177.31 2.11 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 120.99 -1.069 . . . . 0.0 109.808 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.98 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 35.2 Cg_endo -77.67 -47.86 0.11 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.748 2.299 . . . . 0.0 110.287 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.436 HG22 ' H ' ' A' ' 53' ' ' VAL . 2.0 m -88.95 75.64 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.685 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 26.1 m-20 -93.69 -67.05 0.1 Allowed Pre-proline 0 N--CA 1.486 1.363 0 O-C-N 121.062 -1.024 . . . . 0.0 111.317 -177.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.685 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 36.4 Cg_endo -74.16 103.07 1.61 Allowed 'Trans proline' 0 C--N 1.317 -1.088 0 C-N-CA 121.999 1.799 . . . . 0.0 111.147 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.633 HG11 ' O ' ' A' ' 68' ' ' GLU . 8.3 t -137.49 95.62 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 O-C-N 120.98 -1.075 . . . . 0.0 110.026 -179.776 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.469 ' HG2' ' O ' ' A' ' 45' ' ' VAL . 0.0 OUTLIER -140.63 137.59 33.73 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.674 -1.211 . . . . 0.0 110.736 179.506 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -135.0 156.11 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.53 -0.731 . . . . 0.0 109.546 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.556 ' OD1' ' CE2' ' A' ' 65' ' ' TYR . 9.4 t0 -111.74 135.27 52.57 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.42 -0.8 . . . . 0.0 109.334 179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.42 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 27.8 m120 -88.71 -16.89 31.11 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.144 -0.973 . . . . 0.0 110.557 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.471 ' O ' ' OD1' ' A' ' 38' ' ' ASP . . . 74.5 13.6 81.68 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.449 ' C ' ' OD2' ' A' ' 38' ' ' ASP . 25.4 p-10 -121.07 35.7 4.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.4 -1.059 . . . . 0.0 109.361 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.649 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 74.9 -4.96 34.67 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 110.354 -1.099 . . . . 0.0 110.354 179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 41.8 p -127.1 146.0 50.53 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.206 -1.173 . . . . 0.0 109.751 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.605 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.6 m-85 -124.11 155.29 38.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 110.194 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.41 ' OD2' ' ND2' ' A' ' 60' ' ' ASN . 1.5 p30 -127.76 131.32 49.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.208 -0.933 . . . . 0.0 109.849 -179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.835 HG11 HG11 ' A' ' 45' ' ' VAL . 2.4 m -126.99 144.12 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.633 ' O ' HG11 ' A' ' 56' ' ' VAL . 35.3 mp0 -153.59 130.48 10.94 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 120.499 -1.376 . . . . 0.0 112.617 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.673 ' CD1' HG21 ' A' ' 47' ' ' ILE . 2.6 p90 -133.65 156.33 48.09 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 176.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.48 96.57 3.62 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 120.542 -1.349 . . . . 0.0 110.226 -178.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.497 ' HG2' ' SG ' ' A' ' 18' ' ' CYS . 36.4 Cg_endo -79.05 178.79 7.11 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 C-N-CA 123.16 2.573 . . . . 0.0 111.903 -179.821 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.538 ' O ' ' CZ ' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -139.72 31.53 2.05 Favored 'General case' 0 N--CA 1.501 2.112 0 O-C-N 121.415 -0.803 . . . . 0.0 110.533 -179.675 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.477 ' OE2' ' HB2' ' A' ' 50' ' ' PRO . 3.2 pt-20 -154.03 -163.58 1.66 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.134 -1.604 . . . . 0.0 108.562 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -89.68 117.74 28.77 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.572 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -159.55 163.41 33.52 Favored Glycine 0 N--CA 1.487 2.068 0 C-N-CA 119.357 -1.402 . . . . 0.0 110.887 -176.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 21.5 p-10 -111.83 157.91 20.03 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.798 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.8 m-85 -112.22 140.99 46.45 Favored 'General case' 0 C--N 1.296 -1.756 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.768 -177.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.68 ' C ' HD13 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -116.09 130.34 70.98 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 176.612 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.783 HD13 ' N ' ' A' ' 79' ' ' ILE . 0.0 OUTLIER -107.77 157.89 7.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-O 123.131 1.443 . . . . 0.0 112.789 -176.579 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 46' ' ' THR . 5.1 m120 -149.72 112.81 4.88 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 1.083 HD23 HG22 ' A' ' 45' ' ' VAL . 0.6 OUTLIER -137.01 114.29 10.83 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.061 ' OG1' HG13 ' A' ' 44' ' ' VAL . 2.5 p -125.73 134.82 51.64 Favored 'General case' 0 C--N 1.29 -1.984 0 C-N-CA 119.02 -1.072 . . . . 0.0 112.397 -176.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.902 HD13 ' O ' ' A' ' 83' ' ' LEU . 1.0 OUTLIER -140.71 75.5 1.51 Allowed 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.129 177.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.565 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 15.7 m-20 143.95 -25.74 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.132 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 135.82 1.14 3.06 Favored Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.958 ' O ' HG22 ' A' ' 82' ' ' THR . 2.3 p30 -133.2 176.23 8.7 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.719 -1.459 . . . . 0.0 108.484 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.527 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 0.0 OUTLIER -102.67 154.09 19.48 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.507 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.741 ' CG2' HD12 ' A' ' 81' ' ' LEU . 12.8 t -66.48 170.08 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.246 -0.909 . . . . 0.0 108.806 -179.581 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.555 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 5.6 m-80 -78.66 17.39 0.7 Allowed 'General case' 0 N--CA 1.5 2.069 0 O-C-N 120.718 -1.239 . . . . 0.0 111.996 -177.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.62 10.14 3.44 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.967 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 6.6 m-85 -107.96 -37.97 0.15 Allowed Pre-proline 0 N--CA 1.487 1.39 0 O-C-N 121.282 -1.128 . . . . 0.0 113.443 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.569 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 30.5 Cg_endo -73.26 14.05 0.61 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 N-CA-C 108.244 -1.483 . . . . 0.0 108.244 178.681 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.539 ' H ' ' C ' ' A' ' 91' ' ' PHE . 8.7 tttm -100.86 173.15 6.63 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.575 HG23 ' O ' ' A' ' 77' ' ' TYR . 75.5 m -129.23 130.96 46.92 Favored 'General case' 0 C--N 1.293 -1.853 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.943 -179.175 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.739 HG21 ' O ' ' A' ' 13' ' ' LEU . 5.6 t -98.33 155.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 178.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.498 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 35.7 m -120.12 138.58 53.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.736 -1.228 . . . . 0.0 113.28 -176.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.798 HG21 ' OH ' ' A' ' 77' ' ' TYR . 2.7 t -126.07 134.19 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.596 ' CB ' ' HD3' ' A' ' 99' ' ' PRO . 1.6 mttm -124.87 -63.26 0.02 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 120.994 -1.066 . . . . 0.0 112.835 -178.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.596 ' HD3' ' CB ' ' A' ' 98' ' ' LYS . 33.9 Cg_endo -75.02 82.29 2.04 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 121.616 1.544 . . . . 0.0 112.012 -177.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.886 ' HB1' ' CE2' ' A' ' 19' ' ' PHE . . . . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.324 -0.86 . . . . 0.0 108.83 178.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.533 ' O ' ' CD1' ' A' ' 83' ' ' LEU . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.398 0.618 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . 0.66 ' N ' ' HD3' ' A' ' 3' ' ' PRO . 45.1 t0 53.28 48.25 4.91 Favored Pre-proline 0 C--N 1.299 -1.59 0 O-C-N 121.651 -0.656 . . . . 0.0 110.95 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.66 ' HD3' ' N ' ' A' ' 2' ' ' ASP . 37.3 Cg_endo -80.27 2.62 8.33 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 121.556 1.504 . . . . 0.0 108.321 177.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.425 ' HB3' ' HD2' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -143.89 9.98 1.54 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.609 -0.682 . . . . 0.0 111.559 -177.6 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.54 ' HB3' ' HB ' ' A' ' 29' ' ' VAL . 0.1 OUTLIER -140.44 39.64 1.89 Allowed 'General case' 0 C--N 1.302 -1.479 0 O-C-N 120.507 -1.371 . . . . 0.0 108.295 -179.471 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.571 ' O ' HG22 ' A' ' 88' ' ' VAL . 2.0 m -114.96 118.34 33.18 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 27' ' ' HIS . 11.9 p90 -141.65 146.48 36.22 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.261 -0.899 . . . . 0.0 110.824 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.954 ' HB3' ' CE1' ' A' ' 91' ' ' PHE . . . -125.93 129.94 50.29 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.19 141.31 23.06 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.828 -1.149 . . . . 0.0 110.175 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' ' HA ' ' A' ' 24' ' ' PHE . . . -163.04 175.83 39.34 Favored Glycine 0 N--CA 1.482 1.75 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.48 ' HD2' ' O ' ' A' ' 23' ' ' LYS . 36.2 Cg_endo -80.09 7.88 4.41 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.497 2.131 . . . . 0.0 108.693 176.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.666 ' O ' ' CD2' ' A' ' 13' ' ' LEU . . . -117.7 156.5 15.61 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 1.096 HD12 HD13 ' A' ' 79' ' ' ILE . 0.0 OUTLIER 91.67 -25.92 0.05 OUTLIER 'General case' 0 N--CA 1.505 2.294 0 CA-C-N 117.867 0.834 . . . . 0.0 110.705 179.16 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.645 ' C ' HG11 ' A' ' 95' ' ' VAL . 1.6 m-20 -51.49 -21.42 2.41 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.256 -0.902 . . . . 0.0 108.703 179.344 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.686 ' HA3' ' CG1' ' A' ' 95' ' ' VAL . . . 80.04 -130.85 10.09 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 97' ' ' VAL . . . 67.74 -61.48 0.32 Allowed Glycine 0 N--CA 1.491 2.309 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.409 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.624 ' N ' HG22 ' A' ' 97' ' ' VAL . 43.6 mt-10 -126.66 143.94 51.07 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.943 -1.328 . . . . 0.0 111.605 -178.009 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.729 ' SG ' HG11 ' A' ' 97' ' ' VAL . 1.3 m -88.22 -20.78 25.06 Favored 'General case' 0 N--CA 1.501 2.079 0 C-N-CA 120.046 -0.661 . . . . 0.0 109.851 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.917 ' CD2' ' HB1' ' A' ' 100' ' ' ALA . 13.0 m-85 -89.75 14.55 11.55 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.932 -1.105 . . . . 0.0 110.176 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.42 ' HG2' ' HD2' ' A' ' 21' ' ' PRO . 0.3 OUTLIER -99.18 140.27 21.57 Favored Pre-proline 0 C--N 1.292 -1.902 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 176.538 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.529 ' HB2' ' CD ' ' A' ' 23' ' ' LYS . 29.5 Cg_endo -68.39 130.57 21.36 Favored 'Trans proline' 0 C--N 1.296 -2.228 0 C-N-CA 121.228 1.285 . . . . 0.0 108.793 -179.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.625 ' HB3' ' CD1' ' A' ' 69' ' ' PHE . 0.1 OUTLIER -104.25 109.33 21.11 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 118.323 -1.351 . . . . 0.0 108.975 -178.544 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.581 ' C ' ' CD1' ' A' ' 24' ' ' PHE . 0.1 OUTLIER -148.63 134.77 19.27 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.52 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.668 ' CE2' ' CG2' ' A' ' 67' ' ' VAL . 0.0 OUTLIER -140.65 159.04 43.07 Favored 'General case' 0 C--N 1.293 -1.85 0 O-C-N 121.562 -0.711 . . . . 0.0 109.13 179.74 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -113.36 139.46 48.85 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 1.142 ' CD1' HG21 ' A' ' 45' ' ' VAL . 6.1 mt -106.14 152.71 7.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.529 -0.732 . . . . 0.0 110.027 -178.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.549 ' HB2' ' CZ ' ' A' ' 7' ' ' TYR . 1.5 m80 -142.04 113.64 7.83 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 121.538 0.685 . . . . 0.0 109.905 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.916 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -103.2 141.87 35.14 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.558 -0.714 . . . . 0.0 109.554 179.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 5' ' ' LYS . 2.5 t -129.75 125.33 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.977 -1.077 . . . . 0.0 108.747 179.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.589 ' CB ' ' CD ' ' A' ' 31' ' ' PRO . 0.5 OUTLIER -103.8 -173.84 0.31 Allowed Pre-proline 0 C--N 1.3 -1.56 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.938 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.589 ' CD ' ' CB ' ' A' ' 30' ' ' ASP . 35.1 Cg_endo -79.73 22.16 0.74 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.004 1.803 . . . . 0.0 111.455 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.57 ' OD2' HG21 ' A' ' 34' ' ' VAL . 28.4 t70 -121.65 12.75 10.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.712 -1.242 . . . . 0.0 109.343 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.411 ' C ' ' CG2' ' A' ' 34' ' ' VAL . . . 71.0 33.78 65.3 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 106.333 -2.707 . . . . 0.0 106.333 -178.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.57 HG21 ' OD2' ' A' ' 32' ' ' ASP . 0.5 OUTLIER -150.23 -179.82 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 -177.92 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.632 ' CG ' ' HA3' ' A' ' 63' ' ' GLY . 2.6 m-70 -95.24 57.6 2.02 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 178.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.523 ' N ' ' HB3' ' A' ' 30' ' ' ASP . 62.2 ttt-85 63.44 65.85 0.73 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -178.538 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.461 ' O ' ' C ' ' A' ' 38' ' ' ASP . 15.8 p 46.59 90.25 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 108.856 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 63' ' ' GLY . 0.6 OUTLIER -40.13 156.13 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.172 -0.955 . . . . 0.0 109.939 -179.574 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 86.02 -37.44 3.1 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.909 -1.277 . . . . 0.0 109.909 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -123.04 59.75 0.59 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.554 ' OD1' ' N ' ' A' ' 41' ' ' ASP . 0.1 OUTLIER -98.86 123.36 43.06 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.132 -1.217 . . . . 0.0 109.003 179.994 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.74 ' O ' HD22 ' A' ' 83' ' ' LEU . . . -69.67 63.17 0.66 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 107.648 -2.181 . . . . 0.0 107.648 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.916 ' CE2' ' HB2' ' A' ' 28' ' ' ALA . 0.1 OUTLIER -105.53 128.13 53.41 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.51 -0.994 . . . . 0.0 111.211 -178.027 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 1.02 HG13 ' OG1' ' A' ' 82' ' ' THR . 0.1 OUTLIER -137.55 113.54 11.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 178.03 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 1.142 HG21 ' CD1' ' A' ' 26' ' ' ILE . 46.2 t -122.73 151.56 26.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.135 -0.978 . . . . 0.0 109.389 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.546 ' N ' ' O ' ' A' ' 80' ' ' ASN . 0.0 OUTLIER -160.18 129.43 5.07 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.591 -178.965 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.647 HG21 ' CD1' ' A' ' 69' ' ' PHE . 0.4 OUTLIER -118.58 156.1 20.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.549 ' O ' HG12 ' A' ' 78' ' ' VAL . 0.0 OUTLIER -171.62 155.63 4.11 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.356 -1.338 . . . . 0.0 110.584 177.075 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.438 ' O ' ' OD2' ' A' ' 54' ' ' ASP . . . -161.03 -169.18 23.93 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.475 -1.85 . . . . 0.0 108.475 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.492 ' HG2' ' HA2' ' A' ' 75' ' ' GLY . 34.7 Cg_endo -77.01 71.0 6.42 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 122.337 2.025 . . . . 0.0 110.435 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 1.002 ' HB1' ' HD2' ' A' ' 52' ' ' PRO . . . -156.68 -177.36 0.73 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.188 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 1.002 ' HD2' ' HB1' ' A' ' 51' ' ' ALA . 33.9 Cg_endo -77.27 -61.93 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.443 2.096 . . . . 0.0 111.378 -179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 56' ' ' VAL . 56.3 t -88.71 81.68 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.971 -1.081 . . . . 0.0 108.73 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.627 ' HB2' ' HD3' ' A' ' 55' ' ' PRO . 74.9 m-20 -94.75 -46.92 0.27 Allowed Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.021 -1.049 . . . . 0.0 111.573 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.627 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 37.6 Cg_endo -83.88 106.52 1.25 Allowed 'Trans proline' 0 C--N 1.315 -1.186 0 C-N-CA 122.298 1.999 . . . . 0.0 111.401 -178.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.639 ' CB ' ' O ' ' A' ' 68' ' ' GLU . 12.3 t -145.14 97.69 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 O-C-N 120.756 -1.215 . . . . 0.0 110.965 -179.775 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.459 ' HG2' ' O ' ' A' ' 57' ' ' MET . 0.0 OUTLIER -140.59 136.47 32.83 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.784 -1.198 . . . . 0.0 110.531 178.569 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.99 157.11 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.457 -0.777 . . . . 0.0 110.117 -179.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASP . . . . . 0.551 ' CG ' ' CE2' ' A' ' 65' ' ' TYR . 4.1 t0 -108.56 136.85 47.48 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.495 -0.753 . . . . 0.0 109.652 179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.407 ' N ' ' OD1' ' A' ' 59' ' ' ASP . 14.2 m120 -89.39 -22.1 22.74 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.374 -0.829 . . . . 0.0 110.722 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.7 82.28 Favored Glycine 0 N--CA 1.485 1.93 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.107 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.447 ' OD1' ' OG1' ' A' ' 64' ' ' THR . 31.9 p-10 -119.5 31.67 6.46 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.109 -1.23 . . . . 0.0 109.879 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.632 ' HA3' ' CG ' ' A' ' 35' ' ' HIS . . . 79.59 -6.12 58.98 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.501 ' HA ' ' O ' ' A' ' 26' ' ' ILE . 17.6 p -125.67 146.65 49.64 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.511 -0.994 . . . . 0.0 109.287 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.606 ' N ' ' CD1' ' A' ' 65' ' ' TYR . 6.0 m-85 -125.33 156.01 39.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.214 -0.929 . . . . 0.0 110.243 -179.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -125.65 130.72 52.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.185 -0.947 . . . . 0.0 109.757 -179.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.668 ' CG2' ' CE2' ' A' ' 24' ' ' PHE . 2.2 m -123.63 142.77 39.13 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.639 ' O ' ' CB ' ' A' ' 56' ' ' VAL . 4.1 mp0 -151.09 129.11 11.77 Favored 'General case' 0 N--CA 1.506 2.327 0 O-C-N 120.496 -1.377 . . . . 0.0 113.046 -177.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . 0.68 ' HZ ' ' CD2' ' A' ' 77' ' ' TYR . 2.7 p90 -133.05 156.58 47.11 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 175.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -148.42 107.34 3.57 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 120.528 -1.357 . . . . 0.0 109.878 -178.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.452 ' HG2' ' HA ' ' A' ' 18' ' ' CYS . 36.3 Cg_endo -80.08 -159.68 0.11 Allowed 'Trans proline' 0 C--N 1.315 -1.2 0 C-N-CA 122.949 2.433 . . . . 0.0 111.816 -179.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.607 ' HA ' ' CE1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -143.5 -59.52 0.41 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.571 -0.705 . . . . 0.0 110.431 -179.547 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.479 ' O ' ' SG ' ' A' ' 18' ' ' CYS . 15.5 pt-20 -93.01 -131.71 0.14 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.677 -1.264 . . . . 0.0 110.169 -178.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.689 ' HB2' ' CA ' ' A' ' 99' ' ' PRO . . . -92.14 135.93 33.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.72 -1.237 . . . . 0.0 108.94 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.498 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -161.82 158.07 29.91 Favored Glycine 0 N--CA 1.483 1.814 0 C-N-CA 118.783 -1.675 . . . . 0.0 110.92 -178.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 96' ' ' THR . 7.5 p-10 -115.52 155.55 27.34 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 178.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.762 ' OH ' HG21 ' A' ' 97' ' ' VAL . 4.2 m-30 -115.41 137.58 51.9 Favored 'General case' 0 C--N 1.291 -1.945 0 C-N-CA 118.751 -1.18 . . . . 0.0 111.162 -177.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.549 HG12 ' O ' ' A' ' 48' ' ' GLU . 0.9 OUTLIER -118.07 124.89 73.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.147 0 N-CA-C 105.66 -1.978 . . . . 0.0 105.66 176.288 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 1.096 HD13 HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -104.74 157.31 5.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 CA-C-O 123.005 1.384 . . . . 0.0 112.004 -177.092 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.546 ' O ' ' N ' ' A' ' 46' ' ' THR . 7.2 m120 -148.89 113.38 5.3 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.082 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.89 HD12 HD13 ' A' ' 26' ' ' ILE . 0.4 OUTLIER -141.15 125.05 17.07 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 179.336 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 1.02 ' OG1' HG13 ' A' ' 44' ' ' VAL . 11.7 p -136.05 138.93 42.66 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.924 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.74 HD22 ' O ' ' A' ' 42' ' ' GLY . 2.9 tm? -138.94 74.03 1.46 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.664 -0.814 . . . . 0.0 109.167 178.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.589 ' CB ' ' O ' ' A' ' 83' ' ' LEU . 24.9 m-20 141.96 -23.31 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.269 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 134.5 -2.29 4.15 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -178.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.703 ' O ' HG22 ' A' ' 82' ' ' THR . 0.4 OUTLIER -127.61 173.48 9.85 Favored 'General case' 0 N--CA 1.483 1.185 0 O-C-N 120.958 -1.319 . . . . 0.0 107.56 179.293 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 1.3 p30 -108.46 159.3 16.79 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.772 -1.205 . . . . 0.0 109.6 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.619 ' HB ' HD22 ' A' ' 81' ' ' LEU . 2.6 t -66.89 170.78 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.935 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.567 ' N ' ' CG1' ' A' ' 88' ' ' VAL . 3.7 m-20 -81.77 26.85 0.48 Allowed 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.892 -1.13 . . . . 0.0 111.36 -178.178 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.628 ' O ' HD12 ' A' ' 79' ' ' ILE . . . -149.98 23.2 1.14 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.001 -1.639 . . . . 0.0 109.001 179.137 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.954 ' CE1' ' HB3' ' A' ' 8' ' ' ALA . 4.7 m-85 -118.46 -47.41 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.278 -1.13 . . . . 0.0 113.872 -178.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.686 ' HD2' ' H ' ' A' ' 91' ' ' PHE . 28.7 Cg_endo -71.54 16.04 0.34 Allowed 'Trans proline' 0 C--N 1.31 -1.473 0 N-CA-C 109.011 -1.188 . . . . 0.0 109.011 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . 0.544 ' H ' ' C ' ' A' ' 91' ' ' PHE . 10.1 tttt -99.59 161.39 13.64 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 178.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.566 ' HA ' ' O ' ' A' ' 77' ' ' TYR . 28.4 m -115.89 125.98 53.32 Favored 'General case' 0 C--N 1.295 -1.779 0 C-N-CA 119.706 -0.798 . . . . 0.0 109.91 -179.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.686 ' CG1' ' HA3' ' A' ' 15' ' ' GLY . 16.4 t -99.35 154.91 4.08 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 178.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 90.9 m -122.91 138.31 54.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.488 -1.382 . . . . 0.0 113.269 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.762 HG21 ' OH ' ' A' ' 77' ' ' TYR . 3.0 t -118.58 144.83 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 N-CA-C 106.473 -1.677 . . . . 0.0 106.473 176.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.672 ' CB ' ' HD2' ' A' ' 99' ' ' PRO . 1.7 mttm -93.89 -172.67 0.31 Allowed Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.141 -0.974 . . . . 0.0 109.588 -177.602 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.689 ' CA ' ' HB2' ' A' ' 74' ' ' ALA . 28.5 Cg_endo -68.4 95.82 0.46 Allowed 'Trans proline' 0 C--N 1.322 -0.835 0 C-N-CA 121.367 1.378 . . . . 0.0 111.114 -177.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.917 ' HB1' ' CD2' ' A' ' 19' ' ' PHE . . . . . . . . 0 C--N 1.299 -1.588 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.18 179.621 . . . . . . . . 1 1 . 1 stop_ save_